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by Morteza Yousefi
Respiratory drug delivery has been under the research spotlight for the past few decades,
mainly due to the high incidence of pulmonary diseases and the fact that this type of
delivery offers the highest efficiency for treatment. Despite its invaluable benefits, there
are some major drawbacks to respiratory drug delivery- the most important of which
being poor delivery efficiency and relatively high drug deposition in undesirable regions,
such as the oral cavity. This study focused on improving inhalation therapy devices
function using the results and findings obtained from CFD simulations.
Particle transport and deposition in an idealised oral airway geometry to better optimize
the spacer one way-valve shape and design was studied in the first part of this research.
A key issue in pulmonary drug delivery is improving the medical delivery device for ef-
fective and targeted treatment. Spacers are clear plastic containers attached to inhalers
aimed at delivering more drug particles to the respiratory tract. The spacer’s one way-
valve plays an important role in controlling and initializing the particles into the oral
cavity. Three steady flow rates were used 15, 30 and 60 l/min and a Lagrangian, one-
way coupled particle tracking model with near wall turbulence fluctuation correction was
used to determine the deposition rates. For all three breathing rates, the velocity field
in the mid-sagittal plane showed similar gross fluid dynamics characteristics, such as the
separation and recirculation regions that occur after the larynx. The particle deposition
Abstract xiii
rates compared reasonably well with available experiments. Most particles deposited at
the larynx, where the airway has a decreasing cross-sectional area. For different parti-
cles sizes, most particles introduced at the lower region of the mouth produces higher
possibility to pass through upper airway and enter the trachea and lung airways. The
particle deposition patterns in the airway were traced back to its initial inlet position
at the oral inlet; and this information provides the background for a conceptual and
optimized design of the spacer one way valve.
Pressurized-metered dose inhalers (pMDIs) are the most popular aerosol therapy device
for treating lung diseases. Despite its popularity, they are inefficient in delivering drug
particles to the lung. Improving its performance involves ongoing investigations in the
fields of engineering and medical science. In the second part of this research, the effect of
two spray characteristics (injection velocity and spray cone angle) on the drug delivery
efficiency was discussed. An idealized oral airway geometry, extending from mouth to
the main bronchus, was connected to a pMDI device. Inhalation flow rates of 15, 30 and
60 l/min were used and the drug particle tracking was a one-way coupled Lagrangian
model. The results showed that most particles deposited in the pharynx, where the
airway has a reduced cross-sectional area. Particle deposition generally decreased with
initial spray velocity, and with increased spray cone angle for 30 l/min and 60 l/min flow
rates. However for 15 l/min flow rate the deposition increased slightly with an increase
in the spray velocity and cone angle. The effect of spray cone angle was greater than
the injection velocity on particle deposition. Overall drug delivery to the lungs was best
achieved for 30 l/min, which produced on average 5% increase in pulmonary delivery
compared to inhalation rates of 15 and 60 l/min.
Conventional inhalation therapy devices such as inhalers and nebulizers, nevertheless,
suffer from low delivery efficiencies wherein only a small fraction of the inhaled drug
reaches the lower respiratory tract. This is primarily because these devices are not able
to produce a sufficiently fine drug mist that have aerodynamic diameters on the order of
a few microns. The last part of this study employs using Computational Fluid Dynam-
ics (CFD) to investigate the transport and deposition of the drug particles produced
by a new aerosolization technique driven by surface acoustic waves (SAWs) into an in
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silico lung model geometrically reconstructed using computed tomography (CT) scan-
ning. The particles generated by the SAW are released in different locations in a spacer
chamber attached to a lung model extending from the mouth to the 6th generation of
the lung bronchial tree. An Eulerian approach is used to solve the Navier-Stokes equa-
tions that govern the airflow within the respiratory tract and a Lagrangian approach
is adopted to track the particles, which are assumed to be spherical and inert. Due to
the complexity of the lung geometry, the airflow patterns varies as it penetrates deeper
into the lung. In particular, we find that larger particles above 10µm are unable to
follow the airflow stream immediately after a sharp change in the geometry. As such,
these particles tend to deposit at locations where the geometry experiences a significant
reduction in cross-section. The findings, nevertheless, show that the injection location
can influence the delivery efficiency: injection points close to the spacer centerline re-
sult in deeper penetration into the lung. Additionally, we found that the ratio of drug
particles entering the right lung is significantly higher than the left lung independent of
the injection location.
Abstract xv
Papers Included in the Thesis
1. M. Yousefi, O. Pourmehran, M. Gorji-Bandpy, K. Inthavoung, L.Yeo, J. Tu
“CFD Simulation of Aerosol Delivery to a Human Lung via Surface Acoustic Wave
Nebulization”. Journal of Biomechanics and Modeling in Mechanobiology, 16,
pp.1-16, 2017
2. M. Yousefi, K. Inthavoung, J. Tu “Effect of pMDI Spray Characteristics on
Inhaler Drug Delivery Efficiency”. Journal of Aerosol Medicine and pulmonary
Drug Delivery, 30, pp.1-14, 2017
3. M. Yousefi, K. Inthavoung, J. Tu “Micro-Particle Transport and Deposition in
the Human Oral Airway: Towards the Smart Spacer”. Journal of Aerosol Science
and Technology, 49(11), 2015.
Appendix
4. A. Yazdani, M. Normandie, M. Yousefi, M.S. Saidi, G. Ahmadi “Transport and
deposition of pharmaceutical particles in three commercial spacer-MDI combina-
tions”. Journal of Computers in Biology and Medicine, 54, p. 145-155, 2014
Collaboration Papers Published During Candidature
1. D. Yudistira, A. Boes, B. Dumas, A.R. Rezk, M. Yousefi, B.D. Rouhani, L.Y Yeo,
and A. Mitchell “Phonon-polariton entrapment in homogenous surface phonon
cavities”. Ann. Phys. (Berlin), 1-8 (2016)
2. J.E. Sader, M. Yousefi, J.R. Friend “Uncertainty in least-squares fits to the ther-
mal noise spectra of nano-mechanical resonators with applications to the atomic
force microscope”. Review of Scientific Instruments,85, 2014.
Chapter 1
Introduction
1.1 Motivation
Over the past 50 years, human activities have released many harmful gases into the air.
Particles that are inhaled every day have different properties, ranging from toxic par-
ticulate matter to drug aerosols. According to the latest report released by the World
Health Organization (WHO), the mortality rate caused by Chronic Obstructive Pul-
monary Disease or COPD has nearly doubled in the last thirty years, while the death
rate of most other major diseases has been decreasing over the same period [1]. Ac-
cording to Australian Institute of Health and Welfare, 5,051 deaths attributed to COPD
among Australian aged 55 years in 2007 and asthma is considered as the most signif-
icant health problem in Australia [2]. All evidences imply the importance of reducing
respiratory tract diseases rate, providing efficient and effective treatment to the patients
who suffer from lung diseases.
Pulmonary drug delivery has emerged as a critical method for treating respiratory dis-
ease [3–5]. Administration of drug in the form of particles through inhalation is generally
preferable in the treatment of respiratory disorders [6–8]. The main advantages of in-
halation therapy are:(i) delivering medication directly to the lungs; (ii) small amounts of
drug are sufficient to prevent or treat symptoms; (iii) adverse reactions are usually much
1
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less than those produced by systemic administration; and (iv) there is a rapid and pre-
dictable onset of action [9–11]. Nebulizers, dry powder inhalers (DPIs) and metered-dose
inhalers (MDIs) are common devices that generate fine drug particles, orally delivered
therapy targeting the lung [12].
Nebulizers produce micron size drug particles at slow velocity which can be drawn into
the lung through a mouthpiece or a face mask [13]. In comparison with other devices,
using nebulizers is easier for all ages and patients are not required to precisely coor-
dinate their breathe with the nebulizer actuation time [14]. In contrast to MDIs and
DPIs, two or more drugs in form of liquid can be mixed in the nebulizers and be inhaled
by the patient at the same time. However, compared to MDIs and DPIs, nebulizers: (i)
are not usually portable (ii) cost more, since they have more complicated mechanisms
(iii) consume more dosage to achieve the same therapeutic effect as MDIs and DPIs. In
addition, they have longer treatment time (5-10 minute in average).
In DPIs, a patient inhalation atomizes the medication powder into the fine aerosol par-
ticles [15]. In order to use DPIs efficiently, a minimum airflow rate (at least 30l/min) is
required to disperse the power into the very fine mist. DPIs are not the preferred choice
for kids, elderly and those who are severely ill, since they are mostly not able to provide
enough respiratory flow rate [14, 16, 17].
Among these devices, MDI is the preferred choice by patients for treatment of asthma
and COPD [18, 19]. Its use increased to more than 80% of the aerosol therapy devices
in the global market in 2004 [20]. Lavorini and Corrigan [21] reported that MDI has
been the most frequently prescribed inhalation device in Europe over the time period
2002-2008. However studies have shown patients experience difficulty coordinating the
timing between actuation and inhalation [14, 22–24]. Additionally, large drug particles
and high velocities [25] are produced leading to preferential particle deposition on the
oropharynx, unintended side effects, and a reduction in therapeutic effectiveness. To ad-
dress these issues, spacers are used to delay the time between actuation and inhalation
allowing patients to inhale slower drug particles more deeply to increase lung deposition
[26, 27]. Spacers introduce a chamber of dead volume between the MDI and the patient’s
mouth. Near the mouthpiece some spacers include a one-way valve, which opens during
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inhalation allowing drug particles to exit the spacer, and closes if exhalation occurs,
preventing a return of drug particles [28].
Despite inhalation therapy devices having been considerably improved in last few decades;
they remain inefficient in delivering drug to the lungs and are not convenient for all age
ranges [29]. In this research, it has been aimed to provide some solutions to improve
inhalation therapy of pMDIs and spacers efficiency using numerical methods.
1.2 Research Objectives
One of the drawbacks constantly attributed to pulmonary drug delivery is considerable
deposition in undesired locations. It has been shown that 80-95% of inhaled drug is
deposited in the upper airways and finally reaches the gastrointestinal tract which may
cause unwanted side effects [30]. On the other hand, unfavorable take-up of medication
poses health hazards to the patient.
Among all pharmaceutical administration devices, MDIs are undoubtedly the most pop-
ular of them all. Although in constant use, MDIs are known to result in poor drug take-
up efficiency. This poor efficiency is typically attributed to the fact that MDIs impart
an undesirably high initial momentum to the particles which in turn increases unwanted
deposition of the drug dosage in oral cavity and upper airways. Even a certain MDI
may produce spray jet with different characteristics and this makes assessing MDI spray
effect on drug delivery a considerable challenge. Additionally, the use of this medical
device requires coordination between the respiratory action and MDI priming. Not all
patients have the capacity to use properly a MDI. In fact, some patients may not be
able of such hand-mouth coordination skill.
In order to solve the MDI drawbacks, spacers were developed. Reports of the first spacer-
like devices date from 1956 and 1977. These add-on devices extend the distance between
MDI and patient’s mouth; and they contribute to the reduction of high velocity impact
of the spray on throat and the need for inspiration coordination [31]. Despite a great deal
of experimental and numerical studies devoted to investigating particle transport and
deposition in human upper airways, relatively little work has been conducted in order
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to better quantify the particle transport phenomena in realistic models of commercially
available spacer-inhalers. The fact that the previously utilized geometrical models are
over-simplified (inhalers and spacers’ geometries are often simplified and plastic quad-
rants which have considerable effect on the flow field are not included in the models)
puts the accuracy of prior numerical studies in question and calls for more realistic in-
vestigation.
The spacer valve design plays an important role in effectively delivering drug particles
to patient’s lung. One-way valve in a spacer slides forward during inhalation, creating
an annular air gap and allowing drug particles through. During exhalation the valve
slides back and closes off the spacer. This mechanism introduces inherent blockages in
the particle trajectories into the oral cavity. Modifying the single valve has the potential
to open a new window toward delivering drug particles to the lungs more efficiently and
smartly. This research focused primarily on developing useful and economically viable
CFD approaches, aimed at providing practical solutions to improve drug delivery effi-
ciency of inhalation therapy devices. The overall research objectives can be categorized
into three areas:
 To assess spacer single-way valve role in delivering drug particles to the lung,
 To clarify the MDI spray cone angle and velocity effect on drug delivery efficiency
to the lungs,
 To assess the potential of aerosol delivery to the human lung via surface acoustic
wave nebulization,
 To determine spacers shape and design influence on drug delivery efficiency,
The simulated results aimed to contribute to knowledge of inhalation therapy devices
functionality and performance. The results seek to provide new approaches for pharma-
ceutical industries to improve pulmonary drug delivery efficiency and reduce unwanted
side effects.
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1.3 Thesis Structure
The rationale for conducting this research, the scope and outline of this thesis have been
explained in this Chapter; 1.
Chapter 2 provides an in-depth review of the background for this research. The chapter
begins with an introduction to the anatomy and physiology of the respiratory tract and
is followed by a review of previous studies related to the research. This literature review
provides the framework and context of where the current research has developed from.
Fundamental concepts within the mathematical and numerical methodology for gas and
gas-particle flows are discussed in Chapter 3. The rationale for the chosen turbulence
model and related equations that were solved is discussed. This is followed by the de-
scription of the Lagrangian particle tracking model used and numerical solver procedure.
Chapter 4 was aimed at improving medical devices efficiency and functionality by propos-
ing a new spacer-valve innovation for targeted drug delivery based on computational
modeling. This chapter proposes a new innovative valve design based on 8-sections in
the valve which was aimed at reducing drug deposition waste in the spacer and valve;
and provides targeted drug delivery to specific lung regions. The final valve mechanism
and design was dependent on computational model predictions of inhaled particles and
its deposition sites to identify regional drug deposition in an idealized mouth-throat
model developed by Cheng et al. [32]. It was shown that by correlating the drug par-
ticle’s initial location with its final deposition site, each valve 8-sections can be opened
or closed to provide targeted drug delivery.
Chapter 5 investigates the spray angle and velocity effect on drug delivery efficiency
to the lung. Since spray injection angle and velocity can alter the pMDIs efficiency in
delivery delivering drug to the lung, a better understanding of the significance of these
factors on the drug delivery and particle deposition pattern in the human lung is neces-
sary. A general criterion was presented for efficiency of pMDI drug delivery to the lung
with regards to particles velocity and injection angle. To do so, a commercial pMDI
model attached to an idealized mouth-throat model developed by Cheng et al. [32] was
employed. The spray particle distribution from an experimental data was used to reflect
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the real pMDI spray properties.
In Chapter 6, the transport and deposition of drug particles generated by the Surface
Acoustic Wave (SAW) nebulizer placed within a spacer to an in silico human lung was
investigated, which, to date, has not been studied. While the SAW nebulizer is capable
of generating the requisite 1 − 5µm aerodynamic particle diameter necessary for the
aerosolized drug to reach the lower sections of the lung structures where the alveoli
is in contact with blood capillaries, with control over the size distribution afforded by
adjusting the power, frequency and surface characteristics of the SAW device, we was
attempted to examine using this model the possibility that the use of the spacer allows
for further tuning of the lung deposition characteristics. In particular, computational
model predictions was employed to identify sites of the regional drug deposition of the
inhaled particles in a geometrically reconstructed in silico model from CT scans of an
adult human lung that extends from the oral cavity to the 6th generation of the respira-
tory tract to show that injection positions of the SAW device in the spacer chamber play
an influential role in the drug delivery efficiency to the lung in addition to the particle
size distribution.
The thesis concludes with Chapter 7 by summarizing significant outcomes from each
research section between Chapters 4 to 6. The final sections of this chapter highlight
the potential clinical significance of this study and provide recommendations for further
study.
In Appendix A, the effectiveness of using three commercial spacers paired with a com-
mercial inhaler was examined through numerical investigation of fluid flow and particle
transport phenomena. Particles ranging from 1 to 50µm in diameter were tracked us-
ing a Lagrangian point of view and fluid flow fields are resolved using the LRNk − ω
turbulence model. A novel particle injection method was introduced and demonstrated
which enable us to adequately capture the effects of particle initial momentum. Codes
and programs for pre and post-processing are provided in Appendix B.
Chapter 2
Literature Review
2.1 Human Respiratory System
In order to have a clear picture of particle transport and deposition in the human lung,
an understanding of respiratory system structure and function is necessary. Typically,
a healthy lung of a normal adult process 10 − 25m3 of air in a day. At rest, 0.5 l air
is inhaled in a breathing cycle which occurs normally 12-20 times in a minute. During
heavy work, breathing cycle can be triple and the exchanged air in the human lung can
even be more than three times of its value at the rest condition. The inhaled air travels
through a sequence of 23 airway branches from mouth to the end of the respiratory tract.
The human lung is a branched network containing millions of airways which conducts
air to the alveolar region where the O2 −CO2 gas exchange occurs [33]. From the view
of function, the human lung can be divided into two major parts; Conducting zone and
respiratory zone. The conducting zone starts from the trachea and ends at generation
16, while the respiratory zone includes generations 17 to 23 (Figure 2.1). The average
area of the lung, where the gas exchange takes place, in a healthy adult is 75m2 which
is equal to half of a tennis court and it is covered by 2000km of capillaries [34].
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Figure 2.1: Schematic of human respiratory system [35]
2.2 Geometrical Structure
The respiratory tract can be categorized in three different sections which have significant
differences in airflow structure and sensitivity toward particle deposition. The first region
is called the extra-thoracic region which consists the nasal cavity, oral cavity, pharynx,
larynx and trachea. The second region starts from the trachea and ends at the terminal
bronchioles (16th generation) which is called the tracheo-bronchial (TB) region. This
section is like an inverted tree so that the trachea is considered as its trunk and the
branches become smaller per every branching step. From generation 17th to 23th are
considered as alveolar region. The TB and alveolar regions sometimes are called intra-
thoracic region. As it is shown in Figure 2.1, the trachea after 10 − 12cm reaches to
the two main bronchuses, then every main bronchuses is divided into the lobar bronchus
which are attached to the lobes. In all five lung lobes, there are altogether 20 pulmonary
segments which are connected to the lobar bronchus via segmental bronchus. This
branching patterns goes on until it reaches the terminal bronchiole at 16th generation.
The terminal bronchioles after 6 more generation reach to the alveolar sacs.
Several studies have shown that the average surface area of the airways is 2.5m2 [36, 37],
while the total surface area of the alveolar walls can be up to 140m2 [38], which is almost
equal to 75 times of the human body external surface. The airway wall structure in
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the TB region contains cartilage rings which stabilize the lung structure in the region
during breathing cycle. Thus, the human lung structure in this section can be assumed
unexpandable and rigid. Cartilaginous rings make the airways wall uneven which can
affect the airflow pattern and particle deposition rate [39–41].
When particles are deposited on the airways wall, regarding the deposition site, chemical
and physical properties and remain in the lung for different periods of time. The surface
of TB region is covered with a sticky, viscous layer which is called mucus. Mucus
layer, which contains deposited inhaled particles, gradually moves upward and then it
is swallowed. This cleaning process may take a few hours [33]. Considering that the
last region is responsible for the gas exchanges, airways in this area can not use mucus
as a particle cleaning mechanism. Therefore, particles which enters to this region may
remain in the lung for months or years.
2.3 Breathing Mechanism
During inhalation, the air velocity in the airways slightly increases until the lobar
branches and after that it sharply decreases which is the result of significant increase of
airflow cross section. From lobar branches to respiratory bronchioles, the airways cross
section increases by a factor of 250.
Pressure difference is the driving force in a breathing cycle. There are three main
pressures involved in the breathing process which are known as atmospheric pressure,
intrapleural pressure and intrapulmonary pressure. Atmospheric pressure, as the name
implies, is the pressure of the environment where the respiration process occurs. Intra-
pulmonary pressure refers to the air pressure within the lung. In inhalation, respiratory
muscles expand the chest cavity; results in negative intrapulmonary pressure and con-
sequently the air is drawn into the lung. In contrast, during exhalation, the respiratory
muscles return back to the normal position which makes the intrapulmonary pressure
positive and pushes the air out. Intrapleural pressure refers to the pressure within the
pleural cavity. The pleural cavity is the thin fluid-filled space between the two pleurae
(visceral and parietal) of each lung. Left and right pleural cavities surround the left and
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right lungs respectively. Normally, the pressure within the pleural cavity is slightly less
than the atmospheric pressure [42, 43].
Nose and mouth are the first point of contacts of the inhaled air with the respiratory
tract. Nose breathing is the correct and most optimal way to breathe. The switch from
nasal to oronasal breathing with increasing respiratory ventilation results in a substan-
tial portion of air being inhaled through the mouth. While mouth breathers breathed
oronasally down to ventilation rates of 9 l/min, normal nose breathers were found to
switch from 100% nasal breathing to 43% mouth breathing at a ventilation rate of 35
l/min [44]. At this total ventilation rate (35 l/min), oral ventilation is 15 l/min. This
corresponds to an average inspiratory flow rate of 30 l/min because inspiration occurs
50% of the time [32]. To cover different breathing conditions and regimes, 15, 30 and 60
l/min (representing resting, light and heavy exercise) airflow rates are normally consid-
ered for CFD simulations of airflow and particle transport in human lung [45]. However,
lung diseases may affect these values, which is not in the scope of this study. Although
the airflow regime in the trachea and main bronchus in the maximum breathing rate and
for a normal breathing pattern can be turbulent, the airflow regime in other airways is
laminar. Regarding that the length of airways compare to their diameter is short, the
airflow can not reach to the fully developed conditions.
2.4 Lung Structure
Upper respiratory tract
As shown in Figure 2.1, the upper respiratory tract or the extra-thoracic region is the
first barrier of human respiratory system against inhaled particles. However, this region
plays a significant role in improving drug delivering to the human lung. Extra-thoracic
can be divided into two sub-regions: Oral airway and Nasal airway Figure 2.2. Generally
Extra-thoracic ends at trachea, however in some studies a few branches in the trachea-
bronchial were considered in the extra-thoracic region [46–48]. The extra-thoracic region
complicated geometry is one of the significant challenges in studying particle transport
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and deposition in this area. These geometrical complexities include airway bends and
sudden cross sectional changes which can change the turbulence level of inhaled air
[49, 50].
In order to study particle deposition in the upper airway, in 1999 Cheng, et al. [51]
Figure 2.2: Sagittal section of the Extra-thoracic (©2010 Encyclopedia Britannica,
Inc.)
introduced a model including oral cavity, pharynx, larynx, trachea and three bifurcations
of the tracheo-bronchial section. Using Cheng model, Kleinstreuer, et al. [47] introduced
a mouth-throat model with variable cross section to study particle deposition in the oral
cavity and avoid significant error caused by over simplified models. In this model, the
region from oral cavity to the larynx was simplified as a nearly 180◦ bend which was
already proposed by Cheng, et al. [51]. Kleinstreuer modeled the mouth inlet as a
tube with 2cm diameter and modified soft palate section. This model has been used
in series of researches by Kleinstreuer group [35, 47, 50, 52–54]. Another noticeable
model was proposed by Stapleton, et al. [55] to study aerosol particle transport and
deposition in the upper airway. This model was developed using information provided
by literature [56–59] and data obtained from CT-scan and MRI [55]. It has been used
in many experimental and numerical studies of airflow pattern and particle transport in
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Figure 2.3: The simplified oral airway model with Kleinstruer modification [47]
the upper airway [60–67]. In contrast to Kleinstreuer model, in this model the airway
cross section is not circular and the geometry is more close to the upper airway realistic
and anatomical structure. In addition, the pharynx region is modeled as a elliptical
cylinder [47].
Xi and Longest [68] studied four different models of upper airway to evaluate the effect of
geometry on the airflow field and particle deposition. They compared a realistic model
constructed using CT-scan data with three simplified geometrical models with elliptical,
variable and constant circular cross sections. They found the regional deposition for all
four models when plotted against Stokes number are approximately within one standard
deviation of available experimental data. However, the deposition curve when plotted
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as a function of particle diameter shows the best consistency with experimental data for
the realistic geometry.
Figure 2.4: Geometric surface models of the extrathoracic oral airway including the:
(a) realistic, (b) elliptic, (c) circular, and (d) constant-diameter models. [68]
The geometry used in chapters 6 and 5 was adopted from Cheng, et al. [51] with
Kleinstreuer, et al. modification [47]. Although the upper airway geometry exhibits
inter-subject variability, and even varies in a single person with age, there are common
gross geometrical features that are persistent among all airway models, which dominate
the flow field. This includes the arch in the oral cavity, the 90-degree bend into the
pharynx, and the converging-diverging cross-sectional area at the larynx.
2.4.1 Lower respiratory tract
The lung geometry after the trachea is more complicated than upper airways. In order
to have a better understanding of lung structure, some simplified models with different
level of complexities have been developed so far. In general, almost all lung geometrical
structures start from trachea as a main branch and then it is divided to two other
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branches which are called daughter branches. This branching pattern goes on till the
last airway in the alveolar region. Every branching step is called a generation. The first
generation includes the trachea and two main bronchuses. The size and angle between
daughter branches and the parent branch vary based on different models models (Figure
2.5).
Figure 2.5: A schematic drawing of the lungs and airway tree in which several anatom-
ical structures are indicated. Image adapted from Wikipedia
2.4.2 CT-Scan based models
Improving medical imaging techniques such as Compute Tomography (CT) and Magnetic
Resonant Imaging (MRI) have enabled researches to build a real lung model [49, 69].
CT outlines the bones accurately and it is suitable for lung and chest imaging, while
MRI highlights different tissue using the images contrast level. CT scan is cheaper than
MRI can is commonly used in lung examination, so the most of the lung models are
constructed using data obtained from CT scan. Considering significant improvements
in 3D-printing industry, CT-scan data are getting more attention by scientists in order
to carry out experimental investigations in a 3D-printed lung model [49, 65] or numerical
simulation in a real 3D CAD-model [70–72].
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Figure 2.6: An axial slice of a CT scan with labeled anatomical structures [73].
Although medical imaging technique helps investigators in having a more real lung model
to carry out the numerical simulation; CT/MRI image resolution is not high enough to
give a clear picture of bronchial-tree after generation 6th or 8th. A CT-Scan lung model
,extending from oral cavity to 6th generation, is used in Chapter 7 to investigate the
drug particles transport and deposition.
2.5 Inhalation Therapy Devices
Drug delivery in form of aerosols has played an important role in medical treatment
since 1930’s [74–76]. Administration of drug in the form of particles through inhalation is
generally preferable in the treatment of respiratory disorders [6–8]. The main advantages
of aerosol therapy over intravenous therapy are:(i) Delivers medication directly to the
lungs; (ii) small amounts of drug suffice to prevent or treat symptoms; (iii) adverse
reactions are usually much less than those produced by systemic administration; and
(iv) there is a rapid and predictable onset of action [9, 11, 77, 78].
Aerosolized drug can be either liquid droplets or solid particles. The effect of inhaled
particles depend on their solubility and size. In general, the size of pharmaceutical
inhaled particles is recommended to be between 1 − 5µm in diameter to permit the
medication reach lower sections of the lung structures where the lung is in contact with
blood capillaries [79]. Although the particle sizes is a key parameter in drug delivery
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through inhalation, the airflow structure and breathing pattern has a important effect
on drug delivery efficiency [80].
Among all current aerosol therapy devices MDIs, nebulizers and DPIs are more common
and popular, however the drug delivery efficiency in average reaches 5%-30% for all
aerosol-delivery methods [9, 81–85]. In general, nebulizers produce micron size drug
particles at slow velocity which can be drawn into the lung through a mouthpiece or
a face mask [13]. In comparison with other devices, using nebulizers is more easier
for all ages and patients are not required to precisely coordinate their breathe with
the nebulizer actuation time [14]. In MDIs, patients do not need to breathe fast and
deep; although in order to increase the aerosol therapy efficiency, coordination between
breathing time and MDI activation is required [16]. A general procedure is asked patients
to follow in using a MDI is, breathing in a normal way (30 l/min), then actuate the
MDI and holding the breath for 10 seconds. High speed jet of drug particles along
with the cold propellant gas used in MDI make coordinating the breathing with MDI
actuation difficult. Spacers are hollow chambers which are placed between the MDIs
and the patients mouth in order to lower the spray velocity and reduce the discomfort
of the cold propellant gas [86]. Investigations using radiolabled aerosol particles have
shown that the high inspiration rate results in poor drug delivery efficiency and the slow
inspiration leads to more homogeneous distribution of drug particle into the lung [87].
The main features of the three significant aerosol therapy devices are summarized in
Table2.1.
Table 2.1: Characteristics of medical aerosol generators [9]
MDI DPI Nebuliser
Technique of generation of aerosol Propellant based Patient driven flow Bernoulli’s principle
Particle size 1− 10µm 1− 10µm Variable
Drug deposition 5-10% 9-30% 2-10%
Oropharygeal deposition Significant Variable Insignificant
Patient coordination Required Not applicable Not Required
Breath hold Required Not Required Not Required
Patient generation of flow Not Required Required Not Required
Amount of drug Small doses only Small doses only Large doses possible
Contamination No No Possible
Use for chronic therapy Yes Yes Rarely
Use for emergency management No No Yes
Use for intubated patients Preferred No Second choice
Cost Cheap Cheap Expensive
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2.5.1 Nebulizers
Nebulizers are preferred in clinical centers and home for patients who suffer from severe
asthma [15, 88]. There are two types of nebulizers: jet nebulizer and ultrasonic nebu-
lizer. In jet nebulizer,a high-velocity air jet from a pressurized chamber is directed to a
thin layer of drug suspension; resulting in an atomized therapeutic mist. In ultrasonic
nebulizer, vibration of a piezoelectric crystal atomizes the liquid drug; however ultra-
sonic nebulizers are not very popular compared to jet nebulizers. Ultrasonic nebulizers
are more expensive, not disposable and usually can not produce a continuous atomized
aerosol if the volume of the drug liquid reservoir falls below a certain value. Further-
more, they might not be able to atomize viscous drug suspensions [89], and mechanical
vibration of piezoelectric substrate may damage structure and formulation of certain
drugs [90]. In general, nebulizers like MDIs and DPIs are inefficient and most of atom-
Figure 2.7: A typical jet nebulizer
ized drug deposit in the apparatus and the tubing, however they are able to administer
drug up to 10 times more that MDIs, DPIs or even MDI with spacer. In comparison
to MDIs and DPIs, nebulizers: (i) usually are not portable, although there are some
potable, battery-powered nebulizers in the market (ii) cost more, since they have more
complicated mechanisms and in the clinical centers well-trained personnel should assist
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patients to use it (iii) consume more dosage to achieve the same therapeutic effect as
MDIs and DPIs. In addition, they have longer treatment time (5-10 minute in average).
In contrast to MDIs and DPIs, two or more drugs in form of liquid can be mixed in the
nebulizers and be inhaled by patient at the same time.
2.5.2 Dry Powder Inhalers (DPIs)
In DPIs, patient respiration flow atomizes the medication powder into the fine aerosol
particles [15]. In order to use DPIs efficiently, a minimum airflow rate (at least 30l/min)
is required to disperse the powder into a very fine mist. DPIs are not the preferred
choice for kids, elderly and those who are severally ill, since they are mostly not able
to provide enough respiratory flow rate [14, 16, 17]. In addition, the released power
may discomfort the patient. DPIs are small and portable, and there is no need to use
spacers. Like MDIs and nebulizers they have low drug delivery efficiency, and most of
the atomized drug deposit in the DPIs. It is reported that for a certain drug, MDIs
and DPIs have same efficiency in drug delivery [15]. However the inhalers efficiency
is strongly depend on the patient’s skill in using inhaler. It is estimated that at least
50%-60% of the patients are not able to use DPIs properly [91].
Figure 2.8: A typical dry powder inhaler
2.5.3 Metered Dose Inhalers (MDIs)
MDIs are the most popular aerosol therapy device in the world and it is reported that
roughly 800 million units of MDI were produced in 2000 [92, 93], and they were consti-
tuted more than 80% of the global market in 2004 [20]. The drug either in solution or
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as a suspension of particles mixed with a liquid propellant (usually a CFC or HFA) is
stored in a canister (normally 15-30ml) at a pressure of 2-5 bar [94, 95]. By actuation of
the MDI, the pressurized liquid medication is exposed to the ambient temperature and
pressure resulting in the liquid medication evaporating into an aerosol cloud. Actuation
of the device triggers the release of single metered dose of liquid propellant that contains
the medication [96, 97].
Figure 2.9: A schematic of a typical MDI
The drug solid particles are encapsulated in a liquid cover, which evaporates as the
droplets travels through the air. CFCs were used as propellant in the first MDIs. CFCs
have high stability level and are known as non-toxic, non-flammable and non-reactive
chemical. However, the use of CFCs raised many concerns regarding significant damaged
of the ozone layer. Thus, researchers and pharmaceutical industries replaced the CFCs
by more environmentally friendly hydrofluoroalkane propellant (HFA). In Table 2.2,
some significant physiochemical properties of two main propellants in the MDIs, CFC-
12 and HFA-134a, are listed. In order to deliver the same dosage as CFC-MDIs, the
metering valve of MDIs with HFA as propellant, is required to be redesigned [98, 99].
In general, HFA-MDIs produce more fine particles than CFC-base MDIs [92, 100].
 Spray droplets characteristics
The canister pressure is a very significant factor in designing MDIs, since it influ-
ences the atomized droplet distribution and the shape of the plume. The higher
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Table 2.2: Some physiochemical properties of two main pMDI propellant[93]
Property CFC-12 HFA-134a
Boiling point (°C) -29.8 -26.3
Vapor pressure(kPa) 556 572
Density(g/cm3) 1.33 1.23
Velocity(mPa.s) 0.20 0.21
Surface tension (mN/m2) 9 8
Dielectric constant 2.1 9.5
Water solubility (ppm) 120 2200
pressure level results in higher spray velocity, consequently faster droplet evapo-
ration rate [93]. The smaller actuator orifice produce a finer spray and generate a
slower moving aerosol cloud over longer does emission period [101]. In spite of sim-
ilar plume geometry, HFA-MDIs have slower plume velocity than CFC-MDIs [102].
Based on empirical results Clark [103, 104] developed a correlation to calculate the
MMD of the particle distribution for both CFC and HFA MDIs [93, 105, 106].
D0.5 =
8.02
q0.56ec [(pec − p∞)/p∞]0.46
(2.1)
where D0.5 represents MMD, qec is a flow quality parameter for the mass mean
diameter of the particle which is also used in the Rosin-Rammler distribution,
pec is the pressure in the expansion chamber and the qinf represents the ambient
pressure. Equation 2.1 shows how MDIs geometrical properties and the propellant
gas influence the spray shape.
fine-particle fraction(%) = 2.1× 10−5A−1.5V −0.25C3134 (2.2)
where A, represents the actuator nozzle diameter (in mm), V is the meter volume
size (in µl) and C134 is the fraction of the HFA in the canister (in percent).
 Spray Velocity
Spray droplet velocity varies regarding their position in the spray plume. Droplets
at the center of the spray cone have the maximum velocity and it decreases with the
Chapter 2. Literature Review 21
(a) Droplet velocity vectors represented in half of a mid-section plane measured at the last
moment of the actuation
(b) Droplet mean velocity along the axial distance from the nozzle
Figure 2.10: Velocity profile for a pMDI with HFA-134a as propellant [105]
distance from the spray cone centerline and also from the injection nozzle. Figure
2.10 shows axial and radial velocity profile for a typical HFA-pMDI [105, 106].
2.5.4 Spacers
Some factors influence the efficiency of MDIs in drug delivery to the patient’s lung. Poor
inhalation technique is one of the key elements in using MDIs and it is reported that up
to 90% of the patients are not able to use MDIs properly [21, 107–109]. Furthermore,
synchronizing the MDI actuation with the inspiration is important to take the aerosolized
drug into the lung which is very common problem among patient’s [110]. Moreover, cold
Freon effect is another challenge that makes using the MDIs difficult. In CFC-MDIs the
cold freon gas with high velocity ( 150 m/s) flashes out of the canister which makes
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inhalation difficult for the patient’s. As a result, the patient will not be able to follow
the right procedure in using MDI [8, 111]. Several studies have shown that improving
the patient’s inhalation technique in using aerosol therapy devices is more important
than improving the medication [10, 109, 112, 113].
Spacers are chambers which increases the distance between the MDI and patient’s mouth
and help patients improve the inhalation technique (Figure 2.11). These devices lower
the spray velocity and give more time to the drug droplets before being inhaled by
the patient which results in more evaporation rate and more fine particles [8, 114–117].
Studies have shown the increasing the spacer’s volume, enhance their efficiency; however
making spacers bigger makes using it difficult.
Figure 2.11: A typical Volumetric spacer in the market
Figure 2.12: Drug particle distribution in the human respiratory system with MDI
and MDI-Spacer (Respironics Inc.)
There are different spacers in the market. The Nebuhaler and Volumatic have large
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chambers (about 750 mL), the Inspir–Ease is a 400 mL collapsible bag, and the Ae-
rochamber has a volume of approximately 130mL. Skilstone, et al. [118] reported that
salbutamol MDI attached to a Volumetric spacer deliver 2.3 times more efficient than a
MDI alone used with a well-trained technique. Another study showed that using spacer
with MDI can decrease the oropharyngeal deposition from 81% to 17% and increase
the lung deposition from 8.7% to 21 % with 56% of the dosage deposited in the spacer
[119]. In general, the bigger spacers are more efficient in drug delivery to the lung [120];
however increasing the spacer size challenges its potability and ease of use. Combination
of spacer/MDI can be a good replacement for nebulizers in treatment of sever asthma
or COPD.
Although spacers do not guarantee higher lung delivery, they always decrease oropha-
ryngeal deposition. Spacers can minimize the amount of drug reaching gastrointestinal
tract, thus helping to prevent both systemic (adrenal suppression) and local oropharyn-
geal side effects (thrush and dysphonia) [97, 116, 121]. Different factors are known to
influence the spacer’s efficiency including: (i) spacer volume, as it is mentioned increas-
ing the spacer volume improves the delivery to the lung [122] (ii) electrostatic charge
which is reported can alter the delivered medication in the plastic spacers and reduction
in electrostatic charge can lead to 10-35% improvement in drug delivery [123, 124] (iii)
the spacer valve, which will be discussed in the next chapter exclusivity (iv) the shape
of spacer (v) breathing pattern and (iv) drug/spacer combination.
Chapter 3
Numerical Simulation
Methodology
3.1 Gas Phase Modeling
During past few decades the Computational Fluid Dynamics (CFD) has emerged as a
powerful tool for capturing both airflow and particle transport characteristics in human
airways. CFD is fundamentally based on the governing equations of fluid dynamics.
They represent mathematical statements of the conservation laws of physics [125]. CFD
simulations can be used to directly address complicated, interconnected geometrical and
physical factors related to both particles and airflow, such as flow turbulence [126],
breathing patterns [127], the impact of discrete particles on continuous phase [128], and
Brownian motion of particles [129]. For different physics and scenarios Navier-Stokes
equations can be rearranged and simplified in different forms.
The general objective of this research is to study transport and deposition of therapeutic
particles atomized from a commercially available MDI in combination of the commercial
spacers and the simplified real human upper airway model. The airflow is practically
24
Chapter 3. Methodology 25
transient due to both transient nature of breathing and transient delivery of drug par-
ticles to the spacer inlet. Despite transient nature of breathing and therefore transient
transport of particles, it is well established that steady-state simulations using average
flow rates are computationally efficient and able to provide average deposition patterns
that are in good agreement with in vivo and in vitro experimental results [65, 126].The
transient drug delivery can also be approximate as being steady, at least within the
scope of the present work. Jin, et al. [130] reported the steady and unsteady of par-
ticle deposition efficiency in the upper airway extending from oral cavity to the main
bronchus using LES. Results showed that the deposition efficiency in unsteady simula-
tion is 5% higher than steady simulation for particles dp = 5µm, particle ρp = 600kg/m
3
and airflow of 60 l/min (Fig. 3.1).
Figure 3.1: Comparison of particles DEs between unsteady respiration mode and
steady respiration mode at the case of particle diameter dp = 5µm; particle density
ρp = 600kg/m
3 and breathing intensity Q=60 l/min [130]
Based on the flow Reynolds number, for an inhalation flow rate of 30 lpm and geometrical
irregularities associated with the inhaler and spacers, laminar to transitional and even
fully turbulent flow is expected [131]. To resolve these multiple flow regimes, the low
Reynolds number (LRN) k−ω model is adopted based on its ability to accurately predict
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pressure drop, velocity profiles, and shear stresses for transitional and turbulent flows
[132]. This model has been used successfully to accurately predict particle deposition
profiles for transitional and turbulent flows in models of the oral airway [133] and multiple
bifurcations [126, 134].
3.1.1 Turbulent Modeling
The k − ω turbulence model with low-Reynolds number (LRN) corrections proven to
successfully predict the average velocity profiles, pressure drop, and the shear stresses in
the multi-regime flow field in human airways [126, 134]. The Reynolds-averaged Navier-
Stokes equations governing the conservation of mass and momentum in incompressible
laminar and turbulent fluid flows are represented as Equations 3.1-3.2 [135].
∂ui
∂uj
= 0 (3.1)
∂ui
∂t
+ uj
∂ui
∂xj
= −1
ρ
∂p
∂xi
+
∂
∂xi
[
(ν + νT )
(
∂ui
∂xj
+
∂uj
∂ui
)]
(3.2)
where,ui is time-averaged velocity in the direction referred to by index i(i=1, 2, and 3
for a 3-D field), p the time averaged static pressure,ρ the fluid specific mass, and ν the
kinematic viscosity. The turbulent kinematic viscosity, νT , is as given in Equation 3.3,
in which cµ is a constant with an accepted value of 0.09, and fµ is a function of RT =
k
νω
as defined in Equation 3.4.
νT = cµ fµ
k
ω
(3.3)
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fµ = exp
− 3.4(
1 + RT50
)2
 (3.4)
In the k − ω turbulence model two parameters are defined in order to account for the
turbulent nature of the flow field. These parameters are namely turbulence kinetic
energy, k, and turbulent dissipation rate, ω. These parameters characterize the kinetic
energy associated with the turbulent velocity fluctuations, and the viscous dissipation
rate due to turbulent shear stresses, respectively. The equations governing the transport
of the aforementioned turbulence parameters are given in Equations 3.5-3.6.
∂k
∂t
+ uj
∂k
∂xj
= τij
∂ui
∂xj
− β∗ k ω + ∂
∂xj
[
(ν + σk νT )
(
∂k
∂xj
)]
(3.5)
∂ω
∂t
+ uj
∂ω
∂xj
= α
ω
k
τij
∂ui
∂xj
− βω2 + ∂
∂xj
[
(ν + σk νT )
(
∂ω
∂xj
)]
(3.6)
In which τij is Reynolds stress tensor, and β
∗, σk , α, β, and σω are constants with
accepted values of 1.0, 0.5, 0.555, 0.8333, and 0.5, respectively. The initial boundary
values of parameters k and ω are often determined using empirical correlations, two of
which are given in Equations 3.7-3.8 [136].
k = 1.5 (I × uin) (3.7)
ω =
k1.5
0.6Rh
(3.8)
where, I, uin and Rh are upstream turbulence intensity, average velocity magnitude at
the relevant boundary, and hydraulic radius of the boundary, respectively.
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3.2 Particle Transport and Deposition
3.2.1 Particle Dynamics Theory
Microscopic particles in the air not only have different visibility level, but also can affect
human life’s quality differently [137]. In general, solid or liquid particles suspended in
a gas is called aerosol. Aerosols are two-phase systems which are involved in creating
various natural phenomena like dust, fog, fume etc.
In order to understand the aerosol motion, analyzing the behavior of its components
is required. The most common motion of particle is the uniform motion on a straight
path. This kind of motion is due to superposition of two forces, one external force
like gravitational or electrical force and the second one is gaseous phase resistant force
against particle’s motion. Since in many applications aerosol particles move nearly with
constant velocity, study of particle uniform motion is the base of analysis of particles
behavior in the aerosol. The gas resistant force against particles depends on the relative
velocity between the gas and particle. Newton’s equation is derived based on the force
interaction between an obstacle moving in a gas. On the other hand, the resistant force
which is experienced by the obstacle is the result of accelerating the gas around the
obstacle. The mass flow rate of a gas moving around a spherical obstacle is obtained
as,m˙ = ρg
pi
4d
2V , where d is the obstacle diameter, V is its velocity and ρg is the gas
density. The gas acceleration is proportional to relative velocity between the spherical
obstacle and the gas, thus changing of the momentum per second is, ∝ m˙V = ρg pi4d2V 2.
This momentum changing rate is equal to the force which is required to move a spherical
obstacle in the gas, so the resistant force or the drag force can be expressed as follow:
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FD = K
pi
4
ρgd
2V 2 (3.9)
where K is the coefficient of proportionality. Newton figured out that this coefficient
for a certain shape is independent of velocity. This principle is true for objects with
Re > 1000. Equation 3.9 is the Newton’s law. The general form of this equation is,
FD = CD
pi
8ρgd
2V 2. This general equation is valid for all objects moving in a gas in the
subsonic regime. The drag coefficient for Re > 1000 is constant, but for Re < 1000
it changes as shown in Figure 3.2. Drag coefficient curve in Figure 3.2 is true only for
spherical shapes, however other shapes have a similar curve. Newton’s law is true for
1000 < Re < 2 × 105 and drag coefficient is nearly constant Cd = 0.44. In order to
calculate the drag coefficient for particles which are in the range of Re < 1000, Reynolds
number is required. Since most of the time the particle diameter and velocity are
unknown, particle Reynolds number can not be calculated before solving the problem.
On the left side of log-log drag curve in Figure 3.2, there is a region which drag coefficient
changes linearly versus Reynolds number. This section is called Stokes. Between two
distinguishable linear areas of the curve, i.e. Stokes zone and Newtonian zone, there is
a non-linear transient zone which the drag coefficient is expressed as follow:
CD =
24
Re
(
1 + 0.15Re0.687
)
(3.10)
This formula is obtained by Clifft, et al. in 1978 and shows a very good consistency
with empirical relationship [138]. The discrepancy between theoretical and empirical
relationship for Re < 800 is 4% and for Re < 1000 is only 7%. Newtonian drag (Re >
10000) is applied to the particles where the viscous force is negligible in compare to
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inertial force. In 1851, Stokes introduced a relationship to calculate the drag force for
low-Reynolds regimes. Unlike Newtonian zone, in low-Reynold regime inertial force
can be neglected in compare to viscous force. Due to the particles small size and low
velocity, particle motion mostly occurs in the low-Reynolds regime. Thus Stokes low is
widely used in aerosol study. Stokes law is derived from the Navier-Stokes equation for a
spherical particle in the free stream and far from rigid boundaries in a very low Reynolds
and incompressible flow with the no-slip condition on the particle surface. Using the
assumptions are mentioned above, the net force can be calculated by integration of
normal and tangential forces on the particle surface. The force normal component is,
Fn = piηV d and the tangential component is Ft = 2piηV d. So, the total resistant force
acting against particle motion in a fluid is:
FD = 3piηV d (3.11)
Equation 3.11 is called Stokes law.
Figure 3.2: Variations of drag coefficient with Reynolds number for a spherical particle
Particle motion pushes the surrounding fluid away. Fluid layers around the particle slides
on each other, consequently exerting frictional force to the particle surface. In practice,
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Stokes law is applicable for Re < 1. Error in drag force calculation for particles with
Re = 0.3 and Re = 1 reaches 5% and 12%. Newtonian force action on a particle is equal
to the drag force obtained from Stokes law, so:
FD = 3piηV d = CD
pi
8
ρgd
2V 2 Re < 1 (3.12)
Stokes law considers fluid viscous effect, however the Newton’s equation represents par-
ticle inertial force and contains ρg. By solving Equation 3.12 the drag coefficient in the
Stokes zone will be obtained.
CD =
24η
ρgV d
=
24
Re
(3.13)
Equation 3.13 which contains V and d, represents the linear region on the left side of
the drag coefficient curve(Figure 3.2).The drag force in the Newtonian zone of the curve
is proportional to the d2 and V 2. For the transient zone, a correlation is required which
is able to change the drag coefficient dependency from V 2 to V and from d2 to d or vice
versa. Drag coefficient in the transient zone is calculated using Equation 3.10. One of
the main benefits of Stokes Law is finding the particle settling velocity in the stationary
air. This occurs when the gravity force equals the drag force, FD = FG = mg, so
3piηV d =
(ρp−ρg)pid3g
6 . where g is the gravity acceleration and ρg is the gas density. The
buoyancy force is considered in the drag-gravity balance above, however it is negligible
when ρp is much bigger than ρg. For instance, for water droplet in the air
ρp
ρg
= 800 and
ignoring the buoyancy force can result in 1% error in calculating settling velocity. Using
the above equation, the settling velocity can be calculated as:
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VTS =
ρpd
2g
18η
for dp < 1µm and Rep < 1.0 (3.14)
As VTS is proportional to the square of particle diameter, it increases very quickly with
particle diameter. Also regarding Equation 3.14, settling velocity is proportional to
the gas viscosity inversely and it is not related to the gas density. In the following
sections it will be shown that aerosol particles reach to the settling velocity instantly.
The above equation is not applicable for particles smaller than 1µm, unless the slip
correction factor be considered. A simple form of for spherical particle with standard
density (ρ = 1000 kg/m3) in the standard conditions can be represents as, VTS ∼=
3 × 10−5 1µm < dp < 100µm, where d is in µm. Settling velocity for other external
forces can be calculated similar to the gravity force. Settling velocity of a particle in the
a centrifugal force field is equal to, VTS =
ρpd2ac
18µ , which ac is the particle acceleration
(ac =
V 2T
R ), where VT is the tangential velocity of the particle and R is the radius of the
particle path.
An important assumption of Stokes law is that the gas at particle surface has zero
velocity relative to the particle. This assumption holds well when the particle has a
diameter much larger than the mean free path of gas molecules. The mean free path
is the average distance traveled by a gas molecule between two successive collisions. In
analyses of the interaction between gas molecules and particles, it is convenient to use
the Knudsen number (Kn), a dimensionless number defined as the ratio of the mean
free path to particle radius (2λdp ). For Kn of the order of unity or larger, the drag force
is smaller than predicted by Stokes law. Conventionally this condition is described as
a result of slip on the particle surface. To account for this effect, Cunningham has
proposed a correction factor [139]:
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Cc = 1 + 1.26Kn (3.15)
and
FD =
3piηV d
Cc
(3.16)
where λ is the gas mean free path.
Cunningham correction factor extends applicability range of Stokes law to the particles
smaller than 1µm. Following empirical equation is obtained by Allen and Rabbe for oil
droplets in 1982 [140] and solid particles in 1985 for all particle sizes [141] :
Cc = 1 +
λ
d
[
2.34 + 1.05exp
(
−0.39d
λ
)]
(3.17)
Slip correction factor for a 1µm particle in standard conditions is 1.15 which shows that
this particle reaches to the setting velocity 15% faster than what Stokes law predicts.
For particle with diameter less than 1µm, slip effect sharply increases when particles
become smaller and correction factor should be considered in the particle calculations
[142, 143]. Regarding this fact that decreasing the pressure increases the gas molecules
mean free path, the slip correction factor including the pressure effect can be calculated
as:
Cc = 1 +
1
Pd
[15.60 + 7.00exp(−0.059Pd)] (3.18)
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which p is total pressure in Kpa and d is particle diameter in µm. Since in this research
only particles above 1µm were studied in all simulations, the slip correction factor is set
to 1. Above equation shows the relationship between the slip correction factor and the
pressure, and it gives the slip correction factor for non-standard pressures. However,
the pressure is not directly in the Stokes law, it can affect the the gas mean free path
which in turns influence the small particles settling velocity. As it is shown in Table.3.1,
increasing the gas pressure changes settling velocity of small particles (dp < 0.1µm)
significantly.
Table 3.1: Settling velocity changes versus pressure [34]
Particle diameter(µm) Settling velocity (m/s)
P=0.1 atm P=1.0 atm P=10 atm
0.001 6.9× 10−8 6.9× 10−9 6.9× 10−10
0.01 6.9× 10−7 7× 10−8 8.7× 10−9
0.1 7× 10−6 8.8× 10−7 3.5× 10−7
1 8.8× 10−5 3.5× 10−5 3.1× 10−5
10 0.0035 0.0031 0.0029
100 0.29 0.25 0.17
To account for the effect of the shape of non-spherical particles, a correction factor
known as the dynamic shape factor, χ, is applied to Stokes’ law. It is defined as the
ratio of the resistive force of the irregular particle to that of a spherical particle with
the same volume and velocity:
χ =
FD
3piηV dp
(3.19)
The pharmaceutical companies typically use aerodynamic diameter, to characterize par-
ticles in inhalable drugs. The aerodynamic diameter of an irregular particle, da, is
defined as a diameter of the spherical particle with standard density (1000 kg/m3) and
the same settling velocity as the irregular particle. Neglecting the slip correction, the
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particle settles at the terminal velocity proportional to the square of the aerodynamic
diameter, da:
VTS =
ρ0d
2
ag
18µ
(3.20)
where, ρ0 = 1000kg/m
3, standard particle density. This equation gives the aerodynamic
diameter:
da = dp
(
ρp
ρ0χ
)1/2
(3.21)
In the ambient air, particles are normally in the size range of 10nm-100µm. PMsize in µm
formate is used to show particles category regards to the size. For example, respirable
suspended particle (RSP) which are smaller than 10µm is shown like PM10. Particles
smaller than 2.5µm (PM2.5) can be drawn deep into the lungs generally described as fine
particles. By way of comparison, a human hair is about 100µ, so roughly 40 fine particles
could be placed on its width. Generally particles smaller than 1µm are categorized as
sub-micron particles (PM1). All particles with diameter less than 10nm down to the
size of molecules are categorized as unltrafine particles.
3.2.2 Aerosol Distribution Characteristics
An aerosol consisting of the same size is called a monodisperse aerosol, otherwise is called
a polydisperse aerosol. Ambient aerosols are polydisperse, and monodisperse aerosols
can be carefully produced in the laboratory. Particle sizes in a polydisperse aerosol
can range over two or more order of magnitudes, so statistical means are required to
describe particle size distribution in a polydisperse aerosol. Aerosol sampling devices
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mostly measure the bulk properties of aerosol in a predefined range of particle size. To
calculate aerosol size distribution parameters, the collected property in each size range
should be divided by the number of particles exist in that category. The final step is
presenting the aerosol property in form of the fraction of particles per unit size of the
interval.
The Count Median Diameter (CMD) and Mass Median Diameter (MMD) are two sig-
nificant characteristics of an aerosol. By definition, the half of the total number of
particles in the aerosol are bigger than CMD. Similarly, the half of the total mass of
the aerosol particles belong to the particles which are bigger than MMD. The Probabil-
ity Density function (PDF) or Cumulative Distribution Function (CDF) are two useful
mathematical definition in the representing of the aerosols dispersion function.
 Log-normal distribution
Since in reality, most aerosol particle distributions are skewed (long tail at large
sizes), normal distribution function is rarely used to describe aerosols particle size
characteristics. Assuming that the logarithms of particle diameter are normally
distributed, log-normal distribution can represent most ploydisperse aerosols well.
The general form of PDF of log-normal distribution is:
f(dp;σ, µ) =
1√
2pidpσ
exp
[
−(ln dp − µ)
2
2σ2
]
(3.22)
where µ and σ respectively are, natural logarithm of the count median diameter
(ln CMD) and geometric standard deviation (ln GSD). For log-normal count distri-
bution of spherical particles all having same density, the geometric mean diameter
and CMD have the same value and are equal to CMD = eµ and geometric standard
deviation is GSD = eσ. The Mode diameter which is the point of the maximum of
Chapter 3. Methodology 37
the density function is eµ−σ2 . GSD is a measure of the spread of the aerodynamic
particle size distribution. One of the benefits of log-normal distribution is that
GSD stays constant in number, surface and mass distributions. GSD is typically
calculated as follow:
GSD =
(
d84
d16
)1/2
(3.23)
where d84 and d16 represent the diameters at which 84% and 16% of the aerosol
mass are contained, respectively, in diameters less than these diameters. some
log-normal distribution for different µ and σ are shown in Figure 3.3.
Figure 3.3: Some log-normal density functions with identical location parameter µ
but differing scale parameters σ [34]
All distributions are known, when one distribution parameters have been obtained.
For example, MMD (for mass distribution) can be calculated using CMD (from
count distribution):
MMD = CMD exp
(
3 ln2 GSD
)
(3.24)
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Another useful parameter in aerosol study is Mass Median Aerodynamic Diameter
(MMAD) which can be calculated as follow:
MMAD =
√
ρpMMD (3.25)
where ρp is the particle density in g/cm
3. So, the total number of spherical aerosol
particles in a distribution using MMAD and GSD can be calculated as follow:
N =
6Mp
√
ρ exp
(
4.5 ln2 GSD
)
pi(MMAD)3
(3.26)
where Mp is the mass of the total particles.
 Rosin-Rammler distribution
Rosin-Rammler is widely used in mineral processing to describe particle size distri-
butions. Figure 3.4 shows the sample data obtained from a aerosol sampling device
and three distribution functions including normal, log-normal and Rosin-Rammler
models.
In general, the Rosin-Rammler distribution function is based on the assumption
that an exponential relationship exists between the particle diameter, dp, and the
mass fraction of particles with diameter greater than dp. The probability density
function of a Rosin-Rammler is:
F (dp;λ, n) = 1− exp
[
−
(
dp
λ
)n]
(3.27)
where n > 0 and λ > 0 are called shape and scale parameter of the distribution,
respectively. ’n’ defines the steepness of the cumulative curve and λ is a particle
diameter so that 36.8% of particles are larger than that. The higher ’n’, result
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Figure 3.4: Comparisons of the relative frequency distribution based on the data with
three density functions [34].
in narrower distribution. By rearranging Equation 3.27, Rosin-Rammler can be
presented in a linear form:
ln
[
ln
(
1
1− F (dp)
)]
= n ln dp − n lnλ (3.28)
Equation 3.28 shows that a linear relationship exists when ln
[
ln
(
1
1−F (dp)
)]
is
plotted against lnλ. From the slope and intercept of this straight line, n and λ
can be determined. Weibull distribution is another version of the Rosin-Rammler
and it is useful when the smallest particle size is not zero. The three-parameter
Weibull distribution is:
F (dp;λ, n) = 1− exp
[
−
(
dp − d0
λ
)n]
(3.29)
where d0 is the size of the smallest particle which is the main difficulty in using
this distribution. If distribution begins from zero, Weibull distribution is same as
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Rosin-Rammler.
The distance which a particle ,with initial velocity of V0 and without any external,
travels in the stationary air is very significant in the aerosol study. This distance
is equal to S = V0τ , where S is stopping distance, V0 is the particle initial velocity
and τ is the particle relaxation time. One of most important applications of
stopping distance is when suspended particles in a stream, encounter an obstacle
which sharply changes the flow path. In this case, stopping distance is defined as a
distance particle travels in its primary path. Stopping distance can be considered
as a scale for particle resistance against the flow path changes. Stokes number is
a non-dimensional value which is used for analyzing particles curvilinear motion.
Stokes number can be calculated as follow:
St =
S
D
=
τV0
D
(3.30)
when St << 1, particles immediately adapt their new path with stream when flow
direction changes; while for St >> 1, particles continue moving on their primary
path.
3.2.3 Lagrangian Discrete Particle Tracking
The micro-particles, can be either treated on a continuous Eulerian basis or a discrete
Lagrangian one. To date both approaches have been utilized successfully in case of
respiratory particles. The key point make here is that in treating the particles as a
continuous phase, it is not possible to account for the particle inertia effects on deposition
rates, i.e. deposition due to inertial impaction [144]. However, it is well established that
this is the dominant mechanism effective on the transport and deposition of micron sized
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particles in human upper airways. Since micron-sized inert particles are under the scope
of the present study, a Lagrangian approach is adopted to tackle the particle transport
phenomena. With a Lagrangian approach the particles are treated as a finite number of
discrete entities which may or may not have an impact on the continuous phase. The
effects of discrete particles on continuous phase can be accounted for in terms of source
terms introduced to corresponding governing equations. In essence, the Lagrangian
approach is based on Newton’s second law of motion. Newton’s second law of motion
is written for each discrete particle, and, with known initial velocity, the trajectory of
each particle is determined, starting from a known initial position. Different factors
affecting the trajectory of each particle are introduced into the Newton’s second law of
motion in terms of appropriate force terms. These factors stem from different physics,
such as surface stresses due to the motion of particle relative to the surrounding fluid,
turbulent dispersion of particles as a result of fluid velocity fluctuations, and particle-
particle inter-collisions. The general form of the trajectory equations for a single particle
with constant mass is as follows, Equation 3.31-3.32.
d
−→
U p
dt
= (1 + S)−→g + 1
τp
νrelnˆrel +
−→
f saff (3.31)
d
−→
X p
dt
=
−→
U p (3.32)
in which,
−→
U p and
−→
X p are the velocity and position vectors of particle, respectively. The
force terms on the right-hand side of Equation 3.31a, are gravity-buoyancy, drag, and
Saffman lift forces per unit mass of the particle, respectively. In gravity-buoyancy force
S and −→g are fluid to particle density ratio
(
S =
ρf
ρp
)
and local vector of the gravitational
acceleration, respectively. In drag force expression τp, νrel and nˆrel are relaxation time
of the particle
(
τp =
ρp
ρf ν
2
rel
)
, in which Cc and CD are particle drag coefficient and slip
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correction factor, respectively), the magnitude of fluid velocity relative to the particle,
and the unit vector in the direction of fluid velocity relative to the particle, respectively.
In areas of high fluid deformation rates (velocity gradients) the Saffman lift force becomes
important for micro particles [145]. The general expression of Saffman lift force, is given
in Equation 3.33. In which dij is the deformation tensor,dij =
(
∂ufi
∂xj
− ∂ufj∂xi
)
/2, and K
is a constant with an accepted value of 2.594.
−→
f saff =
2ρf ν
0.5K dij
ρpdp (dkldlk)
0.5
(−→
U f −−→U p
)
(3.33)
In this study, it is assumed that the other forces, which have been known to affect the
particle trajectories under certain circumstances, are negligible, for example Brownian
motion effects, which, for the case of air near standard conditions as carrier fluid, be-
comes important for particles smaller than approximately 1µm in diameter, and Magnus
lift force which is a direct consequence of particle rotation relative to the surrounding
fluid. Slip correction factor also becomes important in such cases that the particle char-
acteristic length is comparable with the mean free path of carrier fluid. Since for the
case of respiratory particles the carrier fluid is essentially near standard air, this factor
is important for particles smaller than approximately 1µm in diameter. The drag coef-
ficient is computed according to Equation 3.34b, in which Rep = vreldp/ν is the particle
Reynolds number.
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CD =
24
Rep
Rep < 1 (a)
CD =
24
Rep
(1 + 0.15Re0.687p ) Rep ≤ 1 ≤ 1000 (b) (3.34)
CD = 44 Rep > 1 (c)
It is well known that the fluid turbulence results in the enhanced dispersion of the par-
ticles [65, 126, 133, 146, 147]. Just like a sub-micron sized particle exhibiting Brownian
motion in air, a particle, depending on its characteristic size and turbulence intensity,
may exhibit rather random but smooth changes of direction while moving through the
fluid. These changes contribute to enhanced dispersion and, as a result, deposition of
particles in human upper airways. The turbulent fluid flow is characterized with velocity
fluctuations, and these fluctuations directly impact the nearby particles. In the course
of tracking a particle, the fluid velocity vector is interpolated to the position of particle
at each particle time-step, and this velocity is used to determine the relative velocity
of particle and so the drag force. A one-way turbulent dispersion on the particle is
performed through the Discrete Random Walk (DRW) or eddy interaction mode inside
Ansys-Fluent 15. This approach assumes that a particle interacts with a succession of
random discrete turbulent eddies, where each eddy is defined by a lifetime, length, and
velocity scale. The velocity scale is determined by a Gaussian distributed random veloc-
ity fluctuation as ue = ζ(2k/3)
1/2 where ζ is a random Gaussian random number with
mean zero and unit variance. The anisotropic turbulent behavior in the near wall [148]
is corrected by applying a damping function [66, 149–152] up to a non-dimensionalised
wall distance of y+ of 30 as:
Chapter 3. Methodology 44
kdamp = [1− exp(−0.02y+)]2k (3.35)
with the eddy lifetime interaction maintained constant as ue = (2kdamp/3)
1/2 using the
User-Defined-Function option in Ansys-Fluent 15. Particle deposition was assumed when
it hit the airway surface (which is covered by a mucus layer) and hence no rebounding
was considered.
3.3 Numerical Solver Procedure
The Navier-Stokes equation for incompressible fluid are converted into their correspond-
ing integral form which is a requirement for control volume based CFD solvers such as
Ansys/FLUENT 15. The domain is then discretized into control volumes. The govern-
ing equations given in Equations 3.1-3.2 are rearranged into an integral form to allow
integration of the equations on each individual control volume cell within the mesh.
A set of algebraic equations for dependent variables such as velocities, pressure and
temperature are then set up and solved. The segregated solver within Ansys/FLUENT
was chosen which solved the governing equations sequentially (i.e., segregated from one
another). The flow chart of the procedure is shown in Figure 3.5.The third order accu-
rate QUICK scheme, based on a weighted average of second-order-upwind and central
interpolations of the variable [153] was used to approximate the momentum equation
while the SIMPLEC algorithm was used to obtain the relationship between velocity and
pressure corrections to enforce mass conservation and also to obtain the pressure.
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Figure 3.5: Overview of the segregated solver solution steps
Chapter 4
Patient Specific and Optimised
Spacer: Toward the Smart Spacer
device
 M. Yousefi, K. Inthavoung, J. Tu “Micro-Particle Transport and Deposition in
the Human Oral Airway: Towards the Smart Spacer”. Journal of Aerosol Science
and Technology 49(11), 2015.
4.1 Introduction
Pulmonary drug delivery has emerged as a critical method for treating respiratory dis-
ease [3–5]. Nebulizers, dry powder inhalers (DPIs) and metered-dose inhalers (MDIs)
are common devices that generate fine drug particles, which are inhaled orally with the
lung as its final deposition target [12]. Among these devices, the MDI is the preferred
choice by patients for treatment of asthma and COPD [18, 19]. However studies have
shown patients experience difficulty coordinating the timing between actuation and in-
halation ([22–24]). Additionally, large drug particles ([154]) and high velocities ([25]) are
produced leading to preferential particle deposition on the oropharynx delivered to the
wrong locations, leading to unwanted side effects and a reduction in its effectiveness. To
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address these issues, spacers are used to delay the time between actuation and inhalation
allowing patients to inhale slower drug particles more deeply, increasing lung deposition
[26, 27].
Spacers introduce a chamber of dead volume between the MDI and the patient’s mouth.
Near the mouthpiece some spacers include a one-way valve (Figure 4.1) which opens
during inhalation allowing drug particles to exit the spacer, and closes if exhalation
occurs preventing a return of drug particles. Studies have shown that the inclusion of
a spacer can reduce oropharyngeal deposition ([107, 155–157]) primarily caused by the
increased spacer volume lowering the particle velocity and turbulence intensity [158].
A number of computational fluid dynamics (CFD) studies have investigated particle
deposition in the mouth-throat and/or lung geometries [54, 61, 64, 159–163].An early
application of CFD analysis of medical devices was conducted by Versteeg, et al. [25]
to predict airflow through an MDI.The authors acknowledged that due to technological
limitations at the time only qualitative agreement between the CFD model and experi-
ment could be achieved. Later computational studies include Coates, et al. [164] which
investigated the performance of DPIs based on design features such as air inlet size,
mouth piece length, and grid size. Kleinstreuer, et al. [53] included a spacer attached
to a human upper airway model and simulated airflow and drug deposition. The results
showed that the spacer increased drug delivery to the lungs by 30 − 50% in a pMDI
device. The simulations however did not include the spacer one-way valve. Yazdani, et
al. [120] investigated drug delivery with a commercially available MDI, coupled with
three commercial spacers. They showed that different spacer shape and also the one-way
valve have a significant effect on particle deposition rate, where 45 − 70% of the drug
deposited wasted on the spacer wall and valve.
Longest and Hindle [165] evaluated the performance of an inhaler device connected to
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a simplified, and realistic mouth-throat geometry using CFD and in-vitro experiments.
The results showed the drug delivery device geometry and patient use significantly re-
duces deposition in the oropharynx. Later the authors developed a stochastic individual
path (SIP) model to predict MDI and DPI drug deposition in the lung airways [166]
which showed that a DPI device delivered the largest dose to the mouth-throat ( 70%)
and the MDI delivered the largest dose to the alveolar airways ( 50%). The same
technique was also applied to investigate fluid-particle dynamics [167] and effects of
inhalation profiles [168] using a low Reynolds number (LRN) k–ω turbulence model
with anisotropic near wall corrections. Kleinstreuer, et al. [35] introduced the idea of
a controlled air-particle stream for targeting drug deposition in the human respiratory
system and the results were used to develop a smart inhaler. Albeit the smart inhaler
idea has improved the drug delivery efficiency; it is yet to be widely developed. The
mechanism for the particle injection makes smart inhaler costly, and a higher level of
patient compliance is required.
Controlled condensational growth provides a method to eliminate extra-thoracic de-
position and potentially target the region of deposition within the airways [169, 170].
Using this method, Tian, et al. [171] studied growth and deposition characteristics of
nasally administrated aerosol throughout the conducting airway including nose, mouth
and throat. They developed streamlined nasal cannula interface idea to control the
particles path and growth in the human lung. Results showed that only 5% of initial
dose losses in the cannula and nasal airway which is a significant reduction in particle
deposition in drug delivery through nasal cavity. what has been reviewed so far, show
the continuous effort of investigators in order to increase the drug delivery efficiency
within the human lung.
This research is aimed at improving medical devices efficiency and functionality by
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Figure 4.1: A metered-dose inhaler attached to a commercially available spacer
(Volumatic®). (b) Close-up view of the mouthpiece containing the one-valve. (c)
Schematic of mouthpiece with a closed valve produced during exhalation. (d) Mouth-
piece with an open valve produced during inhalation.
proposing a new spacer-valve innovation for targeted drug delivery based on computa-
tional modeling. To the best of author’s knowledge, no study has considered the spacer
valve design for delivering medication effectively to the human lung. Figure 4.1 shows a
one-way valve found in a commercially available spacer (Volumatic®) which slides for-
wards during inhalation, creating an annular air gap and allowing drug particles through.
During exhalation the valve slides back and closes off the spacer. This mechanism has
introduces inherent blockages in the particle trajectories into the oral cavity Instead,
this paper proposes a new innovative valve design based on 8-sections in the valve (ref.
Figure 4.2) which is aimed at reducing drug deposition waste in the spacer and valve;
and provides targeted drug delivery to specific lung regions. The final valve mechanism
and design is dependent on computational model predictions of inhaled particles and its
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Figure 4.2: Schematic diagram (a) Segmentation of single-way valve into 8-ports (b)
particle uniform distribution at the model inlet.
deposition sites to identify regional drug deposition in an idealized mouth-throat model
developed by Cheng, et al. [32]. By correlating the initial location of the drug particle’
with its final deposition site, each of the 8-sections in the valve can be opened or closed
to provide targeted drug delivery.
4.2 Methodology
4.2.1 Computational Geometry and Mesh
Cheng, et al. [32] developed a surrogate mouth-throat geometry with a variable circular
cross-section (Figure 4.3) to represent the oral cavity, pharynx and larynx. The geometry
was based on hydraulic diameters measured from a replicate cast of a healthy male adult
with an approximately 50% full mouth inlet that is 2cm in diameter. A block structured
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Figure 4.3: 3D views of the oral airway model and the computational grid in a upper
airway model adopted from Cheng, et al. [32].
mesh was applied with near wall refinements so that the first grid point was within the
viscous sub-layer.
To determine the optimized number of mesh elements, a grid independence study was
performed using three grid sizes of 381,000, 687,000 and 1,328,000 computational cells.
The minimum cross-sectional area (0.714cm2) was found at glottis region which is placed
between larynx and trachea (labeled in Figure 4.3) and axial velocities were taken along
lines R-L(right to left) and P-A (posterior to anterior) on the cross-section for a flow rate
of 30 l/min (Figure 4.4). An increase in computational cells from 381,000 to 687,000
changed the velocity profile by 2.5% and 1.3% along the P-A and R-L, respectively.
However, increasing cells from 687,000 to 1,328,000 did not have a significant effect.
Similarly the grid dependence was evaluated for particle deposition for 1−10µm particles
(at airflow of 30 l/min) which showed an insignificant effect when the number of cells
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increased from 687,000 to 1,328,000. Thus, the model with 687,000 cells was used in
this study which is approximately 13 cells/mm3 in the model.
Figure 4.4: Velocity profiles taken along the minimum cross-sectional area plane
(Glottis) for a flow rate of 30 l/min. (a) Velocity profile along the posterior-anterior
line, P-A (b) Velocity profile along the right-left line (R-L).
4.2.2 Airflow Field Equations and Assumptions
Three flow rate conditions were investigated, 15 l/min, 30 l/min, and 60 l/min. Based on
these flow rate conditions the Reynolds in the upper airway varies from 650 to 13,000,
and is expected to exhibit transition from laminar to turbulence [172]. The k − ω
turbulence model with low-Reynolds number (LRN) corrections has been proven suc-
cessful at predicting the average velocity profiles, pressure drop, and shear stresses in
the multi-regime flow field in human upper airway [126, 133]. The Reynolds-averaged
Navier-Stokes equations for mass and momentum are presented in Equations 4.1-4.2.
∂ui
∂uj
= 0 (4.1)
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∂ui
∂t
+ uj
∂ui
∂xj
= −1
ρ
∂p
∂xi
+
∂
∂xi
[
(ν + νT )
(
∂ui
∂xj
+
∂uj
∂ui
)]
(4.2)
where,ui is time-averaged velocity in the direction referred to by index i(i=1,2, and 3
for a 3-D field), p the time averaged static pressure,ρ the fluid specific mass, and ν the
kinematic viscosity. The turbulent kinematic viscosity,νT , is as given in Equation 4.3,
in which cµ is a constant with an accepted value of 0.09, and fµ is a function of RT =
k
νω
as defined in Equation 4.4
νT = cµ fµ
k
ω
(4.3)
fµ = exp
− 3.4(
1 + RT50
)2
 (4.4)
In the k − ω turbulence model two parameters are defined in order to account for the
turbulent nature of the flow field. These parameters are namely turbulence kinetic
energy,k, and turbulent dissipation rate,ω. These parameters characterize the kinetic
energy associated with the turbulent velocity fluctuations, and the viscous dissipation
rate due to turbulent shear stresses, respectively. The equations governing the transport
of the aforementioned turbulence parameters are given in Equations 4.5-4.6 [135].
∂k
∂t
+ uj
∂k
∂xj
= τij
∂ui
∂xj
− β∗ k ω + ∂
∂xj
[
(ν + σk νT )
(
∂k
∂xj
)]
(4.5)
∂ω
∂t
+ uj
∂ω
∂xj
= α
ω
k
τij
∂ui
∂xj
− βω2 + ∂
∂xj
[
(ν + σk νT )
(
∂ω
∂xj
)]
(4.6)
In which τij is Reynolds stress tensor, and β
∗, σk , α, β, and σω are constants with
accepted values of 1.0, 0.5, 0.555, 0.8333, and 0.5, respectively. The initial boundary
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values of parameters k and ω are often determined using empirical correlations, two of
which are given in Equations 4.7-4.8 [173].
k = 1.5 (I × uin) (4.7)
ω =
k1.5
0.6Rh
(4.8)
where, I, uin and Rh are upstream turbulence intensity, average velocity magnitude at
the relevant boundary, and hydraulic radius of the boundary, respectively. The segre-
gated solver in Ansys-Fluent 14.5 was used with the SIMPLEC1 algorithm for pressure-
velocity congupling and the discretization scheme was second order upwind. The solution
was assumed converged based on a residual convergence criterion of 10−4. The fluid is
the air with a dynamic viscosity of 1.789× 10−4 kg/m.s and density of 1.225 kg/m3.
4.2.3 Particle Flow Simulation
The Lagrangian approach is adopted in this study to investigate the particle transport
taking into account inertia effects. The general form of the trajectory equations for a
single particle with constant mass is given as, The Lagrangian approach is adopted in
this study to investigate the particle transport taking into account inertia effects. The
general form of the trajectory equations for a single particle with constant mass is given
as,
d
−→
U p
dt
= (1 + S)−→g + 1
τp
νrelnˆrel (4.9)
d
−→
X p
dt
=
−→
U p (4.10)
1Semi-Implicit Method for Pressure Linked Equations-Consistent
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Where
−→
U p is the particle velocity and
−→
X p is the position vector. The force terms on the
right-hand side of Equation 4.9, are gravity-buoyancy and drag forces per unit mass of
the particle. S, is the fluid to particle density ratio
(
S =
ρf
ρp
)
and −→g is the gravitational
acceleration vector. In drag force term τp, is the particle relaxation time defined as,(
τp =
ρp
ρf ν
2
rel
)
,where CD and Cc are particle drag coefficient and slip correction factor,
respectively. νrel, is the fluid velocity relative to the particle, and nˆrel is the unit
vector in the direction of fluid velocity relative to the particle. A one-way turbulent
dispersion on the particle is performed through the Discrete Random Walk (DRW) or
”eddy interaction model” inside Ansys-Fluent. This approach assumes that a particle
interacts with a succession of random discrete turbulent eddies, where each eddy is
defined by a lifetime, length, and velocity scale. The velocity scale is determined by
a Gaussian distributed random velocity fluctuation as ue = ζ(2k/3)
1/2 where ζ is a
random Gaussian random number with mean zero and unit variance.The anisotropic
turbulent behavior in the near wall [148] is corrected by applying a damping function
[66, 149–152] up to a non-dimensionalised wall distance of y+ of 30 as:
kdamp = [1− exp(−0.02y+)]2k (4.11)
with the eddy lifetime interaction maintained constant as ue = (2kdamp/3)
1/2 using the
User-Defined-Function option in Ansys-Fluent. Particle sizes ranging from 1−10µm with
a density of 1000 kg/m3 were used. The particles were injected into the inlet with the
same velocity as the airflow and uniformly distributed over the inlet (although in reality
particles at the end of spacer and beginning of the mouth are not uniformly distributed).
Particle deposition was assumed when it hit the airway surface (which is covered by a
mucus layer) and hence no rebounding was considered. The number of particles tracked
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was checked for statistical independence since the turbulent dispersion is modelled based
on a stochastic process. Independence was achieved for 20,000 particles since an increase
of particles to 40,000 particles yielded a difference of 0.1% in the deposition efficiency.
4.3 Results and Discussion
4.3.1 Model Validation
The particle deposition efficiency was compared against experimental results obtained
from Cheng, et al. [32] 4.5. 1997. Deposition efficiency is the fraction of the de-
posited particle over the total injected particles. To account for the particle diameter
and inhalation flow parameters, the set of results collapse into one data set by using
the particle Stokes number. The Stokes number in oropharyngeal region is defined as
Stk = ρpd
2
pUf )/(9µfD) [50] where ρp is the particle density, dp is the particle diameter,
µf is the air dynamic viscosity, Uf is the mean airflow velocity and D represents the
minimum hydraulic diameter which is equal to the airway diameter at glottis (0.96cm).
Deposition curve follow the same trend for all three breathing levels and the deposition
pattern becomes sensitive at the cut-off Stokes number of Stk > 0.1. The results show
a reasonable comparison with the experimental data, although there is a slight over
prediction for Stk < 0.01 and Stk > 0.4.
4.3.2 Airflow
Figure 4.6, shows the velocity contours in the mid-sagittal plane for the three flow rates,
normalized by the local maximum velocity denoted by Vmax. The velocity remains
nearly constant for a short distance from the inlet before slightly accelerating in the
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Figure 4.5: Comparison of simulated particle deposition fraction of oral airway with
the experimental data and numerical results.
mouth. The presence of the tongue creates an arch in the oral cavity, which pushes
the airflow superiorly, and flow separates at the back of the oral cavity. As the airflow
moves from the oral cavity to the pharynx there is a 90-degree bend and flow separation
occurs. Flow is accelerated towards the back of the throat on the outer wall, while a low
velocity recirculating region forms near the inner pharynx wall. The velocity contour
at slice A-A’ shows the flow pattern from a transverse view, consisting of flow rolling
into the centre of the pipe from the outer radial walls, which are Dean vortices that are
characteristic of pipe bend flows.
The airflow is then directed towards the inner wall at the larynx, which coincides with
the end of the semicircular pharynx shape. The change of flow direction from pharynx to
larynx is not as severe as the transition from mouth to pharynx. This leads to a smaller
region of low velocity recirculating flow on the outer wall of the larynx compared with
the recirculating region in the glottis (Slice B-B’). The velocity reaches its maximum and
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Figure 4.6: Normalized velocity magnitude contours in the mid-plane of the mouth-
throat airway.
forms the laryngeal jet [163] at the minimum cross section at the larynx, and remains
in the centre of the airway with a little tendency to move towards the inner wall (Slice
C-C’). A recirculating region forms next to the trachea outer wall, which covers almost
one-third of the trachea caused by the airway expansion from larynx to trachea that
reduces the laryngeal jet.
4.3.3 Particle Deposition
Figure 4.7, shows the particle deposition efficiency for all three breathing patterns for
2 − 10µm particles. There are two general recognizable trends in this curve. First,
increasing the particle diameter is associated with increasing the deposition fraction.
Inertial impaction is the most dominant factor in micro-particle deposition in the upper
airway [134, 174]. The particle Stokes number represents the impaction intensity and it
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is defined as the characteristic response time of the fluid divided by the characteristic
response time of the particle. Larger particles suspended in the fluid have less time
to adjust to sudden changes in the airflow streamlines.Thus, larger particles have more
possibility to deposit on curved boundaries, proportional to d2p. This explains the non-
linear change in deposition efficiency for successive particle diameter increase.
Figure 4.7: Study of particle deposition sensitivity to flow rate and particle diameter.
Increasing the airflow rate also increases the particle deposition. For a given particle
diameter, the distance between two successive deposition curves from an increase in flow
rate, is almost linear and constant. This is consistent with the particle Stokes definition
that is linearly proportional to the fluid velocity. However the effect on particles with
diameters < 6µm is small, for larger particles with diameters > 6µm, the deposition
is very sensitive to the airflow rate. For example, more than 80% incoming of 10µm
particles deposit in the oral airway which is consistent with results obtained by Zhang,
et al. [175]. Figure 4.8, shows deposition patterns for 2, 6, and 10µm particles for flow
rates of (a)15, (b) 30, and (c)60 l/min. The originating positions of escaped particles
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are shown in (i) slice D-D’ and the locations of particles that deposit in (ii) slice D-D’.
The exiting particle positions are shown in (iii) slice E-E’. Particles depositing in the
airway are colour coded by the following regions: mouth (yellow); pharynx (red); larynx
(blue); and trachea (green).
Figure 4.8: Particle distribution patterns in the upper airway for flow rates (a) 15
l/min (b) 30 l/min and (c) 60 l/min for 2µm, 6µm, and 10µm particles. In each
individual image, cross-sectional slices depicting particle positions are shown for (i)
inlet release positions of particles which escape the model (ii) inlet release positions
of particles that deposit on the airway walls (iii) particle positions at the outlet i.e.
trachea exit.
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Deposition in the pharynx and larynx (red and blue) correspond to initial positions
in the upper half of the inlet cross-section for all particles and flow rates. Particles
that deposit in the trachea (green) originate near the center of the inlet, although the
amount depositing is small ( 4.2%). Although larger particles increase the deposition
efficiency the inlet release positions of 2 and 6µm particles are similar for all flow rates.
However, the distribution map changes significantly from 6µm to 10µm. This indicates
that the deposition pattern becomes sensitive at the particle size of 6µm. A small
fraction of particles, deposit on the back of the mouth wall which originates from the
lower regions on the inlet (shown in yellow). Particle deposition is concentrated in
regions corresponding to a sudden change in the geometry due to inertial impaction.
The airflow is predominantly near the outer wall after exiting the oral cavity and as it
enters the pharynx which increases the particle deposition along the outer pharynx wall.
The abrupt reduction in airway diameter, occurring at the transition from pharynx
to larynx, results in an increased airflow velocity in this region, which enhances the
likelihood of particle deposition. For pulmonary therapy, we are interested in particles
that successfully pass through the oral airway and escape into the tracheo-bronchial
airway. It was found that increasing particle diameter created a more dilute distribution
at the outlet. The particle positions at the outlet (iii) slice E-E’ are traced back to
its initial inlet location to determine which initial position locations are more likely
to provide a successful path for particles to enter the lung airways. Generally particles
released from a lower inlet region have more chance to escape the upper airway. For a flow
rate of 15 l/min the inlet position pattern in the upper half for escaped particles (Slice E-
E’) becomes dilute for 10µm particles. This dilution becomes increasingly significant for
increased inhalation (slice E-E’ for 30 l/min and 60 l/min). To investigate the viability of
the proposed 8-sectioned inlet valve,Table.4.1 summaries the fraction of particles across
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each inlet section for escaped particles. For all sections, increased particles size leads to
decreased particle fraction. The lower sections (sections 5-8) have higher potential to
deliver particles to the lungs. For example, for 30 l/min, the results show an increasing
difference between the upper and lower sections for escaped particles, as the particle
size increases. For 2µm the escaped particles fraction changes from 41.5% to 47.5%
(upper to lower section) a difference of 6%, and this difference increases to a maximum
of 18.6% for 10µm particles (12.5% for upper and 31.1% for lower). This characteristic
is consistent for all flow rates. Thus, in order to improve particle deposition in the
lung the one way valve should be designed to redirect the particles entering the mouth
at lower positions represented by sections 5-8 in the inlet valve. The inlet sectioned
valve can also be used to determine the initial inlet particle position for regional particle
deposition based on anatomy. Table.4.2 summaries the fraction of particles in each of the
8-sectioned valve for the pharynx, larynx, and trachea regions respectively. The main
deposition sites are the pharynx and larynx, capturing up to 55% of 10µm particles,
while there is negligible deposition in the trachea. This suggests that particles reaching
the trachea have sufficient relaxation time to navigate the geometry and escape through
to the lungs. Deposition in the airway is found for particles released from the upper half
of the initial inlet positions, described by sections 1-4.
4.3.4 Proposed One-way Valve Design
Two important issues are considered in the new valve design. In the previous valve
design, a small air passage (Figure 4.1) reduces the airflow cross section which increases
the airflow velocity. This results in increased particle velocity in the airstream. Higher
velocity increases the particles relaxation time, meaning that a longer time is needed
to adapt its path with the flow streamlines. To solve this problem, a new swing valve
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mechanism is proposed which provides more opportunity for particles to pass through
the valve section with lower inertial properties. The results showed that the upper region
of the valve provides greater potential for deposition in the airway while the lower region
provides more opportunity for the particles to exit into the lungs. A guiding plate is
proposed after the swing valve to direct the flow path to the desired region (Figure 4.9).
This guiding plate can be designed differently to target a specific area in the airway or
down into the lung.
Figure 4.9: Proposed spacer design with (a) segment guiding plate and (b) circular
guiding plate.
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4.4 Discussion
CFD simulations were carried out to analyze the airflow field and trace drug particles
through a simplified human upperair- way model. Three flow rates of 15, 30, and 60
l/min were investigated and particles ranging from 2to10µm were released from the
inlet. The velocity contours showed that the flow field was similar for all three flow
rates. Particle deposition mainly occurred in the pharyngeal region, precisely where
the airflow streamlines changes direction. Increasing the particle size and the flow rate
increased the deposition and consequently lowered the drug delivery efficiency to the
lungs. Particles that did escape were found to originate in the lower sections of the spacer
valve. Redesigning the spacer valve so that it re-directs particles to the lower sections
provides a greater opportunity for the aerosolized medication to reach the lung. Most
particles that escape the trachea exit are distributed at the central part of the outlet.
A new valve design is proposed aimed at increasing the drug delivery efficiency, and
decreasing unwanted side effects. The new design allows custom movement of a guiding
plate to achieve specific targeted drug delivery. This study provides potential efficiency
improvements in the spacer design moving toward a smart spacer framework. It is
anticipated that this reverse particle tracking technique will provide new opportunities
of innovation and design to be exploited. In the context of the clinical benefit from
the inhaled drugs, the increase in lung deposition may not necessarily be greater than
with a standard spacer, but there would be a significant reduction in unintentional
particle deposition in unintended regions. This would significantly reduce any unwanted
side-effects as the particle release locations that lead to undesired deposition sites are
prohibited via the modified one-way valve. Further studies are required to determine
the effectiveness of re- directing particle-laden inhaled air through the different valve
designs and its impact on respiratory tract deposition. The airflow patterns in the
spacer itself exhibit a complex flow field containing swirl flow and recirculation regions.
The authors’ earlier work showed that of circulatory flow especially downstream of the
spacer entrance and also next to the spacer mouthpiece increases undesirable particle
deposition [120]. From these results, different spacer designs need to be investigated in a
future study to determine optimal conditions needed to precondition the particle-laden
flow to enter the one-way valve sufficiently. This study was aimed at providing potential
efficiency improvements in the spacer design moving toward a smart spacer framework.
It is anticipated that this reverse tracking technique will provide new opportunities
of innovation and design to be exploited further. In this study, an idealized specific
airway model was used to implement the smart spacer idea. The inherent morphological
differences of the upper airway among subjects provides a challenging task to make
generalizations from the results. Instead, the use of an idealized model in this case
with a smoothed curved oropharynx provides a benchmark, where future studies may
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confirm similar or find differences in flow features and particle in-flight dynamics in the
mouth–throat geometries. Future work applying the reverse particle tracking technique
among different geometries would prove invaluable to further confirm and improve the
smart spacer design idea.
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Table 4.1: Fraction of particles reaches to the outlet based on the released position
for different flow rates (%)
(a) Q=15 l/min
Particle Diameter(µm)
Particle’s release position 2 4 6 8 10
Section 1 10.8 10.8 10.8 9.8 8.8
Section 2 10.7 9.5 9.6 7.9 5.3
Section 3 11.0 10.5 10.1 8.7 5.9
Section 4 11.4 11.2 10.7 10.9 10.1
Sum 1-4 43.8 42.0 41.3 37.3 30
Section 5 12.4 12 12 12.3 11.4
Section 6 12.3 12.1 12.5 12.5 12.2
Section 7 11.7 11.8 12.0 12.2 12.0
Section 8 12.0 12 11.7 11.8 11.2
Sum 5-8 48.4 47.9 48.1 48.8 46.7
(b) Q=30 l/min
Particle Diameter(µm)
Particle’s release position 2 4 6 8 10
Section 1 10.6 9.9 9.3 5.9 3.1
Section 2 10.3 9.0 8.0 6.3 4.0
Section 3 9.8 8.8 7.1 4.0 2.7
Section 4 10.8 10.1 8.4 5.1 2.6
Sum 1-4 41.5 37.9 32.9 21.5 12.5
Section 5 12.3 12.0 11.9 10.9 6.2
Section 6 11.9 11.7 12.0 11.8 9.6
Section 7 11.0 11.0 10.9 10.8 8.5
Section 8 12.3 12.2 11.9 11.1 6.9
Sum 5-8 47.5 47.1 46.8 44.6 31.1
(c) Q=60 l/min
Particle Diameter(µm)
Particle’s release position 2 4 6 8 10
Section 1 9.7 8.2 3.7 0.8 0.6
Section 2 10.7 9.2 6.6 4.4 1.2
Section 3 10.3 8.8 4.0 2.4 1.1
Section 4 10.0 9.0 6.1 0.4 0.2
Sum 1-4 40.8 35.3 20.4 7.9 3.1
Section 5 11.9 11.5 10.5 5.1 0.2
Section 6 11.4 11.0 10.6 9.5 2.0
Section 7 11.1 11.0 10.8 10.6 10.6
Section 8 11.2 11.0 10.3 2.6 2.6
Sum 5-8 45.5 44.6 42.3 27.8 15.3
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Table 4.2: Fraction of particles lands on the different regions based on the released
position (%)-(airflow 30 l/min)
(a) Pharynx
Particle Diameter(µm)
Particle’s release position 2 4 6 8 10
Section 1 1.4 2.2 2.5 4.1 6.9
Section 2 1.0 1.1 1.6 2.3 4.6
Section 3 1.2 1.8 2.5 4.0 7.5
Section 4 1.1 1.5 2.0 3.2 6.1
Sum 1-4 4.7 6.7 8.6 13.7 25.8
Section 5 0.2 0.2 0.4 0.7 0.8
Section 6 0.4 0.6 0.5 0.7 0.7
Section 7 0.6 0.7 0.8 1.1 1.3
Section 8 0.3 0.3 0.5 0.6 1.0
Sum 5-8 1.5 1.8 2.1 3.1 3.8
(b) Larynx
Particle Diameter(µm)
Particle’s release position 2 4 6 8 10
Section 1 0.1 0.3 0.9 2.2 2.3
Section 2 1.4 2.0 2.6 3.5 4.2
Section 3 1.6 2.3 3.0 4.2 2.5
Section 4 0.6 0.9 1.9 4.3 3.8
Sum 1-4 3.7 5.6 8.5 14.2 12.8
Section 5 0.2 0.3 0.2 1.1 5.1
Section 6 0.0 0.0 0.0 0.0 1.6
Section 7 0.0 0.0 0.0 0.0 1.8
Section 8 0.0 0.0 0.0 0.7 4.4
Sum 5-8 0.2 0.3 0.2 1.8 12.7
(c) Trachea
Particle Diameter(µm)
Particle’s release position 2 4 6 8 10
Section 1 0. 0.0 0.0 0.0 0.0
Section 2 0. 0.0 0.0 0.0 0.0
Section 3 0.1 0.0 0.0 0.1 0.1
Section 4 0.1 0.0 0.1 0.0 0.0
Section 5 0.0 0.0 0.0 0.1 0.1
Section 6 0.0 0.0 0.0 0.0 0.0
Section 7 0.0 0.0 0.0 0.0 0.0
Section 8 0.0 0.0 0.0 0.0 0.0
Chapter 5
Effect of pMDI Spray
Characteristics and PSD on
Inhaler Drug Delivery Efficiency
 M. Yousefi, K. Inthavoung, J. Tu “Effect of pMDI Spray Characteristics and PSD
on Inhaler Drug Delivery Efficiency”. Journal of Aerosol Medicine and pulmonary
Drug Delivery, Volume 30, pp.1-14, 2017
5.1 Introduction
Pulmonary drug delivery has emerged as a critical method for treating respiratory dis-
eases [4, 7, 8, 79, 108]. Nebulizers, dry powder inhalers (DPIs) and metered-dose inhalers
(MDIs) are common devices that generate fine drug particles, which are inhaled orally
with the lung as its final deposition target [110, 116, 122, 176]. Among these devices,
the MDI is the preferred choice by patients for treatment of asthma and COPD [18, 19].
Its use increased from 440 million units in 1998 to 800 million units in 2000 [177], ,
and constituted more than 80% of the aerosol therapy devices global market in 2004.
In another study, Lavorini, et al. [28] showed that pMDI has been the most frequent
prescribed inhalation device in Europe over the time period 2002-2008.
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In a pMDI, the drug formulation is mixed with a liquid propellant (usually chlorofluoro-
carbon (CFC) or hydrofluoroalkane (HFA)), is stored in a canister (normally 15-30ml)
at a pressure of 2-5 bar. Actuation of the device triggers the release of single metered
dose of atomized drug particles [94, 95]. Despite its widespread use, drug delivery to the
lungs on average reaches only 5%-20% [9, 82–85]. This is primarily due to large drug
particles produced at high velocities depositing in undesired locations in the airway.
This leads to unwanted side effects and a reduction in effectiveness [10, 178].
The pMDI device parameters include propellant composition, device configuration, and
the canister pressure and volume which all significantly affect the atomized spray prop-
erties. For example, the number of particles produced during atomization can change
in the range of 15106 − 300106 per puff [179]. This has prompted many researchers
to investigate the influence of pMDI properties on the spray characteristics to improve
the drug delivery efficiency. Versteeg, et al. [25] used Computational Fluid Dynamic
(CFD) to predict steady-state airflow through an experimental MDI package. However
the authors acknowledged that due to computational limitations at the time only qual-
itative agreement between the CFD model and experiment could be achieved. Cheng,
et al. [161] measured CFC-pMDI and HFA-pMDI drug delivery efficiency in a human
airway replica including the oropharyngeal cavity, larynx, trachea, and nine bronchus
generation. The mass median aerodynamic diameter (MMAD) and geometric standard
deviation (GSD) were 2.33µm (σg = 1.79) and 2.21µm (σg = 1.76) for the in-house CFC
and Proventil HFA formulations, respectively. The results showed that for an inhala-
tion flow of 30 l/min, the CFC-pMDI produced 78% deposition in the oropharyngeal
airway and 16% deposition in the lung; while the HFA-pMDI produced 56% deposition
in oropharyngeal and 24% in the lung. Hochrainer et al. [180] studied the effect of ve-
locity and spray duration on performance of CFC- and HFA-pMDI in comparison with
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a new propellant-free inhaler Respimat® Soft Mist Inhaler (SMI). The pMDI used in
this study had conventional nozzles which produced initial particles in the order of the
nozzle orifice diameter 200− 500µm while Respimat SMI produced particles < 1µm in
median diameter within a short distance of the nozzle. The spray plume mean velocity
by Respimat® SMI measured 0.8m/sec at 10cm distance from the nozzle which was
2.5 to 10.5 times slower than those produced by the pMDIs. The spray duration was
1.5sec for Respimat® SMI and 0.15-0.36sec for the pMDIs. These differences signifi-
cantly contributed to the Respimat® SMI’s increased drug delivery effectiveness to the
lung. Smyth, et al. [181] reported that the pMDI spray plume pattern is affected by
propellant formulation, sump depth, orifice length and size.
Kleinstreuer, et al. [53] numerically studied drug delivery efficiency of HFA and CFC
pMDIs in an oral airway model. 2000 particles were introduced at an initial veloc-
ity of 150 m/s, cone angle 35o, and with a size distribution obtained from Dunbar, et
al. [105, 106]. Results showed that 47% of the inhaled droplets reached the lung for a
HFA134a-pMDI and 23% for a CFC-pMDI. In addition, the pMDI nozzle diameter effect
on drug delivery was studied showing that the bigger nozzle is less efficient. CFC-pMDI
with a 0.5mm nozzle delivers 5.6% of the medication to the lung, while a 0.25mm nozzle
delivers 23.3%.
Brambilla, et al. [101] experimentally measured the pMDI spray temperature for variety
of device properties such as propellant formulation, metering volume, and actuator orifice
diameter. Authors observed the plume temperatures were to be lowest in the proximity
of the actuator mouthpiece where rapid flashing and evaporation of the propellant cause
cooling. They found the minimum plume temperature for different experimental set up
in the range of −54◦C to +4◦C.
Tamura [182] studied spray velocity and plume pattern of seven HFA-pMDIs in addi-
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Figure 5.1: A typical pMDI attached to the oral airway.
tion to one Respimat® SMI, using Particle Image Velocimetry (PIV) technique. Results
showed pMDIs spray velocity changes in the range of 2.5m/s to 9m/s at 80mm distant
from the end of nozzle, however this value reaches 0.84m/s for Respimat ® SMI.
As discussed, design features and propellant formulation can affect the pMDI spray
characteristic including the particles size distribution, particles injection velocity and
the spray cone angle. Cheng, et al. 11 reported the spray angle for both HFA-134a and
CFC, to be 35◦; however Oliveira, et al. [183] measured this angle as 10◦ and 17◦ for
HFA-pMDI [129]. Dunbar, et al. [105] measured the spray jet velocity and drop size
distribution in different distances from the pMDI nozzle. They showed that the volume
mean spray drop size varies with radial distance from 5.2µm to 10.8µm for HFA-134a and
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form 7.5 µm to 16.5 µm for CFC-based pMDI (measurement point 25 mm far from the
pMDI nozzle). Crosland, et al. [184] studied the spray velocity of the different pMDIs
using particle image velocimetry (PIV). They observed that the velocity magnitudes
were much lower than published data from instantaneous single point measurements.
The spray plume peak velocity found to be on average 60m/s at 2.5mm distance from
the nozzle and 40msec after the pMDI actuation. The spray cone angle was also shown
to be unsteady, varying up to 8◦, during the first 100msec of the transient spray event.
As reviewed above, there is a significant discrepancy in measuring the pMDI spray cone
angle and spray emitting velocity. However it is believed that most of these differences
are due to experimental set-up and the precision of measurement tools and techniques.
Regarding that spray injection angle and velocity can alter the pMDIs efficiency in de-
livery drug to the lung, better understanding of the significance of these factors on the
drug delivery and particle deposition pattern in the human lung is necessary. This study
aims to be a CFD investigation of the spray angle and velocity effect on drug delivery
efficiency to the lung. The authors present a general criterion for efficiency of pMDI
drug delivery to the lung with regards to particles velocity and injection angle. To do so,
a commercial pMDI model attached to an idealized mouth-throat model developed by
Cheng, et al. [51] is employed in this study (Figure 5.1). The spray particle distribution
from an experimental data is used to reflect the real pMDI spray properties.
5.2 Methodology
5.2.1 Computational Geometry and Mesh
The geometry used in this work was adopted from Cheng, et al. [32, 51] (Figure 5.2).
This geometry has been widely used in studies of particle transport and deposition in the
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upper airway 18, 27-32. Other upper airway models include the idealized mouth-throat
replica (UofA replica) developed by Stapleton, et al. 33 and the Lovelace Respiratory
Research Institute (LRRI) cast model. Although the upper airway geometry exhibits
inter-subject variability, and even varies in a single person with age, there are common
gross geometrical features that are persistent among all airway models, which dominate
the flow field. This includes the arch in the oral cavity, the 90-degree bend into the
pharynx, and the converging-diverging cross-sectional area at the larynx. The mouth-
throat model by Cheng, et al. [51] uses a variable circular cross-section throughout the
model. The model was based on hydraulic diameters measured from a replicate cast of a
healthy male adult with an approximately 50% full mouth inlet that is 2cm in diameter.
The computational mesh consisted of block-structured cells with near wall refinements
so that the first grid point from the wall was within the viscous sub-layer (e.g. y+ < 5).
A grid independence study was performed using three grid sizes of 1055965, 1361590
and 2003470 computational cells (5.2). Axial velocities for a flow rate of 30 l/min were
taken along lines in the R-L (right to left) and P-A (posterior to anterior) directions on
the minimum airway cross-sectional area. This was 0.7cm2 found at the glottis region
(labeled in 5.2). An increase in computational cells from 1055965 to 1361590 changed
the velocity profile by 3.9% and 1.3% along the P-A and R-L line profiles, respectively.
However, increasing cells from 1361590 to 2003470 did not have a significant effect.
Thus, the model with 1361590 cells was used in this study, which was approximately 20
cells/mm3 in the model.
5.2.2 Airflow Field Equations and Assumptions
The Reynolds number in an idealized extra-thoracic airway was determined experimen-
tally by Johnstone, et al. [172] as 650-13000 for 10-120 l/min airflow rate. In this study,
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Figure 5.2: Computational model of the oral-pharynx-larynx-trachea airway adopted
from Cheng, et al. [32] with a block-structured mesh airway model applied to it
three inhalation rates 15, 30 and 60 l/min were used. Although the Reynolds number
may exhibit a laminar flow in a smooth regular pipe, the irregular and complex shape of
the oral-pharyngeal airway produces separation and recirculation flow dynamics, which
can lead to earlier onset of turbulence. The flow is therefore expected to exhibit some
form of transition from laminar to turbulence even at an inhalation rate of 15 l/min
[47]. The k − ω turbulence model with low-Reynolds number (LRN) corrections has
been proven successful at predicting the average velocity profiles, pressure drop, and
shear stresses in the multi-regime flow field in human upper airway [126, 133]. The
Reynolds-averaged Navier-Stokes equations for mass and momentum are presented in
Equations 5.1-5.2.
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= 0 (5.1)
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(5.2)
where,ui is time-averaged velocity in the direction referred to by index i (i=1, 2 and 3
for a 3-D field), p the time averaged static pressure, ρ the fluid specific mass, and ν the
kinematic viscosity. The turbulent kinematic viscosity, νT is as given in Equation 5.3, in
which cµ is a constant with an accepted value of 0.09, and fµ is a function of RT =
k
νω
as defined in Equation 5.4.
νT = cµ fµ
k
ω
(5.3)
fµ = exp
− 3.4(
1 + RT50
)2
 (5.4)
In the k − ω turbulence model two parameters are defined in order to account for the
turbulent nature of the flow field. These parameters are namely turbulence kinetic
energy, k, and turbulent frequency,ω. These parameters characterize the kinetic energy
associated with the turbulent velocity fluctuations, and the viscous dissipation rate due
to turbulent shear stresses, respectively. The equations governing the transport of the
aforementioned turbulence parameters are given in Equations 5.5-5.6 [135].
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In which τij is Reynolds stress tensor, and β
∗, σk , α, β, and σω are constants with
accepted values of 1.0, 0.5, 0.555, 0.8333, and 0.5, respectively. The initial boundary
values of parameters k and ω are often determined using empirical correlations, two of
which are given in Equations 5.7-5.8 [173].
k = 1.5 (I × uin) (5.7)
ω =
k1.5
0.6Rh
(5.8)
where, I, uin and Rh are upstream turbulence intensity, average velocity magnitude at
the relevant boundary, and hydraulic radius of the boundary, respectively. The segre-
gated solver in Ansys-Fluent 14.5 was used with the SIMPLEC algorithm for pressure-
velocity coupling and the discretization scheme was second order upwind. The solution
was assumed converged based on a residual convergence criterion of 10−4. The fluid is
the air with a dynamic viscosity of 1.789× 10−4 kg/m.s and density of 1.225 kg/m3.
5.2.3 Particle Flow Simulation
The Lagrangian approach is adopted in this study to investigate the particle transport
taking into account inertia effects. In the upper and large airways, the gravitational
force on micron particles is negligible in comparison with the particle drag termThe
gravitational force on micron particles are negligible in comparison with the particle
drag term [152]. The general form of the trajectory equations for a single particle with
constant mass is given as,
d
−→
U p
dt
= (1 + S)−→g + 1
τp
νrelnˆrel (5.9)
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d
−→
X p
dt
=
−→
U p (5.10)
where
−→
U p is the particle velocity and
−→
X p is the position vector. νrel, is the fluid velocity
relative to the particle, and nˆrel is the unit vector in the direction of fluid velocity
relative to the particle. The force terms on the right-hand side of Equation 5.9, are
gravity-buoyancy and drag forces per unit mass of the particle. S, is the fluid to particle
density ratio
(
S =
ρf
ρp
)
and −→g is the gravitational acceleration vector. In drag force
term τp, is the particle relaxation time defined as,
τp =
4ρpdpCc
3ρf CDν
2
rel
(5.11)
where CD and Cc are particle drag coefficient and slip correction factor, respectively.
Since particles under investigation are in the range of 1 − 10µm, the molecular slip
influence on the particles can be neglected, and the Cunningham Correction factor, Cc
is set to one. The drag coefficient, CD is based on the model by Morsi and Alexander
(1972). A one-way turbulent dispersion on the particle is performed through the Discrete
Random Walk (DRW) or ”eddy interaction model” inside Ansys-Fluent. This approach
assumes that a particle interacts with a succession of random discrete turbulent eddies,
where each eddy is defined by a lifetime, length, and velocity scale. The velocity scale
is determined by a Gaussian distributed random velocity fluctuation as ue = ζ(2k/3)
1/2
where ζ is a random Gaussian random number with mean zero and unit variance. The
anisotropic turbulent behavior in the near wall [148] is corrected by applying a damping
function [66, 149–152] up to a non-dimensionalised wall distance of y+ of 30 as:
kdamp = [1− exp(−0.02y+)]2k (5.12)
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with the eddy lifetime interaction maintained constant as ue = (2kdamp/3)
1/2 using the
User-Defined-Function option in Ansys-Fluent. Particle deposition was assumed when
it hit the airway surface (which is covered by a mucus layer) and hence no rebounding
was considered.
5.2.4 Spray Modeling
Considering that Ventolin HFA (albuterol sulfate) is known as very common medication
to treat asthma, it is assumed as a source of particle generation which has been stored
in the inhaler canister. The most significant characteristics of Ventolin HFA which are
important for spray simulation are listed in Table5.1. The particle size distribution
characteristics is taken from Oliveria, et al. [183]. The authors used laser diffraction
technique to measure particles characteristics flashing from a commercial pMDI. They
reported the particle size data in the form of Rosin-Rammler distribution, shown in
Figure 5.3. The Rosin-Rammler model parameters are given in Table5.1.
Table 5.1: Ventolin HFA spray properties
Ventolin properties
Propellant HFA-134a
Density (kg/m3) 1230
Actuation dose (µg) 100
Actuation time (s) 0.1
Particle diameter distribution parameters [183]
Distribution Model Rosin-Rammler
Minimum Diameter (µm) 1.22
Maximum Diameter (µm) 49.5
Mean Diameter (µm) 16.54
Spread parameter 1.86
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Figure 5.3: Graphical representation of the pMDI HFA-134a salbutamol experimental
data and the curve fitting for the Rosin-Rammle model. Measurements have been
obtained at 100 mm from the laser beams [183].
5.2.5 Model Validation
The particle deposition efficiency was compared against experimental results obtained
from Cheng, et al. [51] and Zhou, et al. [5] shown in Figure 5.4. The deposition
efficiency is the fraction of the deposited particle over the total injected particles. To
account for the particle diameter and inhalation flow parameters, the set of results
collapse into one data set by using the impaction parameter. The impaction parameter
is defined as IP = d2aeQ, where dae is the particle aerodynamic equivalent diameter in
µm, and Q is the airflow rate in l/min. The deposition curve follows the same trend
for all three breathing levels and the deposition pattern becomes sensitive at the cut-off
impaction parameter of IP = 3000. The results show a reasonable comparison with the
experimental data, although there is a slight over prediction for IP < 400 and IP >
7000. This discrepancy between the experimental results and simulation can be justified
by two main reasons. First, the airway wall is considered smooth in the simulation;
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however the model surface in the experiment has some roughness, which might affect
particle transport and deposition. Second, heat transfer has not been considered in
simulation, which might affect particles trajectories, especially small particles.
Figure 5.4: Validation of particle deposition efficiency in the human oral airway
models.
In order to investigate the dependency of results on the particle numbers, the particle
deposition rate in the upper airway for 10000, 20000, 40000 and 80000 particles have
been studied. However in Figure 5.5, the deposition rate form 20000 to 40000 particles
changes about ∼ 7.5%; it does not change significantly from 40000 tp 80000 (< 0.5%).
Thus, 40000 particles is used in the current particle transport and deposition.
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Figure 5.5: Computational grid dependency study on number of injected particles.
5.3 Results and Discussion
5.3.1 Airflow Field
The flow field was analysed as it serves as a carrier for transporting the particles through
the airway. It is therefore is a strong indicator for identifying potential deposition sites in
the airway. Figure 5.6 shows a velocity magnitude contour in the mid-sagittal plane for a
flow rate of 30 l/min. The velocity was normalized by its maximum local velocity, so that
the velocity scale is from 0–1. Air enters the inhaler through an annulus surrounding
the canister. It moves down to get to the lower part of the inhaler body and accelerates
through the nozzle where the cross-section area has reduced. This causes an initially
high-velocity flow entry at the mouth. The presence of the tongue creates an arch in
the oral cavity, which pushes the airflow superiorly, enhancing particle deposition in the
upper oral cavity. As the airflow moves from the oral cavity to the pharynx there is
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a 90-degree bend and flow separation occurs. Flow is accelerated towards the back of
the throat on the outer wall, while a low velocity recirculating region forms near the
inner pharynx wall. It’s expected that the outer pharynx wall will be a preferential site
for particle deposition. The airflow is then directed towards the inner larynx wall. The
change in flow direction from pharynx to larynx is not as severe as the transition from
mouth to pharynx. This leads to a smaller region of low velocity recirculating flow on
the outer larynx wall compared with the recirculating region in the glottis. The velocity
reaches its maximum and forms the laryngeal jet ([163]) at the minimum cross-section
at the larynx, and remains in the center of the airway with a little tendency to move
towards the inner wall. A recirculating region forms next to the trachea outer wall, which
covers almost one-third of the trachea caused by the airway expansion from larynx to
trachea that reduces the laryngeal jet.
5.3.2 Particle Deposition Pattern on the Airway
Figure 5.7 shows the particle deposition and transport pattern along the airway for
Q=30 l/min, spray cone angle of 10 deg and spray initial velocity of 110 m/s. Because
the airflow is pushed up after being blocked by the lower part of the inhaler, it is ex-
pected that some particles would be deposited on the upper part of the inhaler nozzle.
Inertial impaction is the most dominant factor in micro-particle deposition in the upper
airway [133, 174]. Larger particles suspended in the fluid have less time to adjust to
sudden changes in the airflow streamlines. Thus, larger particles have more possibility
to be deposited on curved boundaries. The presence of tongue blocks particles’ path and
as a results the large particles cannot adapt their path to the airflow new streamlines,
consequently they are deposited on the mouth wall. In the pharynx, the 90-degree bend
is another major challenge for the particles suspended in the airflow and it is considered
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(a)
(b)
(c)
Figure 5.6: Velocity magnitude normalized by maximum local velocity at mid-sagittal
plane for (A). 15 l/min, (B). 30 l/min and (C). 60 l/min.
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Figure 5.7: Particles transport and deposition pattern on the airway.
as a high-density deposition site in the upper airway. In this airway model, the trachea
is assumed as a straight round pipe and dose not have sharp changes in the geometry,
so few particles are deposited on the airway wall in this region. The trachea ends at
the first bifurcation of the trachea-bronchial tree of the human lung which includes two
main bronchus. The left bronchus has more deviation from the trachea in compare to
the right bronchus, therefore it causes more particles to be deposited on the lower part
of the left bronchus. The obtained results indicated that in all cases for different injec-
tion velocities and spray cone angles most particles enter to the left lung. For example,
for Q=30 l/min and the spray injection velocity of 110 m/s and spray cone angle of
10-degree, 5% of all particles enter to the left lung while this percentage is 4 for the
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right lung.
Particle distribution along the airway in different sections have been investigated. Con-
sidering that the airflow remains next to the outer wall in the pharynx region, it is
expected that particles to be mostly concentrated next to the outer wall. As it is shown
plane-A in Figure 5.7, there is a nearly free particle zone next to the inner wall. This
fact supports the obtained results which shows the high-density deposition sites are
formed next to outer wall. In the Plane-B the particles pattern in the trachea shows
that particles are mainly distributed on the left and right side of the cross-section and
the top and bottom sides are almost free of particles. Plane-C and D represents the par-
ticle distribution when the particles leave the main bronchus to the left and right lung,
respectively. Regarding that the left bronchus is more curved and longer in compare
to the right one, most particles are moved to the lower part of the plane-C. However,
particles in the plane-D are mainly distributed in the center.
5.3.3 Effect of Spray Injection Velocity
The results show that increasing the spray injection velocity over the range of 100-
150 m/s decreases the deposition rate in general. For all three flow rates the delivery
efficiency is less than 10% which is in a good agreement with literature [9, 81, 82] (91.8%
deposition rate for 30 l/min, injection velocity 110 m/s and injection angle 10◦, Figure
5.7).
Figure 5.8 shows the injection velocity effect on the three inspiration flow regimes. The
deposition rate for all injection velocities for 30 l/min is obviously lower than 15 and
60 l/min, while the 15 and 60 l/min deposition curves have surprisingly identical trend.
The 30 l/min airflow rate shows about 5% improvement in average in drug delivery to
the lung in compare to 15 l/min and 60 l/min. The injection velocity does not show a
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Figure 5.8: Spray velocity change effect on deposition efficiency.
significant effect on the deposition rate. Changing the spray initial velocity from 100
m/s to 150 m/s decreases the deposition rate by 1% and 1.5% for 30 and 60 l/min
respectively, while for 15 l/min it is less than 1%. In brief, changing the spray velocity
from 100 m/s to 150 m/s has minimal effect on the inhaler efficiency and it only shows
1-2% improvement.
Calculating of the particle stopping distance can give us more deep understanding of
the spray injection velocity effect of the deposition rate. Particle stopping distance is a
path that a particle travels with its initial inertial force, and then the drag force from
the fluid flow would be the main driving force. The stopping distance for a spherical
particle in micron scale can be calculated as, Xp = τv0, where τ is particle relaxation
time and v0, is the particle initial velocity. For the most frequent particle size in the
spray which is 16.54µm (given in Table 5.1), the stopping distance for v0 = 100m/s
changes from ∼ 104mm to ∼ 156mm for v0 = 150m/s. In comparison with the scale
of the upper airway (the diameter of the mouth inlet is 20mm) these stopping distances
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values guarantee deposition of most particles in the airway walls. However, changing the
initial velocity from 100m/s to 150m/s does not make much difference in the particles
deposition rates. For the dp = 1.22µm ,which is the minimum particle diameter in the
spray, the stopping distances reaches ∼ 0.85mm for v0 = 150m/s which is negligible
in compare to the airway scale. Thus, the injection initial velocity does not have a
significant effect on small particles and the airflow pattern is the main cause of the small
particles deposition. Note that the stopping distance has been calculated without the
airflow drag effect, which basically increases the stopping distance.
5.3.4 Effect of Spray Injection Angle
Spray cone angle effect on inhaler performance is investigated over the range of 2◦-10◦
(Figure 5.9). For all spray cone angles, the deposition rate for 30 l/min is lower than
15 and 60 l/min. The deposition efficiency for 30 and 60 l/min decreases when the
spray cone angle increases. However for 15 l/min, the spray cone angle does not show
remarkable effect on the deposition curve. The 30 l/min curve shows more sensitivity to
the spray angle so that 8◦ degree changes from 2◦ to 10◦ causes 4% drop in deposition
rate. This value is nearly 2% for 60 l/min and less than 1% for 15 l/min. Results
indicate that increasing the injection angle helps more particles be delivered to the
lung. However, very high injection angle will direct particles to the inhaler nozzle and
mouth cavity boundaries, which in turns can increase the deposition rate and lower the
efficiency.
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Figure 5.9: Spray cone angle change effect on deposition efficiency.
5.3.5 Effect of Particle Size Distribution
Variations in the particle size distribution (PSD) can be caused by many factors such
as atomizer nozzle design, propellant, drug formulation, actuation pressure. The way
a patient activates the inhaler can also affect the particle size distribution. A range of
PSDs were created by changing the mass-median aerodynamic diameter (MMAD) value
of the initial Rosin-Rammler distribution used in Figure 5.3.
The resulting PSDs are given in Figure 5.10a where smaller MMADs shifted the dis-
tribution to the left and hence a smaller size range of particles are formed. We also
replicated measured PSD data from Lewis [186] using the Rosin-Rammler distribution
function. The distribution is given in Figure 5.10b. The effect of decreasing the MMAD
on a particle size distribution decreases the deposition efficiency (Figure 5.11), however
this effect is not substantial until the MMAD is sufficiently small.
The results show that decreasing MMAD from the original value of 16.5µm to 10µm
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(a)
(b)
Figure 5.10: Additional particle size distribution used for analysis: (a) particle size
distributions based on Oliveria, et al. [185] with different MMAD values (b) particle
size distributions from Lewis [186] compared with the original data used from Oliveria
et al. [185]
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Figure 5.11: Deposition efficiency with particle size distributions with different
MMAD for all spray cone angles. Airflow rate of 30 l/min.
had negligible effect with the deposition efficiencies overlapping. A further decrease to
MMMAD of 6µm showed a small decrease in the deposition efficiency, and it required
the MMAD to reach 2µm for the deposition efficiency to decrease to as low as 70% (at
spray cone angle of 10o). The deposition pattern for MMAD of 2µm and 6µm is shown
in Figure 5.12 where deposition remains dominantly in the oro-pharynx region.
This suggests that the fraction of larger particles continue to deposit in the oro-pharynx
region. There is negligible deposition in the trachea which suggests that the smaller
sized (and therefore lower inertial) particles are able to navigate through the airway
geometry. Consequently, there is an increase in the fraction of particles that enter
both left and right lungs. The deposition efficiency for the PSDs from Lewis [186] is
compared with the original profile obtained from Oliveria, et al. [185] shown in Figure
5.13 and Figure 5.14. There is a very large difference where the PSDs from 10µm show
a much smaller deposition efficiency. The lowest deposition occurs for the highest spray
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Figure 5.12: Particle deposition pattern for different MMAD, for airflow rate 30 l/min
(size distribution by Oliveira, et al. [185].
cone angle tested which was 10o and the highest initial spray velocity tested which was
150m/s. The MMAD values used in the Lewis [186] PSDs were 2.3µm and 3.3µm and
both distributions produced approximately 66% deposition efficiency for a spray cone
angle of 10o. Comparatively, the PSD from Oliveria et al. [185] with an MMAD of
2mum yielded a deposition efficiency of 70% for a spray cone angle of 10o.
This suggests that there is some consistency in predicting the deposition efficiency from
different distribution curves with the same or similar MMAD values despite the PSDs
being obtained independently from each other (PSDs from Oliveria et al. [185] and
Lewis [186])
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Figure 5.13: Spray cone angle change effect on particle deposition in the upper airway
for different spray size distribution.
5.4 Discussion
Spray injection velocity and the cone angle are investigated in an idealized upper airway
extending from mouth to the main bronchus. The air flow structure for all three main
flow rates 15, 30, and 60 l/min reproduced the same characteristics. The first high
velocity region occurred at pMDI nozzle, but as the air enters the mouth, the airway
expands leading to a decelerated flow in the mouth. The flow patterns show a second
high velocity region at the transition from the oral cavity to the pharynx and the airway
experiences a 90o bend. A third high velocity region is found at the glottis, where
the minimum cross-section in the airway is found. These gross airflow structures are
consistent with the flow patterns reported by Xi and Longest [68] for simplified and
realistic models of oral airway. Particle deposition results by Kleinstreuer, et al. [53]
showed that at a flow rate of 30 l/min, deposition in the upper airway for HFA-pMDI
and CFC-pMDI reached 53.4% and 94.8%, respectively. However, in this study de-
position rate for a HFA-pMDI falls in the range of 90%–92% for 30 l/min and with
an injection angle of 10o. The main reason for this difference is (i) the distance of the
particle injection location and the oral cavity shape and (ii) the spray size distribution
that was obtained from different experimental data sets (5.2–10.8µm for HFA-134a and
7.5–16.5µm for CFC-based pMDI). The deposition rate shows more dependency on spray
injection angle than the injection velocity. The PSD characteristics changes with the
inhaler type, the measurement distance from the nozzle, the measurement method, and
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Figure 5.14: Spray injection velocity change effect on particle deposition in the upper
airway for different spray size distribution.
the time delay after inhaler actuation. Cheng, et al. [161] showed that HFA-based pMDI
produced lower deposition in the upper airway than a CFC-based propellant. This was
attributed to the HFA-propellant producing a lower initial spray velocity, initial droplet
evaporation rate, and possibly initial droplet. However, our results showed that spray
injection velocity had little effect on the deposition rate than the spray cone angle
and inhalation rate. Different PSDs were simulated using the same conditions. The
results showed that the deposition efficiency was dependent on the particle MMAD.
When a similar MMAD particle size was used but a different distribution curve was
produced, a very similar deposition efficiency curve was found. The deposition curve
was insensitive to PSD curves when the MMAD is high enough (≥ 8µm). It should be
noted that aerosolization of pressurized medication through inhaler produces particles
with electrostatic charge [26]. The effect of electrostatic charge has not been investigated
in this study, which might have an influence on the results. Moreover, the evaporation
and agglomeration of aerosolized medication have not been considered in this study. In
addition, a single idealized geometry is used that does not represent all features of a real
upper airway. Further study is required to tackle these issues.
Chapter 6
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6.1 Introduction
Administration of drugs in the form of aerosol particles via inhalation is generally prefer-
able for the treatment of respiratory disorders [187–189].This is because the drug can
be delivered directly to the local site where it is required, therefore reducing the dose
required to prevent or treat the symptom, and consequently, increasing the speed and
predictability in the onset of action whilst minimizing adverse reactions of the body to
the drug [190–192]. Nebulisers, dry powder inhalers (DPIs) and pressurized metered-
dose inhalers (pMDIs) are commonly used to generate the fine drug particles required
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for pulmonary drug administration. Among these, the pMDI is the inhalation device of
choice by patients for the treatment of asthma and COPD [193, 194], the proportion of
its use increasing to more than 80% of all aerosol therapy devices in the global market
in 2004 [195]. The pMDI was also the most frequently prescribed inhalation therapy de-
vice by practitioners in Europe over 2002-2008 [196]. Nevertheless, despite its popularity
among patients and practitioners alike, studies have shown patients experience consid-
erable difficulty in coordinating the timing between breath actuation and inhalation
[197–200]; this inability for correct usage factoring significantly in the poor lung dose ef-
ficiencies, which are typically between 5–30% [9, 85]. Even with the use of a spacer, only
50–75% have been reported to reach the main bronchus [53]. In DPIs, the inspiratory
flow of the patient is used to disperse the medication powder into fine aerosol particles
[201–203].As such, a minimum airflow rate of at least 30 l/min is required for efficient
use. As such, DPIs are not the preferred choice for juveniles, the elderly and those who
suffer from severe respiratory conditions as they mostly tend not to be able to deliver the
requisite flow rate [199, 204–206]. Nebulizers, on the other hand, produce micron size
drug particles at slow velocity via an active aerosolisation mechanism, which can then
be drawn into the lung through a mouthpiece or a face mask [207]. In comparison with
inhalers, nebulizers are easier to use and more effective for patients of all ages as they
do not require precisely coordination of their breath with the nebulizer actuation [199].
Moreover, in contrast to MDIs and DPIs, combinations of two or more drugs in liquid
form can be mixed and inhaled at the same time. However, unlike MDIs and DPIs, neb-
ulizers (i) are usually large and cumbersome to use, and are hence not portable for home
use, (ii) cost considerably more as they have more complicated aerosolization mecha-
nisms, (iii) require more dosage to achieve the same therapeutic effect as MDIs and DPIs,
and, (iv) require longer treatment times—typically 5-10 minutes on average [191, 208].
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Nebulization technology has nevertheless significantly improved in recent years. Ultra-
sound and electro-hydrodynamic atomization methods can produce the requisite micron
dimension fine mist for deep lung delivery and are able to control the particle size dis-
tribution more precisely [209–213]. These new technologies can be integrated into small
scale devices (microelectromechanical systems, or MEMS) that allow miniaturization
and hence portability, therefore replacing the bulky and cumbersome conventional jet
and ultrasonic nebulizers that have been used to date [214, 215]. However, they still
suffer from inherent limitations such as mechanical reliability in the case of MEMS,
and safety issues associated with the use of high-voltage (typically several kVs) in the
case of electrohydrodynamic atomization. More recently, surface acoustic wave (SAW)
[216–218] nebulization has been demonstrated as an alternative aerosolization technique
for pulmonary drug delivery [219]. Surface acoustic waves are MHz to GHz-order elec-
tromechanical waves that propagate along the surface of a piezoelectric material with a
displacement amplitude of just a few nanometers. Given the confinement of the SAW
energy along the surface of the material, the SAW is considerably more efficient than
the bulk transmission of the sound wave energy in conventional ultrasonic nebulizers
[220], and hence SAW nebulisers consume about a tenth to a hundredth less power
[217, 221, 222], thus allowing the integration of its electronic power supply and thus
its miniaturization into a compact, portable, handheld device [219, 223]. Additionally,
unlike conventional ultrasonic nebulisers, a significant advantage of the SAW nebuliser is
its ability to deliver large macromolecular drugs such as DNA [224] , peptides [225] and
proteins [226], and even stem cells [227], all of which constitute the next generation in
therapeutics, with little denaturation due to its high frequency operation that minimizes
hydrodynamic shear and suppresses cavitational damage. In this work, we investigate,
using computational modelling, the transport and deposition of drug particles generated
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by the SAW nebulizer placed within a spacer to an in silico human lung (Figure 6.1),
which, to date, has not been studied. While the SAW nebulizer is capable of generating
the requisite 1− 5µm aerodynamic particle diameter necessary for the aerosolized drug
to reach the lower sections of the lung structures where the alveoli is in contact with
blood capillaries [228–232], with control over the size distribution afforded by adjusting
the power, frequency and surface characteristics of the device [233], we will attempt to
examine using this model the possibility that the use of the spacer allows for further
tuning of the lung deposition characteristics. In particular, we employ computational
model predictions to identify sites of the regional drug deposition of the inhaled particles
in a geometrically reconstructed in silico model from CT scans of an adult human lung
that extends from the oral cavity to the 6th generation of the respiratory tract to show
that injection positions of the SAW device in the spacer chamber play an influential role
in the drug delivery efficiency to the lung in addition to the particle size distribution.
6.2 Material and Methods
6.2.1 Geometry reconstruction using CT scan images
Figure 6.2 illustrates the computational domain employed in this study, which generally
comprises the spacer within which the aerosol generator is placed, and the respiratory
airway. The spacer geometry was modeled as an elliptical hollow chamber within which
the particles are produced by the SAW device and subsequently transmitted to the lung.
The air enters the spacer from the one end and carries the suspended particles to the
oral cavity at the other end. The lung geometry was obtained from the CT scan data
of the respiratory tract of a healthy 48-year-old, non-smoking Caucasian female. The
multi-slice scanner was used in a helical mode with a 500-mm field of view (FOV) at 120
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Figure 6.1: Schematic illustration of the placement of the SAW nebulization device
within a spacer that is used to examine drug deposition within an in silico human lung
model that is geometrically reconstructed from CT scans.
kV peak and 50 mA. 1023 contiguous images (slices in the transverse Z direction), each
with 0.5-mm thicknesses, were acquired from the mouth to generation G6. Following
image acquisition, the CT images were modified to reconstruct the desired domain.
Parameters such as region-grow thresholds were manually manipulated by visual exam-
ining each slice in turn. In this case, the lining of mucus was determined by measuring
pixels that possess a different color to that of the main airway mask found at the interface
region between the airway wall and the actual airway. The geometry was then imported
into ANSYS Workbench 15 in order to split the geometry in the Design-Modeler module
from which the computational mesh is generated. Finally, the mesh file was read into the
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(i)
(ii)
Figure 6.2: Computational domain used in this work (lung image from Kleinstreuer,
et al. [54] ) b. Lung geometry extending from the oral cavity to the 6th generation of
the airway in the lung.
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FLUENT 15 to carry out the numerical simulation of the air flow and particle transport.
6.2.2 Governing Equations and Assumptions
Fluid phase
An Eulerian approach is adopted to solve for the fluid flow within the spacer and the lung
reconstruction. Assuming that the inhaled air is assumed incompressible and Newtonian,
we solve the three-dimensional equations governing conservation of mass, momentum
and energy specified by the continuity equation, the Reynolds-averaged Navier–Stokes
equations and the two-equation model governing the turbulence kinetic energy k and
specific dissipation rate in terms of a pseudo-vorticity ω [234]:
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= 0 (6.1)
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It has been shown that this model agrees fairly well for both steady and unsteady
inspiratory flow fields, except during the deceleration phase and near flow reversal areas
[49, 127]. Due to the presence of transitional flow characteristics in the spacer and the
upper airways, the k − ω low Reynolds number (LRN) model is expected to be more
appropriate than the standard k − ω model for the current problem [47, 235]. The
difference in these two models arises in the turbulent eddy viscosity, defined by
υT = a
∗ k
ωˆ
; ωˆ = max
(
ω,
7
8
√
2S¯ijS¯ij
β∗0/α∗
)
(6.7)
where the a∗ is equal to unit for the standard k − ω model. In the LRN method, υT is
modified in the following manner to dampen the turbulent eddy viscosity wherever the
Reynolds number is sufficiently low:
a∗ = a∗∞
(
βi/3 + Ret/Rk
1 + Ret/Rk
)
(6.8)
where
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9
; β0 = 0.0708; (6.10)
β∗0 = 0.09; a
∗
∞ = 1; σω = σk = 0.5
No slip is imposed on the airway walls and a uniform mass flow rate is applied at the
spacer inlet. The static pressure is assumed to be constant over the model 13 outlets
(R1-R7 and L1-L6 shown in Figure 6.2).
Particle phase
The discrete phase model (DPM) and a Lagrangian particle tracking approach (One-way
coupling) have been adopted to simulate the particle trajectories. In this approach, the
trajectories of individual particles are tracked by integrating the force balance on each
particle:
~F = mp · d
−→u p
dt
(6.11)
where ~up is the particle velocity, and ~F is the force term. The ~F in the above comprises
12 different components:
~F = ~FD+~Fb+~Fg+~FSaffman+~Fvirtualmass+~Fp.gradian+~FFaxen+~FBasset+~FB+~FT+~Fm+~FM
(6.12)
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namely, the drag, buoyancy, gravity, Saffman lift, virtual mass, pressure gradient, Faxen,
Basset, Brownian, thermophoresis, Magnus and magnetic forces, respectively. Because
of the relatively large density of particles (ρp = 824kg/m
3) in comparison with that
of the fluid (ρf = 1.225kg/m
3), the buoyancy and Basset forces are negligible. Grav-
itational settling is only significant at the very low flow rates that occur within the
lower airways from generation G9 onwards [236]. Brownian motion and the Saffman’s
lift force are only prominent for particles of submicron dimension [237, 238] whereas
the thermophoretic force is caused by the unequal momentum exchange between the
particles and the fluid due to temperature gradient, which, in the present system, can
be assumed inconsequential given that any differences in the air temperature within
the airways is minute compared to the body temperature. The Magnus lift force arising
from particle rotation as a result of a pressure and hence velocity differential across both
sides of the particle can be neglected as these effects should be small. The virtual mass
and pressure gradient forces, on the other hand, are only considerable when the fluid
density is larger than that of the particle. The magnetic force can be neglected, since
there is no magnetic field affecting particle trajectories in the present study. Finally,
the Faxen force can be neglected as it only becomes significant when the characteristic
length scales of the particle and system geometry are at the same order. In light of the
aforementioned assumptions,the drag force is the only dominant force and thus Eq. 6.12
reduces to
~F = mp
dup
dt
=
−→
F D (6.13)
The Stokes drag force on a smooth spherical particle is given as [239]
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−→
F D =
18µ
ρpd2p
mpfRep
24
(uf − up)ne (6.14)
from which we can define a drag coefficient, CD
f = a1 +
a2
Rep
+
a3
Re2p
(6.15)
In which Rep ≡ ρfdp|up−uf |µf is the particle Reynolds number. Here, uf , up, µf , ρf , ρp and
dp are gas (air) velocity, particle velocity, molecular viscosity of the fluid, fluid density,
particle density and particle diameter, respectively. Where a1, a2 and a3 are empirical
constants that apply over the range of 0 ≤ Rep < 5 × 104 [240]. It should be noted
that particle evaporation and aggregation effects as well as the influence of electrostatic
charging along the spacer and lung walls have been neglected for simplicity.
6.2.3 Solution Methodology
The reconstructed in silico lung geometry comprising the mouth up to the 6th genera-
tion in the airway were discretized into an unstructured mesh consisting of tetrahedral
cells. The steady governing equations given by Eqs. (6.1)–(6.15) using the SIMPLE
algorithm with pressure–velocity coupling. To capture the airflow structures in the tur-
bulent flow regimes for internal flow, the low Reynolds number k − ω turbulence model
was implemented. The convective terms of the transport equations were discretized us-
ing a second-order-upwind scheme in order to obtain sufficiently accurate solutions. The
steady-state solution of the fluid flow was assumed to be converged when the dimension-
less mass and momentum residual ratios were 106. A fundamental assumption made in
the DPM model is that the dispersed second phase occupies a low volume fraction, even
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though high mass loading (m˙particle ≥ m˙fluid) is acceptable. It was therefore essential to
monitor this volume loading in each cell to ensure that the value of this parameter did
not exceed 12%, which is the upper limit for the model to be valid. One-way coupling
is assumed between the particle and air flow fields, and interaction between the par-
ticles were neglected given that the dilute loading (i.e., the particle volume fraction is
< 0.1%). The step length factor, which is a parameter that is inversely proportional to
the integration time step and is roughly equivalent to the number of time steps required
to traverse the current continuous phase control volume, is chosen as 5. The outlets were
set to allow particles to escape from the domain while the wall of the spacer and airway
were set to trap the particles. Thereby, the deposition efficiency could be determined
by calculating the percentage of particle streams that were trapped, and can be defined
based on the particle number or mass as
DEN =
Number of deposited particles in a specific region
Number of particles entering this region
× 100 (6.16)
DEM =
Mass of deposited particles
Total mass of injected particles
× 100 (6.17)
Another criterion which describes the behaviour of the “escaped” particles is also pro-
posed:
EscapedN =
Number of escaped particles from the domain
Number of particles entering this region
× 100 (6.18)
EscapedM =
Mass of escaped particles
Total mass of injected particles
× 100 (6.19)
Given that the escaped particles are defined as the fraction of particles which leave the
computational domain and flow toward the lower branches of the airway, it is assumed
that they still end up in the lung .
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6.2.4 Spray Modeling
To interface the computational model with the device output, we consider, as input to
the model, the particle size distribution generated by the SAW nebulizer in Qi, et al.
[219] for salbutamol dissolved in the octanol at a concentration of 0.5 mg/ml under an
input power of 1.5 W (Figure 6.3). At this power, the reported particle nebulization rate
was 2.4 ml/hr. In this study, 60,000 of these particles were then injected into the spacer
from a 5 mm-diameter circular surface represents the surface of the parent droplet on the
device that was nebulized. The number of particles in each size range is given in Table
6.1; we note that this is considerably lower than the 106 order in the number of particles
that are typically generated by the SAW over an inhalation cycle but nevertheless allows
a fair representation in light of the limitation on computational resources.
Figure 6.3: Volume based particle size distribution, measured using laser diffraction,
from the nebulization of salbutamol/octanol at 1.5 W with the SAW device method
(Qi, et al. [219]).
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Table 6.1: Particle size distribution employed in present study
size(µm) Number Total Diameter (m)
1.04 400 0.000416
1.2 1400 0.00168
1.42 2900 0.004118
1.63 4800 0.007824
1.93 6700 0.012931
2.26 8200 0.018532
2.63 8900 0.023407
3.02 8500 0.02567
3.52 7200 0.025344
4.18 5200 0.021736
4.79 3300 0.015807
5.59 1600 0.008944
6.52 700 0.004564
7.6 200 0.00152
Sum 60000 0.172493
The initial injection velocity was set at 2 m/s and an injection angle of 23o equal to
the Rayleigh angle-defined as the ratio of the sound speeds in both droplet and SAW
substrate, i.e., θR = sin
−1 (cl/cs) wherein cl and cs are the sound speed in the droplet and
substrate, respectively-is assumed. It is generally well known that particles generated
during SAW nebulization are ejected at this velocity and angle. It is generally well
known that particles generated during SAW nebulization are ejected at this velocity
and angle.
In order to study the influence of the position at which the SAW devices are mounted in
the spacer on the deposition of the particle in the lung, five different injection locations
were considered (Figure 6.4). Injection points 1, 2 and 3 are located 4 mm below the
spacer centerline with distances of 20, 40 and 60 mm from the airflow inlet, respectively,
whereas injection points 4 and 5 are located 4 mm above and exactly on the centerline,
respectively, at a distance 40 mm from the inlet. All of the five injection points are
located along the mid-sagittal plane of the spacer.
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Figure 6.4: Injection locations where the SAW nebulization device is placed in the
spacer.
6.2.5 Mesh Study and Validation
Mesh independence test
Given the complexity of the airflow in the in silico lung geometry and the sensitivity
of the to the regional turbulence effects, it is necessary to take account of sublayer and
near-wall grid resolution to sufficiently refine the mesh. Erstwhile, Tian and Ahmadi
[241] proved that in order to achieve deposition results independent of the near wall grid
size, the grid near the wall should be sufficiently refined such that y+ ≤ 2. In this study,
the ANSYS/Meshing module to generate a sufficiently refined near wall non-uniform
grid for y+ ≤ 2 in all cases. As shown in Figure 6.5, the mesh comprises five prism
layers with an aspect ratio of 1.2 near the wall. Tri/Tetrahedral computational cells
were applied to discretize the other regions in the lung model.
A grid independence test for the spacer chamber has already been carried out previously
[120]. The computational domain of the in silico lung model, on the other hand, was
tested for four different grid numbers, i.e., 2,300,000, 3,100,000, 4,300,000, 5,000,000 and
cells. Comparing the velocity profiles for each case in Figure 6.6 revealed less than 1%
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(i) Oral cavity.
(ii) The cross-section of the mesh in the oral cavity
Figure 6.5: Computational domain employ in the study that is representative of a.
the oral cavity and b. the cross-section of the mesh in this region.
difference in the velocity magnitude between the 4,300,000 and 5,000,000 grids. Thereby,
a scheme that contained 4,300,000 grids was adopted.
Model validation
Preliminary particle deposition model validation tests were performed by introducing
particles ranging from 1µm to 10µm into a simplified oral–pharynx cavity (Figure 6.7).
This particle size range was used as it replicates the experimental work by Cheng, et
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Figure 6.6: Velocity magnitude for grid independency test (Q=15 l/min) and gener-
ated mesh. a) Planes position, b) Velocity magnitude on line A-A’, c) Velocity magni-
tude on line B-B’
al. [51], allowing for direct comparison. The particles were introduced uniformly over
the circular cross-section of the mouth and tracked down to the trachea. To account
for the different particle diameters and inhalation flow rates so as to allow comparison
of the experimental results with Cheng, et al. [51] and Zhou, et al.[5], the results were
collapsed into a single data set by using an impaction parameter IP = d2aeQ, where dae
is the particle aerodynamic equivalent diameter in µm, and Q the airflow rate in l/min.
The experimental data of Cheng, et al. [51] for oral deposition in the replica is shown
by the curve fit for the deposition efficiency in Figure 6.8, whereas that for Zhou, et
al.[5] comprises prediction of the particle deposition using the U-of-A and LRRI models.
Despite the slightly different geometries employed, a similar trend was found among
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Figure 6.7: Sample deposition patterns of 2µm particles in a simplified upper airway
for airflow rates of 30 l/min.
the different models as seen in Figure 8 for three flow rates. The results from the
present model shows reasonable agreement, although we note a slight over prediction
for IP < 400 and IP > 7000. This discrepancy between the experimental results and
simulation could possibly arise due to two factors. Firstly, there exists a difference
in the airway surface representation: in the CFD simulations, the surface is assumed
to be perfectly smooth whereas microscale roughness is present on the surface of a
real airway which affects near wall fluid and particle interaction. Secondly, the use
of RANS turbulence models does introduce some slight errors particularly for complex
geometries where significant pressure gradients, flow separation, and recirculatory effects
are present.
Higher order turbulence models such as Large Eddy Simulations provide more accu-
rate flow field results but are very computationally intensive and thus prohibitive in
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Figure 6.8: Validation of particle deposition efficiency predicted by various human
oral airway models with the experimental data of Cheng, et al. [51].
many cases. As a compromise, we thus adopt a RANS turbulence model that has been
demonstrated to perform well in the literature despite that it is not always necessarily
perfect.
6.3 Results
Airflow pattern
As the airflow serves as a carrier for transporting the particles through the airway, we
first analyse its velocity field given that it provides a strong indication for identifying
potential deposition sites in the spacer and airways. Figure 6.9 shows contours of the
velocity magnitude, normalized by the maximum local velocity, for a flow rate of 30
l/min. Air first enters the spacer through a circular inlet, forming a high speed jet at
the center of the spacer surrounded by regions of lower pressure region around it. These
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low-pressure regions, which generate considerable recirculation in a significant portion
of the spacer chamber as seen in Section A in Figure 6.9 as well as in Figure 6.10,
constitute a potential trap for the injected particles and can increase the deposition rate
dramatically. The sharp difference in the cross-sectional area between the mouthpiece
of the spacer and that of the oral cavity also causes significant acceleration as the air
leaves the spacer and enters the mouth. In similar fashion, this high velocity region is
surrounded by low velocity regions driving appreciable deposition in the mouth. This
is compounded by the presence of the tongue, which creates an arch in the oral cavity,
thus pushing the airflow superiorly, and thus driving further particle deposition in the
oral cavity. It can be seen in Figure 6.9 (Section B) that the high velocity region occurs
next to the tongue whereas regions of low velocity are observed at the top. The velocity
field of the airflow as it passes from the pharynx to the larynx can be seen in Section
C in Figure 6.9, wherein the upper airway geometry has the smallest cross-section such
that the velocity there is at its maximum. A sharp 90o bend from the pharynx to the
larynx leads to the formation of a high-speed region next to the outer wall at which
we expect preferential deposition. The velocity field in the middle of the trachea as the
air moves down toward the lung is shown in Section D in Figure 6.9. The curvature of
the airway geometry from the larynx to the trachea keeps the airflow stream next to
the inner wall leading to a low pressure region along the outer wall that gives rise to a
recirculatory pattern as shown. As the air leaves the trachea and enters the first lung
bifurcation, we note higher velocities associated with the air entering the right lung given
that the right main bronchus deviates less from the trachea centerline. Concomitantly,
a low-velocity region can be seen next to outer wall of the left main bronchus where the
airway significantly deviates from the trachea centerline.
Chapter 6. Toward a New Inhalation Therapy Device 114
Figure 6.9: Magnitude of the normalized velocity with respect to the maximum local
velocity at different sections of the airway for an airflow rate of 30 l/min.
Deposition pattern
Figure 6.11 illustrates the deposition pattern of particles injected from position 5 for
an airflow rate of 30 l/min. Of the 60,000 particles that were injected with the SAW
device placed within the spacer, we observe 18.7% (equivalent to a mass-based deposi-
tion efficiency of 19.5%) to deposit on the walls of the spacer and the upper airways.
50% (50.8% mass-based deposition efficiency) and 30.5% (30.5% mass-based deposition
efficiency) of the particles’ total mass proceed further to reach the right and left lung,
respectively; both the number- and mass-based calculations showing that the right lung
receives almost 20% more particles than the left lung.
The spacer chamber, in particular, the surfaces at both ends which constitutes the main
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Figure 6.10: The sample airflow streamline in the sagittal plane in the spacer.
deposition sites, traps a significant amount of the injected particles and hence comprises
a noticeable barrier for drug delivery to the lung. This is because despite the large
proportion of particles that are injected along the centerline of spacer following the
high speed airflow towards the oral cavity, a fraction of particles are trapped within the
spacer due to the recirculatory flow observed in Figure 6.9 and therefore collide such
that they deposit on the end surfaces. Once into the upper airway, inertial impaction is
the most dominant mechanism by which the particles deposit [134, 174]. In particular,
large particles suspended in the airflow have less time to adjust to sudden changes in
the airflow streamlines and thus have more tendency to be deposited on the airway
walls when a sharp change arises in the airway geometry. The presence of the tongue
further blocks the particles’ path, preventing these large particles from adapting their
path to react to the variation in the airflow streamlines. As a consequence, a large
proportion of these particles are deposited on the mouth wall . A second high intensity
deposition site is observed to arise at the glottis where the airway geometry changes from
the pharynx to the larynx. This sudden reduction in cross section in the upper airway
is thus accompanied by a significant deposition rate. On the other hand, the trachea
geometry possesses more gradual changes in both cross section and curvature and hence
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Figure 6.11: Particle disposition and deposition efficiency for an airflow of 30 l/min
(particles are injected from position 5).
the particle deposition exhibits a disperse pattern on the trachea wall as seen in Figure
6.11. Finally, we observe in Figure 6.11 that the deposition rate increases to 81.25%
in the lung bronchial section when the main airway bifurcates to two smaller as the
larger particles are not able to immediately follow the new airflow trajectories, and have
therefore the tendency to collide and be trapped on the airway wall. The percentage
of escaped particles from each outlet is shown in Figure 6.12. We observe the particle
mass leaving the lung model for the lower parts of the lung to be slightly less than for
that calculated from a number-based delivery efficiency. Whichever the case, however,
more particles are observed to enter the right lung, consistent with that reported earlier
in Figure 6.11. More generally, we note that particles have higher tendencies to enter
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(i)
(ii)
Figure 6.12: Mass and number-based particle delivery efficiency at different outlets
for an airflow rate of 30 l/min.
the branch which is more aligned with the parent airway, as expected.
Finally, we briefly investigate the effect of the device positioning within the spacer on
the particle deposition characteristics. Figures 6.13 and 6.14 reports the mass-based
deposition efficiency of particles injected from different locations within the spacer for
an airflow rate of 30 l/min. In general, we observe from the number-based particle
deposition efficiencies in Figures 6.13 that these are typically 1% lower than the mass-
based deposition efficiencies. Positions 1 and 2, which are located below the spacer
centerline show similar performance in delivering almost 79% of total particle mass to
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the lung. We have discovered, however, that position 3, which is closer to the spacer
outlet and hence the oral cavity, is only slightly (0.4% ) more efficient, with 20.6% of
the total particle mass injected from this position depositing on the lung and spacer
walls. Placing the device in a mirror location above the spacer centerline (position 4)
only results in a slightly better performance.
Figure 6.13: Mass-based particle deposition efficacy for the different injection posi-
tions within the spacer chamber for an airflow rate of 30 l/min.
Position 5, however, which is along the spacer centerline where the airflow velocity is
the highest results in the best performance in delivering the particles to the lung with
lowest deposition on the airway walls. It can be seen from Figure 6.9 that more than
81% of particles injected from this position are transported to the oral cavity and into
the deep lung without being deposited on the spacer and airway walls right up to the
6th generation. This is because injection along the spacer centerline gives the particles
the best chance of avoiding the recirculation zones below and above the centerline as
shown in Figure 6.12ii, which has been shown above to result in trapping, collision and
hence deposition of the particles on the spacer walls . In any case, such large particle
deposition efficiencies are consistent with the high in vitro (∼ 80%) lung doses reported
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by Qi, et al. [219] using a twin-stage impactor model, although in the absence of a
spacer.
Figure 6.14: Number-based particle deposition efficacy for the different injection
positions within the spacer chamber chamber for an airflow rate of 30 l/min.
6.4 Conclusion
The transport and deposition of aerosol particles generated via nebulization using a novel
SAW device were numerically investigated using computational fluid dynamics together
with a geometrical reconstruction of a human lung obtained through a CT scan that
extended from the mouth to the 6th generation in the airway network. In particular, we
examine the effect of the positioning of the SAW device within a spacer chamber on the
fate of the particles in the lung. As expected, the air flow structure varies considerably
as it is passes through the spacer and into the complex geometry of the pulmonary air-
ways into the lung. The airflow entering the spacer forms two distinct regions, namely a
high-velocity region along the centerline of the chamber and a surrounding low-velocity
recirculation region. This recirculatory airflow within the chamber results in the trap-
ping of the particles, resulting in their tendency to be deposited on the spacer wall,
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particularly at the two spacer ends. Reducing or eliminating this recirculation area is
thus a strategy to be examined to improve the delivery efficiency of the setup. Once
within the airways, we observe an increased tendency for particles to deposit given the
changes in the airway cross section and orientation, which leads to marked variations in
the flow velocity contours along the airway. A second region where significant deposi-
tion occurs and which there- fore presents a barrier to delivery of particles to the lung
exists at the pharynx wall where the air flow encounters an almost right angle bend in
the geometry as it traverses from the oral cavity to the pharynx. There is a further
site at which noticeable deposition occurs at the transition from the pharynx to the
larynx where the airway cross section shrinks abruptly at the glottis and, as such, gives
rise to a velocity maximum, in agreement with other studies [47, 50]. Within the lar-
ynx, the airway geometry also experiences some changes in cross section and direction
downstream into the tracheal region. This causes larger particles close to the airway
wall, which are unable to follow the airflow streamlines, to be deposited along the wall.
Finally, the bifurcations in the lower airway pose yet a further barrier for delivery with
particle deposition noticeable at the carina ridges. With the SAW nebulization platform
in particular, we observe a particle delivery efficiency of up to 80% to the 6th generation
airway, broadly consistent with the lung doses reported previously by Qi, et al. [242]
from in vitro deposition studies using a twin-stage impactor and considerably higher
than the typical 5–30% deposition efficiencies using pMDIs [243]. In addition, we also
observe that less particles deposit in the left lung, especially that in the lower branches,
which is consistent with that observed in the experimental studies of Bennett [244],
Bennett et al. [245] and Moller, et al. [246], as well as the numerical study of Lambert,
et al. [247]. This was attributed to the tendency for particles at a bifurcation junction
to enter the sub-branch which is more closely aligned with the main parent branch. The
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computational model also allowed us to examine the effect of the device position within
the spacer on the particle delivery efficiency. Given the recirculation zones within the
spacer, the model predicts that positioning the device such that particles are injected
along the centerline of the spacer where the velocity is the highest minimizes their trap-
ping within the recirculation zone and hence their tendency to be deposited at the walls
on both ends of the spacer chamber. We also found that positioning the device farther
from the inlet also aids in transporting the particles into the oral cavity and into the
lung. These results demonstrate the computational model as a valuable in silico tool
to assess the performance as well as to facilitate the optimization of the novel SAW
nebulizer for drug delivery to the human lung, especially given that the wide morpho-
logical differences in the airway geometries inherent among clinical subjects that arise
from a myriad of epigenetic factors make it extremely challenging to obtain conclusive
results from expensive clinical trials that place considerable constraints in the number
of test subjects. In this study, we have attempted to explore different aspects of drug
delivery to the lung using SAW. The results will be used to design and optimize a novel
SAW nebuizer for drug delivery to the human lung. This computational model enables
us to minimize the significant time and cost, which are naturally part of the clinical
trial. Although the lung geometry exhibits inter-subject variability and even varies in a
single person with age, there are common gross geometrical features that are persistent
among all airway models, which dominate the flow field. In our future work, we aim to
collect a large number of samples that will provide more definitively the most relevant
and influential parameters affecting drug delivery.
Chapter 7
Conclusion and
Recommendations
Over the past 50 years, human activities have released many harmful gases into the
air which caused an dramatic increase in lung diseases rate. Intravenous (injection)
medications do not reach to the human lung directly, inhaleling drugs in the form of
aerosol particles minimize side effects, directly absorb in the lung and provide immediate
relief. MDI and spacer known as main devices to effectively deliver drug to the lung;
however they still suffering from low drug delivery efficiency. The spacer geometry and
spacer valve design influence on drug delivery efficiency were investigated in this study.
In addition, MDI spray characteristics effect on MDI efficiency were discussed using a
common MDI type attached to a simplified oral airway model. In this chapter, major
findings, problems solved and research methods developed are discussed.
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7.1 Towards the Smart Spacer
Conclusion
In Chapter 4, CFD simulations were carried out to analyse the airflow field and trace
drug particles through a simplified human upper airway model. Three flow rates of 15,
30 and 60 l/min were investigated and particles ranging from 2 to 10µm were released
from the inlet. The velocity contours showed that the flow field was similar for all three
flow rates. Particle deposition mainly occurred in the pharyngeal region, precisely where
the airflow streamlines changes direction. Increasing the particle size and the flow rate
increased the deposition and consequently lower drug delivery efficiency to the lungs.
Particles that did escape were found to originate in the lower sections of the spacer valve.
Redesigning the spacer valve so that it re-directs particles to the lower sections provides
a greater opportunity for the aerosolized medication to reach the lung. Most particles
that escape the trachea exit are distributed at the central part of the outlet. A new
valve design is proposed aimed at increasing the drug delivery efficiency, and decreasing
unwanted side effects. The new design allows custom movement of a guiding plate
to achieve specific targeted drug delivery. This research provides potential efficiency
improvements in the spacer design moving towards a smart spacer framework. It is
anticipated that this reverse particle tracking technique will provide new opportunities
of innovation and design to be exploited. In the context of the clinical benefit from
the inhaled drugs, the increase in lung deposition may not necessarily be greater than
with a standard spacer, but there would be a significant reduction in unintentional
particle deposition in unintended regions. This would significantly reduce any unwanted
side-effects as the particle release locations that lead to undesired deposition sites are
prohibited via the modified one-way valve. Further studies are required to determine the
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effectiveness of re-directing particle-laden inhaled air through the different valve designs
and its impact on respiratory tract deposition. The airflow patterns in the spacer itself
exhibits a complex flow field containing swirl flow and recirculation regions. In the first
part of this research, it was showed that of circulatory flow especially downstream of the
spacer entrance and also next to the spacer mouthpiece increases undesirable particle
deposition.
Recommendation for Further Study
From these results, different spacer designs need to be investigated in a future study
to determine optimal conditions needed to precondition the particle-laden flow to enter
the one-way valve sufficiently. This study was aimed at providing potential efficiency
improvements in the spacer design moving towards a smart spacer framework. It is
anticipated that this reverse tracking technique will provide new opportunities of in-
novation and design to be exploited further. An idealized specific airway model was
used to implement the smart spacer idea. The inherent morphological differences of the
upper airway among subjects provides a challenging task to make generalisations from
the results. Instead the use of an idealised model in this case with a smoothed curved
oro-pharnx provides a benchmark, where future studies may confirm similar or find dif-
ferences in flow features and particle in-flight dynamics in the mouth-throat geometries.
Future work applying the reverse particle tracking technique among different geometries
would prove invaluable to further confirm and improve the smart spacer design idea.
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7.2 pMDI Spray Characteristics
Conclusion
In Chapter 5, spray injection velocity and the cone angle were investigated in an idealized
upper airway extending from mouth to the main bronchus. The air flow structure for all
three main flow rates 15, 30 and 60 l/min reproduced the same characteristics. The first
high velocity region occurred at pMDI nozzle but as the air enters the mouth, the airway
expands leading to a decelerated flow in the mouth. The flow patterns show a second
high velocity region at the transition from the oral cavity to the pharynx and the airway
experiences a 90-degree bend. A third high velocity region is found at the glottis, where
the minimum cross-section in the airway is found. These gross airflow structures are
consistent with the flow patterns reported by Xi, et al. [68] for simplified and realistic
models of oral airway. Particle deposition results by Kleinstreuer, et al. [53] showed
that at a flow rate of 30 l/min, deposition in the upper airway for HFA-pMDI and
CFC-pMDI reached 53.4% and 94.8%, respectively. However in this study deposition
rate for a HFA-pMDI, falls in the range of 90-92% for 30 l/min and with an injection
angle of 10◦. The main reason for this difference is (i) the distance of the particle
injection location and the oral cavity shape, and (ii) the spray size distribution which
were obtained from different experimental data sets. Zhang, et al. [60] experimentally
studied the deposition in three mouth-throat models with Qvar® inhaler (pMDI). Their
results showed deposition rates of 25.8 ± 4.2%, 24.9 ± 2.8% and 12.2 ± 2.7% for the
idealized, highly idealized and USP mouth-throat models, respectively. These values
are significantly different from the deposition rate obtained in our current study which
was generally ≥ 90%. The main reason for this considerable discrepancy is the particle
size distribution. The MMAD of Qvar® inhaler is in the range of 0.9m−1.1µm 60, while
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the MMAD of Ventolin® pMDI-HFA134a used in current study is 16.5µm 57, 61. Our
particle size distribution shows a range of 1−50µm and a modal point at 10µm. Smaller
particles show more scattered deposition pattern. For all three airflow regimes increasing
the spray initial velocity over the range of 100-150 m/s and spray angle over the range
2◦ − 10◦, decreases the deposition rate. The deposition rate shows more dependency
on spray injection angle than the injection velocity. The 30 l/min airflow rate shows
a better performance in the delivery of drug particles to the lung than the 15 and 60
l/min airflow rates. The high airflow rate increases particles’ inertial force, resulting in
higher deposition in the upper airway. The lower airflow rate probably does not produce
enough drag force to conduct the particles through the upper airway and particles may
separate from the main air stream and deposit on the airway wall. Therefore, 30 l/min
is the optimum airflow rate that carries drug particles more efficiently to the lung.
Recommendation for Further Study
The aerosolization of pressurized medication through inhaler produce particles with
electrostatic charge. The effect of electrostatic charge has not been investigated in
this study, which might have influence on the results. Moreover, the evaporation and
agglomeration of aerosolized medication have not been considered in this study. In
addition, a single idealized geometry is used which does not represent all features of a
real upper airway. Further study is required to tackle these issues.
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7.3 Toward a New Inhalation Therapy Device
Conclusion
In Chapter 6, the transport and deposition of aerosol particles generated via nebuliza-
tion using a novel SAW device was numerically investigated using computational fluid
dynamics together with a geometrical reconstruction of a human lung obtained through
a CT scan that extended from the mouth to the 6th generation in the airway network. In
particular, we examine the effect of the positioning of the SAW device within a spacer
chamber on the fate of the particles in the lung. As expected, the air flow structure
varies considerably as it is passes through the spacer and into the complex geometry of
the pulmonary airways into the lung. The airflow entering the spacer forms two distinct
regions, namely, a high-velocity region along the centerline of the chamber, and, a sur-
rounding low-velocity recirculation region. This recirculatory airflow within the chamber
results in the trapping of the particles, resulting in their tendency to be deposited on
the spacer wall, particularly at the two spacer ends. Reducing or eliminating this re-
circulation area is thus a strategy to be examined to improve the delivery efficiency of
the setup. Once within the airways, we observed an increased tendency for particles
to deposit given the changes in the airway cross-section and orientation, which leads to
marked variations in the flow velocity contours along the airway. A second region where
significant deposition occurs and which therefore presents a barrier to delivery of parti-
cles to the lung exists at the pharynx wall where the air flow encounters an almost right
angle bend in the geometry as it traverses from the oral cavity to the pharynx. There is
a further site at which noticeable deposition occurs at the transition from the pharynx
to the larynx where the airway cross section shrinks abruptly at the glottis, and, as
such, gives rise to a velocity maximum, in agreement with other studies [47, 50, 248].
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Within the larynx, the airway geometry also experiences some changes in cross section
and direction downstream into the tracheal region. This causes larger particles close to
the airway wall, which are unable to follow the airflow streamlines, to be deposited along
the wall. Finally, the bifurcation in the lower airway pose yet a further barrier for deliv-
ery with particle deposition noticeable at the carina ridges. With the SAW nebulization
platform in particular, we observe a particle delivery efficiency of up to 80% to the 6th
generation airway, broadly consistent with the lung doses reported previously by Qi, et
al. [219] from in vitro deposition studies using a twin-stage impactor, and considerably
higher than the typical 5%-30% deposition efficiencies using pMDIs [9, 85]. In addition,
we also observe less particles to deposit in the left lung, especially that in the lower
branches, which is consistent with that observed in the experimental studies of Bennett
et al. [244, 245, 249] and Moller, et al. [246], as well as the numerical study of Lambert,
et al. [71]. This is attributed to the tendency for particles at a bifurcation junction to
enter the sub-branch which is more closely aligned with the main parent branch. The
computational model also allowed us to examine the effect of the device position within
the spacer on the particle delivery efficiency. Given the recirculation zones within the
spacer, the model predicts that positioning the device such that particles are injected
along the centerline of the spacer where the velocity is the highest minimizes their trap-
ping within the recirculation zone and hence their tendency to be deposited at the walls
on both ends of the spacer chamber. We also found that positioning the device farther
from the inlet also aids in transporting the particles into the oral cavity and into the
lung.
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Recommendation for Further Study
These results demonstrates the computational model as a valuable in silico tool to assess
the performance as well as in facilitating the optimization of the novel SAW nebulizer for
drug delivery to the human lung, especially given that the wide morphological differences
in the airway geometries that are inherent among clinical subjects that arise from a
myriad of epigenetic factors that makes it extremely challenging to obtain conclusive
results from expensive clinical trials that place considerable constraints in the number
of test subjects.
Appendix A
Transport of pharmaceutical
particles in three commercial
spacer-MDI
 A. Yazdani, M. Normandie, M. Yousefi, M.S. Saidi, G. Ahmadi “Transport and
deposition of pharmaceutical particles in three commercial spacer-MDI combina-
tions”. Journal of Computers in Biology and Medicine, 54, p. 145-155, 2014
A.1 Introduction
Respiratory drug delivery is currently considered to be the most promising method for
directly relieving or treating respiratory diseases, such as asthma, pneumonia, cystic
fibrosis, etc. In essence, there are some unique advantages to respiratory drug adminis-
tration such as lack of exposure to the digestive acids and enzymes, almost direct contact
with blood flow, and quick effect especially when it comes to tackle the disorders of the
pulmonary system. On the other hand one of the drawbacks constantly attributed to
pulmonary drug delivery is considerable deposition in undesired locations which in turn
reduces its effectiveness. Also, unfavorable take-up of medication poses health hazards
to the patient.
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Among all pharmaceutical administration devices, metered-dose inhalers (MDIs) are
undoubtedly the most popular. Although in constant use, MDIs are known to result
in poor drug take-up efficiency. This poor efficiency is typically attributed to the fact
that MDIs impart an undesirably high initial momentum to the particles which in turn
increases unwanted deposition of particles in oral cavity and upper airways. In order
to reduce the initial momentum of drug particles, it is getting more and more common-
place to use some sort of an extension between inhaler outlet and mouth inlet. Such
extensions are typically referred to as a respiratory spacer or simply a spacer. Making
use of a spacer is likely to improve the quality of respiratory drug delivery by providing
a space for pharmaceutical particles to lose their initial momentum. As a result, drug
particles are less likely to be hit against the immediate walls of upper airways.
During past few decades the Computational Fluid Dynamics (CFD) has emerged as a
powerful tool for capturing both airflow and particle transport characteristics in human
airways. CFD simulations can be used to directly address complicated and intercon-
nected geometrical and physical factors related to both particles and airflow, such as
flow turbulence [126], breathing patterns [250], the impact of discrete particles on con-
tinuous phase [128], and Brownian motion of particles [129].
The general objective of this research work is to study transport and deposition of ther-
apeutic particles bursting out of a commercially available MDI in realistic models of
the inhaler itself coupled with three commercial spacers. As will be described, the flow
is practically transient due to both transient nature of breathing and transient deliv-
ery of drug particles to the spacer inlet. Despite transient nature of breathing, it is
well established that steady-state simulations using average flow rates are computation-
ally efficient and are able to estimate the average deposition patterns that are in good
agreement with in vivo and in vitro experimental results [65, 126]. Therefore, transient
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delivery of drug can also be approximated as being steady, at least within the scope of
the present work.
Based on the flow Reynolds number (for an inhalation flow rate of 30 l/min) and ge-
ometrical irregularities associated with the inhaler and spacers, laminar to transitional
and even fully turbulent flow is expected. To resolve these multiple flow regimes, the
low Reynolds number (LRN) k − ω model is adopted based on its ability to accurately
predict pressure drop, velocity profiles, and shear stresses for transitional and turbu-
lent flows [132]. This model has been used successfully to accurately predict particle
deposition profiles for transitional and turbulent flows in models of the oral airways
[133, 146]) and multiple bifurcations [126]. In 2000, the first application of CFD to
study inhaler design was conducted by Versteeg, et al. [25], where CFD was utilized to
predict steady state airflow through an experimental MDI package and the Astra Zeneca
Pulmicort MDI, and to model an aerosol plume emitted within a USP induction port
(USP-IP). Flow fields through both MDIs were found to be similar and highly complex.
Jet flows emerging from the annulus around the canister were simulated and multiple
regions of recirculation were evident resulting in high levels of turbulence. Modeling
of the aerosol emitted within the USP-IP showed initial droplet trajectories dominated
by inertia, however, after relatively short distances, entrainment of surrounding air and
evaporation resulted in a slowing of the propellant plume and a reduction in droplet size.
Resulting droplet sizes and trajectories were consistent with a stochastic random walk
caused by turbulent effects. In this case the majority of deposition was found within the
horizontal regions of the USP throat, which is consistent with findings of more recent
research [146]. However, details of the CFD solution process utilized in this study were
limited and as such assessing the accuracy of the CFD simulation was difficult. In addi-
tion, Versteeg, et al. [25] acknowledged that due to technological limitations at the time
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only qualitative agreement between the CFD model and experiment could be achieved.
Subsequent studies into MDI and spacer devices utilizing CFD have been done with a
particular focus on the deposition of droplets within the device or spacer and the USP-IP
or realistic mouth throat geometries (MT). In a recent study, Longest and Hindle [165]
evaluated the performance of the Respimat Soft Mist Inhaler (SMI) through the con-
current use of CFD and in vitro dispersions into the USP-IP and realistic mouth throat
geometry (MT). In vitro dispersions indicated a substantial drug deposition loss of 27-
29%, however, deposition of the Respimat within the USP-IP and the MT was relatively
low, with most of the drug deposition occurring within the Respimat® mouthpiece.
This high drug deposition observed within the mouthpiece was in good agreement with
the CFD solution (within 20% error).
A comprehensive study was done by Kleinstreuer, et al. [53] to simulate the airflow,
droplet spray transport, and aerosol deposition in an MDI attached to a human upper
airway model. Different device propellants, nozzle diameters, and spacer use were also
investigated in this study. From the CFD simulations, multiple vortices were observed
within the inhaler and attached spacer at 30 l/min. The use of spacer significantly
reduced droplet deposition within the oral cavity and a greater proportion of droplets
reaching the lung in comparison with the absence of a spacer. In the case of CFC-MDIs
actuated in the absence of a spacer, only 5.2% of released droplets reached the lung
whilst 52.9% of droplets reached the lung when a spacer was used. Similarly, in HFA
MDIs, 46.6% of released droplets reached the lung in the absence of a spacer whilst
74.6% reached the lung when a spacer was used. These simulated results were in good
agreement with both in vitro and in vivo tests.
Although a rather great deal of experimental and numerical studies have been devoted
to investigate particle transport and deposition in human upper airways, relatively little
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work has been conducted in order to better quantify the particle transport phenomena
in realistic models of commercially available spacer inhalers. The fact that geometrical
models that have been utilized are oversimplified puts the validity of numerical stud-
ies in question and calls for more realistic investigation. In addition particles injection
conditions need to be more realistic so that the effects of particle initial momentum
is appropriately captured. In present work realistic models, based on direct measure-
ments of three commercially available spacers and one MDI are developed, and care is
exercised to capture almost all associated geometrical complexities. A novel particle
injection method is proposed which is argued to be capable of properly capturing the
impact of initial particle momentum and injection jet penetration on particle transport
and deposition characteristics without the need to account for compressibility effects
due to high jet velocity. This injection method will be discussed in detail later.
A.2 Methodology
A.2.1 Fluid Phase Governing Equations
The k − ω turbulence model with low Reynolds number (LRN) corrections has been
proved to be able to successfully predict the average velocity profiles, pressure drop, and
the shear stresses in the multi-regime flow field in human airways [126, 133, 146]. The
Reynolds-averaged Navier-Stokes equations governing the conservation of mass and mo-
mentum in incompressible laminar and turbulent fluid flows are represented in Equations
A.1-A.2 [135].
∂ui
∂uj
= 0 (A.1)
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where,ui is time-averaged velocity in the direction referred to by index i(i=1, 2, and 3
for a 3-D field), p the time averaged static pressure,ρ the fluid specific mass, and ν the
kinematic viscosity. The turbulent kinematic viscosity,νT , is as given in Equation A.3,
in which cµ is a constant with an accepted value of 0.09, and fµ is a function of RT =
k
νω
as defined in Equation A.4.
νT = cµ fµ
k
ω
(A.3)
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)2
 (A.4)
In the k − ω turbulence model two parameters are defined in order to account for the
turbulent nature of the flow field. These parameters are namely turbulence kinetic
energy,k, and turbulent dissipation rate,ω. These parameters characterize the kinetic
energy associated with the turbulent velocity fluctuations, and the viscous dissipation
rate due to turbulent shear stresses, respectively. The equations governing the transport
of the aforementioned turbulence parameters are given in Equations A.5-A.6.
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In which τij is Reynolds stress tensor, and β
∗, σk , α, β, and σω are constants with
accepted values of 1.0, 0.5, 0.555, 0.8333, and 0.5, respectively. The initial boundary
values of parameters k and ω are often determined using empirical correlations, two of
which are given in Equations A.7-A.8 [127].
k = 1.5 (I × uin) (A.7)
ω =
k1.5
0.6Rh
(A.8)
where, I, uin and Rh are upstream turbulence intensity, average velocity magnitude at
the relevant boundary, and hydraulic radius of the boundary, respectively.
A.2.2 Particle Phase Governing Equations
In previous section an Eulerian approach was introduced to resolve the continuous phase
flow field. The micro-particles, on the other hand, can be either treated on a continuous
Eulerian basis or a discrete Lagrangian one. To date both approaches have been utilized
successfully in case of respiratory particles. The key point make here is that in treating
the particles as a continuous phase, it is not possible to account for the particle inertia
effects on deposition rates, i.e. deposition due to inertial impaction [144]. However, it
is well established that this is the dominant mechanism effective on the transport and
deposition of micron sized particles in human upper airways. Since micron-sized inert
particles are under the scope of the present study, a Lagrangian approach is adopted to
tackle the particle transport phenomena. With a Lagrangian approach the particles are
treated as a finite number of discrete entities which may or may not have an impact on the
continuous phase. The effects of discrete particles on continuous phase can be accounted
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for in terms of source terms introduced to corresponding governing equations. In essence,
the Lagrangian approach is based on Newton’s second law of motion. Newton’s second
law of motion is written for each discrete particle, and, with known initial velocity, the
trajectory of each particle is determined, starting from a known initial position. Different
factors affecting the trajectory of each particle are introduced into the Newton’s second
law of motion in terms of appropriate force terms. These factors stem from different
physics, such as surface stresses due to the motion of particle relative to the surrounding
fluid, turbulent dispersion of particles as a result of fluid velocity fluctuations, and
particle-particle inter-collisions. The general form of the trajectory equations for a single
particle with constant mass is as follows, Equations A.9-A.10.
d
−→
U p
dt
= (1 + S)−→g + 1
τp
νrelnˆrel +
−→
f saff (A.9)
d
−→
X p
dt
=
−→
U p (A.10)
in which,
−→
U p and
−→
X p are the velocity and position vectors of particle, respectively. The
force terms on the right-hand side of Equation A.9a, are gravity-buoyancy, drag, and
Saffman lift forces per unit mass of the particle, respectively. In gravity-buoyancy force
S and −→g are fluid to particle density ratio
(
S =
ρf
ρp
)
and local vector of the gravita-
tional acceleration, respectively. In drag force expression τp, νrel and nˆrel are relaxation
time of the particle
(
τp =
ρp
ρf ν
2
rel
)
, in which Cc and CD are particle drag coefficient
and slip correction factor, respectively), the magnitude of fluid velocity relative to the
particle, and the unit vector in the direction of fluid velocity relative to the particle,
respectively. In areas of high velocity gradients the Saffman lift force becomes impor-
tant for micro particles [251]. The general expression of Saffman lift force, which is
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used in the present study, is as given in Equation A.11. In which dij is the deformation
tensor,dij =
(
∂ufi
∂xj
− ∂ufj∂xi
)
/2, and K is a constant with an accepted value of 2.594.
−→
f saff =
2ρf ν
0.5K dij
ρpdp (dkldlk)
0.5
(−→
U f −−→U p
)
(A.11)
In this study, it is assumed that the other forces, which have been known to affect the
particle trajectories under certain circumstances, are negligible, for example Brownian
motion effects, which, for the case of air near standard conditions as carrier fluid, be-
comes important for particles smaller than approximately 1µm in diameter, and Magnus
lift force which is a direct consequence of particle rotation relative to the surrounding
fluid. Slip correction factor also becomes important in such cases that the particle char-
acteristic length is comparable with the mean free path of carrier fluid. Since for the
case of respiratory particles the carrier fluid is essentially near standard air, this factor
is important for particles smaller than approximately 1µm in diameter. The drag coef-
ficient is computed according to Equation A.12, in which Rep = vreldp/ν is the particle
Reynolds number.
CD =
24
Rep
Rep < 1 (a)
CD =
24
Rep
(1 + 0.15Re0.687p ) Rep ≤ 1 ≤ 1000 (b) (A.12)
CD = 44 Rep > 1 (c)
It is well known that the fluid turbulence results in the enhanced dispersion of the par-
ticles [34, 126, 133, 146, 147]. Just like a sub-micron sized particle exhibiting Brownian
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motion in air, a particle, depending on its characteristic size and turbulence intensity,
may exhibit rather random but smooth changes of direction while moving through the
fluid. These changes contribute to enhanced dispersion and, as a result, deposition of
particles in human upper airways. The turbulent fluid flow is characterized with ve-
locity fluctuations, and these fluctuations directly impact the nearby particles. In the
course of tracking a particle, the fluid velocity vector is interpolated to the position of
particle at each particle time-step, and this velocity is used to determine the relative
velocity of particle and so the drag force. The reason why the effect of turbulent velocity
fluctuations is not included automatically is that in turbulence modeling using RANS
equations time-averaged velocity field is determined which is free from any time-varying
fluctuations.
In fact in time-averaged turbulence modeling the turbulent nature of the flow field is cast
into scalar turbulent parameters, in this case turbulent kinetic energy and dissipation
rate. Practically each velocity component should be regarded as being composed of a
time-averaged and a time-varying component, Equation A.13. Therefore in the course
of tracking a discrete particle in a turbulent field it is required that at each time-step
the time-averaged velocity vector be superimposed by the velocity fluctuations, which
should be appropriately estimated from scalar turbulent parameters at the location of
particle.
ui = ui + u
′
i (A.13)
Since the turbulent kinetic energy is by definition the kinetic energy attributed to the
velocity fluctuations, it is reasonable to use its value in order to estimate the magnitude
of time-varying velocity components, Equation A.14. Note that this should be regarded
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as a time-averaged absolute value, and therefore adding it up to directly would lead
to erroneous and unrealistic results. In fact in this approach, which is referred to as
random walk method, is sampled from a natural Gaussian distribution with an average
value of and a standard deviation of unity [252, 253].
u′i =
√
2K
3
(A.14)
Each turbulent eddy is characterized with a kinetic energy, and a finite lifespan, which
is the characteristic time required for to be dissipated away. Therefore, in random walk
method the particle time-step is set equal to the minimum of eddy lifespan and the
characteristic time required for the particle to cross the turbulent eddy, Equation A.15.
In which is the eddy length scale.
4 tp = min
{
0.15
ω
,−τpln
(
1− Le
τpvrel
)}
(A.15)
The main shortcoming of this Random Walk approach is the isotropy assumption for
turbulent velocity profiles, which does not hold true especially in near wall regions.
In essence in the vicinity of a solid wall the fluctuating velocity components in the
direction normal to the wall are attenuated relative to those in its tangential directions.
Thus the aforementioned approach for determining the turbulent velocity components
overestimates the velocity fluctuations in wall normal direction, and this, in turn, results
in overestimation of particle deposition. In order to account for turbulence anisotropy,
especially in near-wall regions, more sophisticated models are required that are not
considered in this study.
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(i) (ii) (iii)
Figure A.1: Three common commercial spacers
A.2.3 Geometry and Boundary Condition
In order to develop realistic geometrical models, a commercial inhaler, Albuterol HFA,
and three spacers were procured. Great care was practiced to measure the respective
dimensions of each and develop its 3-dimensional model. The isometric views of the
spacer-inhaler pairs are given in Figure A.1i-A.1iii. Each spacer demonstrates an ex-
pansion region which is, supposedly, to harness the initial momentum of the therapeutic
burst leaving the inhaler. The expansion region is followed by an obstruction which is
apparently intended to filter out undesirably coarse particles through inertial impaction
and preventing them from finding their way to the patient’s airways.
In previous works this impaction section has not been included in the model as well as
geometrical irregularities associated with the pressured gas canister and its holder. The
spacers also exhibit a one-way valve which allows airflow through inhaler-spacer to mouth
during inhalation and prevents airflow from mouth to inhaler-space during exhalation.
This is how these spacers let the patient breathe in the medication during several strokes
and, thereby, provides a second chance for those particles that cannot pass the spacer
during the first breath. In spacers type I and III the impaction plane is, respectively,
followed and preceded by a set of four plastic quadrants which deflect open during
inhalation and close during exhalation. In spacer type II, the impaction plane slides
open and close during inhalation and exhalation, respectively. The geometrical models
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Figure A.2: Isometric views of three commercial spacer-inhaler pairs; the spacers are
referred to as A. type I; B. type II; and C. type III
are only created with the valves open, since the scope of this study is the transport
and deposition of therapeutic particles during inhalation. In spacers type I and III the
presence of plastic quadrants leaves a considerable impact on fluid flow fields that not
including them in the physical models leads to highly erroneous results especially in
the course of particle tracking. A constant volume flow rate of 30 l/min is imposed on
spacer outlet and a gauge pressure of zero on inhaler inlet. Drug particles have been
reported to leave the inhaler at an initial velocity of approximately 150 m/s for the
inhaler of our interest [105]. The injection period was measured by means of sequential
photography as shown in Figure A.3i-A.3iii. The time interval between the images is
1/60 s and total injection time is, therefore, approximately 0.05 s. Since the injection
time is relatively small as compared to the inhalation time, 1.3 s, and the injection
orifice diameter is small (approximately 0.5 mm) [105], one common approximation
would be ignoring the effects of short-term burst and investigate the problem under the
aforementioned mass-flow and pressure boundary conditions. But the main challenge
arises when one considers injecting drug particles in a rather realistic manner. It is
argued that micron-sized particles quickly adapt themselves to the flow filed. Therefore,
realistic model injected particles in a realistic manner it is needed to model the carrier
gas in a realistic manner. Injection orifice is 0.5 mm in diameter with an injection speed
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Figure A.3: Therapeutic cloud at times A. 1/60; B. 2/60; and C. 3/60 s; a and c
mark the start and stop of injection, respectively.
150 m/s. If one attempts to include them completely, the first fact results in undesirably
small mesh sizes at injection port and the latter one brings about convergence problems
if the flow near the injection plane is not assumed to be compressible, just as in the
case of this study. As we aim at imparting the particles a realistic initial momentum
the injection plane is assumed to have a diameter of 4 mm which is 8 times its original
value.Assuming constant momentum rate, it can be readily concluded that the injection
velocity should be taken 1/8 times its initial value. This assumption can be set on a
more solid foundation with the argument that follows. If it is assumed that jet is a
cylindrical fluid element which has a kinetic energy proportional to ρD2V 2, where ρ,
D and V are density, diameter and velocity of the jet respectively. The work done by
viscous effects on the jet is proportional to τaveDL where L is penetration length of the
jet. Equating these two expressions yields L = ρDV 2/τave. Assuming shear stress is
directly proportional to V (since τ = µ∂V∂x ≈ µ∆V∆x = µV−0x−0 ) results in L ∝ DV . Then it
follows that penetration length is approximately equal values provided that the product
of DV remains unchanged. Therefore, the particles are assumed to be injected with a
carrier flow of a velocity of about 20 m/s through an orifice of 4 mm in diameter. In order
to provide a better picture, velocity contours are compared in Figgure A.4 for cases of
V=20 m/s, D=4 mm and V=40 m/s, D=2 mm, and striking similarity is observed in the
two flow fields in addition particle tracking results showed that their particle deposition
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(ii)
Figure A.4: Mid-plane velocity contours for inhaler spacer type III for A. V=20 m/s,
D=4 mm, and B. V=40 m/s, D=2 mm.
results are the same with at most 5% error.
A.3 Results and Discussions
A.3.1 Grid Study
Grid study results for spacer type III are shown in Figure A.6i-A.6iv. As illustrated
in Figure A.5, the A-B line is taken as reference in order to compare the velocity com-
ponents and velocity magnitudes for different computational grids. Flow fields are re-
solved for computational grids comprising approximately 700,000; 1,300,000; 1,600,000;
3,000,000; and 3,800,000 computational cells. The elements are mainly refined in high
velocity gradient regions and near walls. It is observed that the results of the two latter
grids are in good agreement with each other. Particle deposition efficiency is taken as
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Figure A.5: The A-B line is taken as reference in order to compare the velocity
magnitude and components for different computational grids.
another criterion for grid-independency examination because it is highly dependent on
grid quality specially near walls. As shown in Figure A.7i-A.7ii once again the latter
two grids result in acceptably identical particle deposition curves with less than 5% er-
ror. Therefore, the grid with 3,000,000 computational cells is considered to yield results
that are grid-independent. The same procedure is performed for the other two pairs.
However, the results are not presented here for the sake of brevity.
A.3.2 Flow Fields
Fluid flow fields are resolved using k− ω turbulence model of Ansys-Fluent commercial
code. Ideally, the therapeutic jet should leave the canister aligned with the central axis
of the spacer. Otherwise, the impaction sections of the spacers do not function properly.
According to the geometry of the inhaler-spacer, if the carrier flow is assumed to leave
in the direction perpendicular to the injection plane, the therapeutic jet turns out to
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Figure A.6: Comparison of A.Velocity magnitude, B.X-velocity, C.Y-velocity, D.Z-
velocity for computational grids 1-5 comprising 700,000; 1,300,000; 1,600,000; 3,000,000;
and 3,800,000 computational cells, respectively. The results of grid 4 and 5 are in good
agreement with each other.
be off-axis. Therefore, carrier gas should be assumed to be injected in the direction of
spacer axis rather than perpendicular to the injection port. Mid-plane velocity contours
for the case of perpendicular injection are presented in Figure A.8 for inhaler spacer type
I, II, and III, respectively. For the sake of comparison, contours of velocity magnitude
for the case of axial injection are presented in Figure A.8a-c for inhaler spacer type
I, II, and III, respectively. It is simply observed that in the latter case particle blast,
heads straight toward the impaction plane and spacer exit afterwards. In this way the
impaction section filters out the particles smaller than the respective cut off diameter
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Figure A.7: Comparison of particle deposition fraction (Number of particles deposited
in spacer divided by the number of particles released from inhaler) for A.Mean-velocity
particle tracking and B.Stochastic particle tracking for computational grids 1 to. The
results of grid 4 and 5 are in good agreement with each other(less than 5% error).
efficiently.
A.3.3 Particle Transport and Deposition
For the particles under these flow conditions, two different deposition mechanisms can
be considered effective; first one being inertial impaction which is deposition of larger
particles with less ability to adapt their path to velocity field variations due to their
inertia, and the second one being turbulent dispersion which is due to diffusive mo-
tion of particles under the effect of turbulent eddies. Particle deposition curves for the
three inhaler-spacers are presented in Figure A.9 for three different injection conditions,
namely, zero-momentum particle injection, non axial injection with carrier gas, and ax-
ial injection with carrier gas. Sample deposition patterns are also presented in Figure
A.10 For the sake of generality, no emphasis is paid to one particular inhaler with its
associated particle size distribution and particles ranging from 1− 50µm are considered
in the course of particle tracking. To calculate deposition fraction, for each particle size
1000 mono-disperse particles are released from the injector surface and tracked. Because
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Figure A.8: Contours of velocity magnitude for the case of axial injection at mid-
planes of a. inhaler spacer I, b. inhaler spacer II, and c. inhaler spacer III
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Figure A.9: Particle deposition curves for zero momentum injection (A), non axial
injection (B), and axial injection (C).
of the randomness that exists in stochastic particle tracking method this procedure is
repeated for 3 times and the average of these 3 times is taken as deposition result. The
results of the case with zero initial momentum are of less interest because they are not
realistic. For non-axial injection, on the other hand, rather interesting result is that
at least nearly 30% of the particles are filtered out through the spacer type II;under
the same injection conditions, this minimum deposition fraction is 40% and as high as
almost 70% for spacer type III and I, respectively. For the more realistic condition of
axial injection, the minimal deposition fractions are roughly 45, 55, and 70% for spacer
type II, type III, and type I, respectively.
One fact contributing to excessively high entrapment of particles in spacer type I is its
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small length and diameter that might prove insufficient to suppress the initial momen-
tum of particles. Another fact is that in the case of spacer III the impaction section is
preceded by plastic quadrants, while it is followed by an equivalent set of plastic quad-
rants in the case of spacer I. It is concluded that for spacer III the particles are well
directed and accelerated toward the impaction section no matter the injection is axial
or non-axial.But for the case of spacer I quite a large number of particles entrapped in
the circulating regions downstream impaction deposit on plastic quadrants. Figure A.9
supports this fact well, as compared with respective patterns of the other two types of
spacer. It is observed that in inhaler-spacer type II, the deposition curves do not exhibit
sharp cut-off diameters, because in inhaler-spacer type II the expansion region is large
enough to suppress the initial momentum of particles almost completely. Therefore, it
can be said that the sliding plane in this type of spacers acts as a one-way valve not an
impaction section.It is also observed that in all three cases deposition fractions are the
highest for spacer type I and the lowest for spacer type II. The latter can be attributed
to the fact that impaction mechanism is not effective for spacer type II as discussed
before. In the case of mean velocity particle tracking, as shown in Figure A.10, particle
trajectories are smooth; but, in Random Walk particle tracking, particle paths are not
smooth because of the effect of velocity fluctuations on particles, which in turn increases
particle deposition significantly. .
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Figure A.10: Mean velocity (A) and random walk model(B) particle paths in case of
axial injection for inhaler-spacer type II for 20µm particle
Appendix B
MATLAB Pre/Post-processing
Codes
B.1 Particle distribution file generator
clear all;clc;
r0 =0.00998; % radious of the circle
N_ring =200;
dr=r0/N_ring;
particle_dens =20140;
x0=0;y0= -1.21E-09;z0=0; % centre of the particle distribution
dp=13e-06; % paricle diameter
T=300; % Tempretutre
u=0; % intitial velocity in x-direction
v=0; % intitial velocity in y-direction
w=0; % intitial velocity in z-direction
ms=1e-24; % mass flow
% count =1000; % particle Density Index
%fid1=fopen(’Injection -dp -13.inj ’,’w’);
fid2=fopen(’Injection -St -0.1- coor.txt ’,’w’);
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y=y0;
injectionName=’dp -13’;
k=0; % particle counter
b=1; % Particle counter in the inj file
for i=1:N_ring -1;
r=i*dr;
q=round(particle_dens*r);
for j=1:q;
tet=rand *2*pi;
p(j)=r+dr*rand;
x(j)=p(j)*cos(tet); %definition of x-coordinate
z(j)=p(j)*sin(tet); %definition of y-coordinate
% plot(x(j),y(j));
% hold on;
% plot(x,y);
% hold on;
% fprintf(fid1 ,’((%f %f %f %f %f %f %f %f %f))\n’,
x,z,y,u,v,w,dp ,T,ms);
% fprintf(fid2 ,’%f %f %f\n’, x,y,z);
% z(j)=z0;
k=k+1;
end;
for l=1:q
% fprintf(fid1 ,’((%e %e %e %e
%e %e %e %e %e)%s:%i)\n’,x(l),y0 ,z(l),u,v,w,dp ,T,ms,injectionName ,b-1);
fprintf(fid2 ,’%f %f %f\n’,x(l),y0,z(l));
b=b+1;
end;
a=5;
scatter(x,z,a,’b’);
hold on;
end;
k
% fclose(fid1);
fclose(fid2);
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B.2 DPM file analyzer
clc; clear all;
for p=1:10 %%% Folder ID Counter %%%%%%%%%
%%
%%%%%%%% Swaping Folders %%%%%%%%%%%%%%%%
cd(sprintf (’%30s%d’,’F:\ Fluent \60 lit per min -1000\ Dp\’,p));
delete (’*.txt ’); %%% delete all text file to avoid any mistake %%%%%
%***************** Reading particle distribution file ********************
formatSpec =’((%f %f %f %f %f %f %f %f %f)’;
str=sprintf(’Injection -dp -%d.inj ’,p);
fid=fopen(sprintf(’%s’,str ));
HH{1}= textscan(fid ,formatSpec ,[9 Inf ]);
tline = fgetl(fid);
j=2;
while ischar(tline)
HH{j}= textscan(fid ,formatSpec ,[9 Inf ]);
j=j+1;
tline = fgetl(fid);
end;
%%%% Sorting data from HH Cell to G cell %%%%
for u=1:9
for v=1:j-1
G(v,u)=HH{v}(1,u);
end;
end;
%%%%%%% Converting G cell to H matrix %%%%%%%%%%%%
H=cell2mat(G);
[ee ,ss]=size(H); %%%%% Injection Matrix size
fclose(fid);
%%
%%%%%%******* Data Manipulation for wall -larynx.dpm file ********************
formatSpec =’((%f%f%f%f%f%f%f%f%f%f%f%f)%9s%1s%1f%1s%f%1s)\r\n’;
fid_1=fopen(’wall -larynx.dpm ’);
linesToSkip =2;
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for ii = 1: linesToSkip -1
fgetl(fid);
end
tline=fgetl(fid);
i=1;
while ischar(tline)
A{i}= textscan(fid ,formatSpec );
tline=fgetl(fid);
i=i+1;
end;
%%%%%%%%%%% putting data for the first 12 elements into the matrix %%%%%%%
for u=1:12
for v=1:i-1
FA(v,u)=A{v}(1,u);
end;
end;
%%%%%%%%%%%%%%% putting the 17th element (particle counter) into the matrix %%%%%
for v=1:i-1
FA(v ,13)=A{v}(1 ,17);
end;
%%%%%%% Converting G cell to H %%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
WA=cell2mat(FA);
[n,m]=size(WA);
%********* Extracting Particles Depostion Coordinate for wall -larynx.dpm ***************
for i=1:n
AA(i,1)=WA(i,1);
AA(i,2)=WA(i,2);
AA(i,3)=WA(i,3);
end;
%%%******* Extracting Deposited Particles ID for Wall -larynx *********
for i=1:n
QA(i,1)=H(WA(i,m)+1 ,1);
QA(i,2)=H(WA(i,m)+1 ,2);
QA(i,3)=H(WA(i,m)+1 ,3);
end;
% %%%*********** Exporting in the form of a txt file -Deposition *******************
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filename=’larynx -Dep.txt ’;
file_D=fopen(filename ,’a’);
fprintf(file_D ,’TITLE="wall -larynx -Dep"\ nVARIABLES ="X","Y","Z"\nZONE T="wall -larynx -Dep"\n’);
dlmwrite(filename ,AA,’-append ’,’delimiter ’,’\t’,’precision ’,’%1.3e’);
fclose(file_D );
%%%%%% Exporting in the form of a txt file -Released position %%%%%%%%%%%%%%%%
filename=’larynx -Ini.txt ’;
file_I=fopen(filename ,’a’);
fprintf(file_I ,’TITLE="wall -larynx -Ini"\ nVARIABLES ="X","Y","Z"\nZONE T="wall -larynx -Ini"\n’);
dlmwrite(filename ,QA,’-append ’,’delimiter ’,’\t’,’precision ’,’%1.3e’);
% %%%%*** percentage of Peresence of particles at Inlet ***************
s1=0;s2=0;s3=0;s4=0;s5=0;s6=0;s7=0;s8=0;
for i=1:n
l=180/pi*atan2(QA(i,3),QA(i,1));
if -180<=l && l<-135
s1=s1+1;
elseif -135<=l && l<-90
s2=s2+1;
elseif -90<=l && l<-45
s3=s3+1;
elseif -45<=l && l<0
s4=s4+1;
elseif 0<=l && l<45
s5=s5+1;
elseif 45<=l && l<90
s6=s6+1;
elseif 90<=l && l<135
s7=s7+1;
elseif 135<=l && l<=180
s8=s8+1;
end;
end;
perc_s1 =(s1/ee )*100;
perc_s2 =(s2/ee )*100;
perc_s3 =(s3/ee )*100;
perc_s4 =(s4/ee )*100;
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perc_s5 =(s5/ee )*100;
perc_s6 =(s6/ee )*100;
perc_s7 =(s7/ee )*100;
perc_s8 =(s8/ee )*100;
Dep_larynx=perc_s1+perc_s2+perc_s3+perc_s4+perc_s5+perc_s6+perc_s7+perc_s8;
Sec=fopen(’Sections.txt ’,’w’);
fprintf(Sec ,’SECTIONS -Larynx\nSection -1=%f\nSection -2=%f\nSection -3=
%f\nSection -4=%f\nSection -5=
%f\nSection -6=%f\nSection -7=%f\nSection -8=%f\n\n’
,perc_s1 ,perc_s2 ,perc_s3 ,perc_s4 ,perc_s5 ,perc_s6 ,perc_s7 ,perc_s8 );
%%%****** Data Manipulation for wall -pharynx.dpm file *****************
formatSpec =’((%f%f%f%f%f%f%f%f%f%f%f%f)%9s%1s%1f%1s%f%1s)\r\n’;
fid=fopen(’wall -pharynx.dpm ’);
linesToSkip =2;
for ii = 1: linesToSkip -1
fgetl(fid);
end
tline=fgetl(fid);
i=1;
while ischar(tline)
B{i}= textscan(fid ,formatSpec );
tline=fgetl(fid);
i=i+1;
end;
%%%%%%%%%%% putting data for the first 12 elements into the matrix %%%%%%%
for u=1:12
for v=1:i-1
FB(v,u)=B{v}(1,u);
end;
end;
%%%%%%%%%%%%%%%%%%%%%%%%%
for v=1:i-1
FB(v ,13)=B{v}(1 ,17);
end;
%%%%%%% Converting G cell to H matrix %%%%%%%%%%%%
WB=cell2mat(FB);
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[n,m]=size(WB);
%***** Extracting Particles Depostion Coordinate for wall -larynx.dpm **********
for i=1:n
BB(i,1)=WB(i,1);
BB(i,2)=WB(i,2);
BB(i,3)=WB(i,3);
end;
% %%************ Extracting Deposied Particles ID for pharynx *********
for i=1:n
QB(i,1)=H(WB(i,m)+1 ,1);
QB(i,2)=H(WB(i,m)+1 ,2);
QB(i,3)=H(WB(i,m)+1 ,3);
end;
%%%%*********** Exporting in the form of a txt file -Deposition ************************
filename=’pharynx -Dep.txt ’;
file_D=fopen(filename ,’a’);
fprintf(file_D ,’TITLE="pharynx -Dep"\ nVARIABLES ="X","Y","Z"\nZONE T="pharynx -Dep"\n’);
dlmwrite(filename ,BB,’-append ’,’delimiter ’,’\t’,’precision ’,’%1.3e’);
fclose(file_D );
%%%%%%%%%%%% Exporting in the form of a txt file -Released position %%%%
filename=’pharynx -Ini.txt ’;
file_I=fopen(filename ,’a’);
fprintf(file_I ,’TITLE="pharynx -Ini"\ nVARIABLES ="X","Y","Z"\nZONE T="pharynx -Ini"\n’);
dlmwrite(filename ,QB,’-append ’,’delimiter ’,’\t’,’precision ’,’%1.3e’);
fclose(file_I );
% %%******** percentage of Peresence of particles at Inlet ***************
s1=0;s2=0;s3=0;s4=0;s5=0;s6=0;s7=0;s8=0;
for i=1:n
l=180/pi*atan2(QB(i,3),QB(i,1));
if -180<=l && l<-135
s1=s1+1;
elseif -135<=l && l<-90
s2=s2+1;
elseif -90<=l && l<-45
s3=s3+1;
elseif -45<=l && l<0
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s4=s4+1;
elseif 0<=l && l<45
s5=s5+1;
elseif 45<=l && l<90
s6=s6+1;
elseif 90<=l && l<135
s7=s7+1;
elseif 135<=l && l<=180
s8=s8+1;
end;
end;
perc_s1 =(s1/ee )*100;
perc_s2 =(s2/ee )*100;
perc_s3 =(s3/ee )*100;
perc_s4 =(s4/ee )*100;
perc_s5 =(s5/ee )*100;
perc_s6 =(s6/ee )*100;
perc_s7 =(s7/ee )*100;
perc_s8 =(s8/ee )*100;
Dep_pharynx=perc_s1+perc_s2+perc_s3+perc_s4+perc_s5+perc_s6+perc_s7+perc_s8;
fprintf(Sec ,’SECTIONS -Pharynx\nSection -1=%f\nSection -2=%f\nSection -3=
%f\nSection -4=%f\nSection -5=%f\nSection -6=%f\nSection -7=%f\nSection -8
=%f\n\n’,perc_s1 ,perc_s2 ,perc_s3 ,perc_s4 ,perc_s5 ,perc_s6 ,perc_s7 ,perc_s8 );
%%%%******* Data Manipulation for wall -mouth.dpm file ********************
formatSpec =’((%f%f%f%f%f%f%f%f%f%f%f%f)%9s%1s%1f%1s%f%1s)\r\n’;
fid=fopen(’wall -mouth.dpm ’);
linesToSkip =2;
for ii = 1: linesToSkip -1
fgetl(fid);
end
tline=fgetl(fid);
i=1;
while ischar(tline)
C{i}= textscan(fid ,formatSpec );
tline=fgetl(fid);
i=i+1;
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end;
%%%%%%%%%%% putting data for the first 12 elements into the matrix %%%%%%%
for u=1:12
for v=1:i-1
FC(v,u)=C{v}(1,u);
end;
end;
%%%%%%%%%%%%%%%%%%%%%%%%%
for v=1:i-1
FC(v ,13)=C{v}(1 ,17);
end;
%%%%%%% Converting G cell to H matrix %%%%%%%%%%%%
WC=cell2mat(FC);
[n,m]=size(WC);
%***** Extracting Particles Depostion Coordinate for wall -mouth.dpm **********
for i=1:n
CC(i,1)=WC(i,1);
CC(i,2)=WC(i,2);
CC(i,3)=WC(i,3);
end;
% %%************ Extracting Deposied Particles ID for mouth *********
for i=1:n
QC(i,1)=H(WC(i,m)+1 ,1);
QC(i,2)=H(WC(i,m)+1 ,2);
QC(i,3)=H(WC(i,m)+1 ,3);
end;
%%%%*********** Exporting in the form of a txt file -Deposition ***********
filename=’mouth -Dep.txt ’;
file_D=fopen(filename ,’a’);
fprintf(file_D ,’TITLE="mouth -Dep"\ nVARIABLES ="X","Y","Z"\ nZONE T="mouth -Dep"\n’);
dlmwrite(filename ,CC,’-append ’,’delimiter ’,’\t’,’precision ’,’%1.3e’);
fclose(file_D );
%%%%%%%% Exporting in the form of a txt file -Released position %%%%%%%%%%%%%%%%
filename=’mouth -Ini.txt ’;
file_I=fopen(filename ,’a’);
fprintf(file_I ,’TITLE="mouth -Ini"\ nVARIABLES ="X","Y","Z"\ nZONE T="mouth -Ini"\n’);
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dlmwrite(filename ,QC,’-append ’,’delimiter ’,’\t’,’precision ’,’%1.3e’);
fclose(file_I );
% %%%************ percentage of Peresence of particles at Inlet **************
s1=0;s2=0;s3=0;s4=0;s5=0;s6=0;s7=0;s8=0;
for i=1:n
l=180/pi*atan2(QC(i,3),QC(i,1));
if -180<=l && l<-135
s1=s1+1;
elseif -135<=l && l<-90
s2=s2+1;
elseif -90<=l && l<-45
s3=s3+1;
elseif -45<=l && l<0
s4=s4+1;
elseif 0<=l && l<45
s5=s5+1;
elseif 45<=l && l<90
s6=s6+1;
elseif 90<=l && l<135
s7=s7+1;
elseif 135<=l && l<=180
s8=s8+1;
end;
end;
perc_s1 =(s1/ee )*100;
perc_s2 =(s2/ee )*100;
perc_s3 =(s3/ee )*100;
perc_s4 =(s4/ee )*100;
perc_s5 =(s5/ee )*100;
perc_s6 =(s6/ee )*100;
perc_s7 =(s7/ee )*100;
perc_s8 =(s8/ee )*100;
Dep_Mouth=perc_s1+perc_s2+perc_s3+perc_s4+perc_s5+perc_s6+perc_s7+perc_s8;
fprintf(Sec ,’SECTIONS -Mouth\nSection -1=%f\nSection -2=%f\nSection -3=%f\nSection -4=
%f\nSection -5=%f\nSection -6=%f\nSection -7=%f\nSection -8=
%f\n\n’,perc_s1 ,perc_s2 ,perc_s3 ,perc_s4 ,perc_s5 ,perc_s6 ,perc_s7 ,perc_s8 );
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%%***** Data Manipulation for wall -trachea.dpm file ********************
formatSpec =’((%f%f%f%f%f%f%f%f%f%f%f%f)%9s%1s%1f%1s%f%1s)\r\n’;
fid=fopen(’wall -trachea.dpm ’);
linesToSkip =2;
for ii = 1: linesToSkip -1
fgetl(fid);
end
tline=fgetl(fid);
i=1;
while ischar(tline)
D{i}= textscan(fid ,formatSpec );
tline=fgetl(fid);
i=i+1;
end;
%%%%%%%%%%% putting data for the first 12 elements into the matrix %%%%%%%
for u=1:12
for v=1:i-1
FD(v,u)=D{v}(1,u);
end;
end;
%%%%%%%%%%%%%%%%%%%%%%%%%
for v=1:i-1
FD(v ,13)=D{v}(1 ,17);
end;
%%%%%%% Converting G cell to H matrix %%%%%%%%%%%%
WD=cell2mat(FD);
[n,m]=size(WD);
%***** Extracting Particles Depostion Coordinate for wall -larynx.dpm **********
for i=1:n
DD(i,1)=WD(i,1);
DD(i,2)=WD(i,2);
DD(i,3)=WD(i,3);
end;
% %%******************* Extracting Deposied Particles ID for Wall -1 *********
for i=1:n
QD(i,1)=H(WD(i,m)+1 ,1);
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QD(i,2)=H(WD(i,m)+1 ,2);
QD(i,3)=H(WD(i,m)+1 ,3);
end;
% %%%*********** Exporting in the form of a txt file -Deposition *****************
% filename=’trachea -Dep.txt ’;
% file_D=fopen(filename ,’a’);
% fprintf(file_D ,’TITLE="trachea -Dep"\ nVARIABLES ="X","Y","Z"\nZONE T="trachea -Dep"\n’);
% dlmwrite(filename ,DD,’-append ’,’delimiter ’,’\t’,’precision ’,’%1.3e’);
% fclose(file_D );
%%%%%% Exporting in the form of a txt file -Released position %%%%%%%%%%%%%%%%
filename=’trachea -Ini.txt ’;
file_I=fopen(filename ,’a’);
fprintf(file_I ,’TITLE="trachea -Ini"\ nVARIABLES ="X","Y","Z"\nZONE T="trachea -Ini"\n’);
dlmwrite(filename ,QD,’-append ’,’delimiter ’,’\t’,’precision ’,’%1.3e’);
fclose(file_I );
% %******* percentage of Peresence of particles at Inlet ****************
s1=0;s2=0;s3=0;s4=0;s5=0;s6=0;s7=0;s8=0;
for i=1:n
l=180/pi*atan2(QD(i,3),QD(i,1));
if -180<=l && l<-135
s1=s1+1;
elseif -135<=l && l<-90
s2=s2+1;
elseif -90<=l && l<-45
s3=s3+1;
elseif -45<=l && l<0
s4=s4+1;
elseif 0<=l && l<45
s5=s5+1;
elseif 45<=l && l<90
s6=s6+1;
elseif 90<=l && l<135
s7=s7+1;
elseif 135<=l && l<=180
s8=s8+1;
end;
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end;
perc_s1 =(s1/ee )*100;
perc_s2 =(s2/ee )*100;
perc_s3 =(s3/ee )*100;
perc_s4 =(s4/ee )*100;
perc_s5 =(s5/ee )*100;
perc_s6 =(s6/ee )*100;
perc_s7 =(s7/ee )*100;
perc_s8 =(s8/ee )*100;
Dep_Trachea=perc_s1+perc_s2+perc_s3+perc_s4+perc_s5+perc_s6+perc_s7+perc_s8;
fprintf(Sec ,’SECTIONS -Trachea\nSection -1=%f\nSection -2=%f\nSection -3=%f\nSection -4=
%f\nSection -5=%f\nSection -6=%f\nSection -7=%f\nSection -8=
%f\n\n’,perc_s1 ,perc_s2 ,perc_s3 ,perc_s4 ,perc_s5 ,perc_s6 ,perc_s7 ,perc_s8 );
%%%%%%******* Data Manipulation for outlet.dpm file ********************
formatSpec =’((%f%f%f%f%f%f%f%f%f%f%f%f)%9s%1s%1f%1s%f%1s)\r\n’;
fid=fopen(’outlet.dpm ’);
linesToSkip =2;
for ii = 1: linesToSkip -1
fgetl(fid);
end
tline=fgetl(fid);
i=1;
while ischar(tline)
E{i}= textscan(fid ,formatSpec );
tline=fgetl(fid);
i=i+1;
end;
%%%%%%%%%%% putting data for the first 12 elements into the matrix %%%%%%%
for u=1:12
for v=1:i-1
FE(v,u)=E{v}(1,u);
end;
end;
%%%%%%%%%%%%%%%%%%%%%%%%%
for v=1:i-1
FE(v ,13)=E{v}(1 ,17);
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end;
%%%%%%% Converting G cell to H matrix %%%%%%%%%%%%
WE=cell2mat(FE);
[n,m]=size(WE);
%***** Extracting Particles Depostion Coordinate for outlet.dpm ***************
for i=1:n
EE(i,1)=WE(i,1);
EE(i,2)=WE(i,2);
EE(i,3)=WE(i,3);
end;
% %%************* Extracting Deposied Particles ID for outlet *********
for i=1:n
% if WE(i,m)~=0
QE(i,1)=H(WE(i,m)+1 ,1);
QE(i,2)=H(WE(i,m)+1 ,2);
QE(i,3)=H(WE(i,m)+1 ,3);
% end;
end;
% %***** Exporting in the form of a txt file -Deposition ***************
filename=’outlet -Dis.txt ’;
file_D=fopen(filename ,’a’);
fprintf(file_D ,’TITLE="outlet -Dis"\ nVARIABLES ="X","Y","Z"\nZONE T="outlet -Dis"\n’);
dlmwrite(filename ,EE,’-append ’,’delimiter ’,’\t’,’precision ’,’%1.3e’);
fclose(file_D );
%%%%%%%%% Exporting in the form of a txt file -Released position %%%%%%%%%%%%%%%%
filename=’outlet -Ini.txt ’;
file_I=fopen(filename ,’a’);
fprintf(file_I ,’TITLE="outlet -Ini"\ nVARIABLES ="X","Y","Z"\nZONE T="outlet -Ini"\n’);
dlmwrite(filename ,QE,’-append ’,’delimiter ’,’\t’,’precision ’,’%1.3e’);
fclose(file_I );
% %%***** percentage of Peresence of particles at Inlet ******************
s1=0;s2=0;s3=0;s4=0;s5=0;s6=0;s7=0;s8=0;
for i=1:n
l=180/pi*atan2(QE(i,3),QE(i,1));
if -180<=l && l<-135
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s1=s1+1;
Qs1(s1 ,1)=EE(i,1);
Qs1(s1 ,2)=EE(i,2);
Qs1(s1 ,3)=EE(i,3);
elseif -135<=l && l<-90
s2=s2+1;
Qs2(s2 ,1)=EE(i,1);
Qs2(s2 ,2)=EE(i,2);
Qs2(s2 ,3)=EE(i,3);
elseif -90<=l && l<-45
s3=s3+1;
Qs3(s3 ,1)=EE(i,1);
Qs3(s3 ,2)=EE(i,2);
Qs3(s3 ,3)=EE(i,3);
elseif -45<=l && l<0
s4=s4+1;
Qs4(s4 ,1)=EE(i,1);
Qs4(s4 ,2)=EE(i,2);
Qs4(s4 ,3)=EE(i,3);
elseif 0<=l && l<45
s5=s5+1;
Qs5(s5 ,1)=EE(i,1);
Qs5(s5 ,2)=EE(i,2);
Qs5(s5 ,3)=EE(i,3);
elseif 45<=l && l<90
s6=s6+1;
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Qs6(s6 ,1)=EE(i,1);
Qs6(s6 ,2)=EE(i,2);
Qs6(s6 ,3)=EE(i,3);
elseif 90<=l && l<135
s7=s7+1;
Qs7(s7 ,1)=EE(i,1);
Qs7(s7 ,2)=EE(i,2);
Qs7(s7 ,3)=EE(i,3);
elseif 135<=l && l<=180
s8=s8+1;
Qs8(s8 ,1)=EE(i,1);
Qs8(s8 ,2)=EE(i,2);
Qs8(s8 ,3)=EE(i,3);
end;
end;
perc_s1 =(s1/ee )*100;
perc_s2 =(s2/ee )*100;
perc_s3 =(s3/ee )*100;
perc_s4 =(s4/ee )*100;
perc_s5 =(s5/ee )*100;
perc_s6 =(s6/ee )*100;
perc_s7 =(s7/ee )*100;
perc_s8 =(s8/ee )*100;
Dis_Oulet=perc_s1+perc_s2+perc_s3+perc_s4+perc_s5+perc_s6+perc_s7+perc_s8;
fprintf(Sec ,’SECTIONS -Outlet\nSection -1=%f\nSection -2=%f\nSection -3=
%f\nSection -4=%f\nSection -5=%f\nSection -6=%f\nSection -7=%f\nSection -8=
%f\n\n’,perc_s1 ,perc_s2 ,perc_s3 ,perc_s4 ,perc_s5 ,perc_s6 ,perc_s7 ,perc_s8 );
fclose(Sec);
dlmwrite(’Qs1.txt ’,Qs1 ,’delimiter ’,’\t’,’precision ’,’%1.3e’);
dlmwrite(’Qs2.txt ’,Qs2 ,’delimiter ’,’\t’,’precision ’,’%1.3e’);
dlmwrite(’Qs3.txt ’,Qs3 ,’delimiter ’,’\t’,’precision ’,’%1.3e’);
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dlmwrite(’Qs4.txt ’,Qs4 ,’delimiter ’,’\t’,’precision ’,’%1.3e’);
dlmwrite(’Qs5.txt ’,Qs5 ,’delimiter ’,’\t’,’precision ’,’%1.3e’);
dlmwrite(’Qs6.txt ’,Qs6 ,’delimiter ’,’\t’,’precision ’,’%1.3e’);
dlmwrite(’Qs7.txt ’,Qs7 ,’delimiter ’,’\t’,’precision ’,’%1.3e’);
dlmwrite(’Qs8.txt ’,Qs8 ,’delimiter ’,’\t’,’precision ’,’%1.3e’);
%%****** Total Deposited Particle Coordination ********
I=vertcat(AA ,BB,CC,DD);
filename=’Total -Dep.txt ’;
file_D=fopen(filename ,’a’);
fprintf(file_D ,’TITLE="Total -Dep"\ nVARIABLES ="X","Y","Z"\ nZONE T="Total -Dep"\n’);
dlmwrite(filename ,I,’-append ’,’delimiter ’,’\t’,’precision ’,’%1.3e’);
fclose(file_D );
%%%%%%%% Calculating Deposition Fraction %%%%%%%%%%%%%%%%%%%%%%%%
[x,y]=size(I);
z=(x/ee )*100;
RR=’Dep_fraction.txt ’;
UU=fopen(RR ,’a’);
fprintf(UU,’Total Tracked Particles =%d\nTotal Deposited Particles=
%d\nDepsoition Efficiency =%d’,ee,x,z);
fclose(UU);
end;
fclose(’all ’);
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